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[…] “I have a new love for that glittering 
instrument, the human soul. It is a lovely and 
unique thing in the universe. It is always attacked 
and never destroyed – because Thou mayest.”
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Abstract 
The pharmaceutical industry is going through a rather turbulent period. Many 
blockbuster drugs have fallen off patent over the past two years and many more are 
expected to do so in the near future. In response, pharmaceutical companies have 
continued searching for products that will replace those that have lost patent 
protection. However, drug development and approval is extremely time-consuming and 
costly. So that this critical issue is addressed, industry experts and regulatory agencies 
have jointly proposed the implementation of Quality by Design (QbD) principles in the 
development and manufacture of all new drugs. Adoption of QbD is expected to reduce 
drug development cost and approval time. It is also expected to encourage innovation 
by developing drugs, and the processes used to manufacture them, around the 
mechanisms that relate process inputs with end product quality. Within this context, 
monoclonal antibodies (mAbs) are currently the highest-selling products of the 
biopharmaceutical industry and are projected to account for nearly half of the world’s 
top-selling drugs by 2018. All currently commercialized mAbs contain N-linked glycans 
(complex carbohydrates) bound to their protein backbone. These carbohydrates, in 
turn, have been widely reported to impact the safety and efficacy of mAbs. Furthermore, 
it has widely been reported that bioprocess conditions heavily impact the composition 
and distribution of these glycans. For these reasons, mAb glycosylation is considered a 
critical quality attribute (CQA) of these therapeutic proteins under the QbD scope. 
Based on QbD principles, the objective of this thesis was to generate a mathematical 
model that mechanistically relates the effect of nutrient availability throughout cell 
culture with the glycan profile of a mAb. The model was constructed from three 
individual ones. The first model describes the N-linked glycosylation process which 
occurs in the Golgi apparatus. The second model is unstructured and describes cell 
culture dynamics. The third and final model describes the biosynthetic pathway for 
nucleotide sugars. All three models were developed independently, but were adapted 
with features so that they could be interconnected. The glycosylation model 
approximates the Golgi apparatus to a single plug flow reactor where resident proteins 
(glycosylation enzymes and transport proteins) are recycled from distal portions of the 
Golgi space to proximal ones. Optimisation-based methods were developed to estimate 
unknown parameters of the model. The cell culture dynamics model was developed to 
represent cell growth, nutrient consumption and mAb synthesis. It was originally based 
on Monod kinetics, but was adapted to include experimentally-encountered complexity. 
The model for nucleotide metabolism was heuristically reduced from 35 constituting 
reactions to 7. Additional mechanistic features were adapted or included to ensure 
model fidelity. 
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Experimentally, batch cultures were performed with hybridoma (CRL-1606 from 
ATCC). Data for viable cell density, glucose, glutamine, lactate, ammonia and mAb titre 
were collected. Intracellular samples were produced by perchloric acid extraction. 
These samples were then analysed for nucleotide sugar content using a high 
performance anion exchange chromatographic method which was optimized to quantify 
eight nucleotide sugars and four nucleotides in 30min. mAb bound glycans were 
analysed by MALDI mass spectrometry. The experimental data was used to estimate the 
unknown parameters of the models. 
The models – along with their associated parameters – were then combined to produce 
a coupled model that mechanistically relates nutrient availability with mAb 
glycosylation-associated quality. With further validation, such a model could be used for 
bioprocess design, control and optimization. 
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Notation 
• iOS : Oligosaccharide chain i (Acceptor) 
• kPc : Nucleotide-sugar precursor k (Donor) 
• kB : By-product k. It is the nucleotide component of the NSDs (UDP, GDP or CMP) 
• inF : Flowrate of oligosaccharide 1 into the Golgi cisterna 
• 
,k inF : Flowrate of NSD k into the Golgi cisterna 
• q : Volumetric flowrate into the Golgi cisterna 
• iD : Internal diameter of the Golgi space 
• 
,i jν : Stoichiometric coefficient of oligosaccharide i in reaction j 
• 
,k jν : Stoichiometric coefficient of NSD k in reaction j 
• jr : Rate of reaction j 
• ( )jE z : Concentration of enzyme j along Golgi length, z 
• 
,j MAXE : Peak concentration of enzyme j 
• 
,j MAXz : Localization of the peak concentration of enzyme j 
• jω : Width of the concentration profile of enzyme j 
• ( )kTP z : Concentration of TP k along Golgi length, z 
• 
,k MAXTP : Peak concentration of TP k 
• 
,k MAXz : Localization of the peak concentration of TP k 
• kω : Width of the concentration profile of TP k 
• jfk , : Rate-limiting turnover rate 
• idK , : Dissociation constant of the Acceptor-Enzyme complex 
• zOS : Competing oligosaccharide substrates for the same enzyme (Competitor) 
• zdK , : Dissociation constant of the Competitor-Enzyme complex 
• 1−iOS : Oligosaccharide product in the mannosidase reactions 
• 
,d kK : Dissociation constant of the Donor-Enzyme complex 
• BkdK , : Dissociation constant of the BP-Enzyme complex 
• 1+iOS : Oligosaccharide chain with additional sugar residue added (Product) 
• kdK , : Dissociation constant of the Donor-Enzyme complex 
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• 1, +idK : Dissociation constant of the Enzyme-Product complex 
• kTk , : Transport turnover rate 
• GA : Surface area of the Golgi cisterna 
• GV : Volume of the Golgi cisterna 
• 
Cyt
kPc : Nucleotide-sugar precursor k concentration on the cytosolic side of Golgi 
• 
Cyt
PcK : Dissociation constant of the transport protein-NSD complex 
• 
..LG
kBP : By-product k in the Golgi lumen (same as Bk) 
• 
..LG
BPK : Dissociation constant of the transport protein-byproduct complex 
• ManI: α-1,2 Mannosidase I 
• GnTI: α-1,3 N-acetylglucosaminyl transferase I 
• ManII: α-1,3/α-1,6 Mannosidase II 
• GnTII: α-1,6 N-acetylglucosaminyl transferase II 
• FucT: α-1,6 Fucosyltransferase (also known as FUT8) 
• GalT: β-1,4 Galactosyltransferase 
• SiaT: α-1,6 Sialyltransferase 
• TP1: transport protein for UDP-GlcNAc/UMP 
• TP2: transport protein for GDP-Fuc/GMP 
• TP3: Transport protein for UDP-Gal/UMP 
• TP4: Transport protein for CMP-Neu5Ac/CMP 
• Xv: Viable cell density 
• Xd: Dead cell density 
• Glcext: Extracellular glucose concentration 
• Glnext: Extracellular glutamine concentration 
• Lact: Extracellular lactate concentration 
• Amm: Extracellular ammonia concentration 
• Prod: Extracellular product (mAb) concentration 
• IVC: Integral viable cell concentration 
• µ: Specific growth rate 
• kd: Specific death rate 
• qGlc: Specific glucose consumption rate 
• qGln: Specific glucose consumption rate 
• qLact: Specific lactate production rate 
• qAmm: Specific ammonia production rate 
• qProd: Specific product (mAb) production rate 
• FGlc,in: Molar flowrate of glucose into the cell 
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• FGln,in: Molar flowrate of glutamine into the cell 
• rmet,Glc: Rate of intracellular glucose consumption for metabolism 
• rmet,Gln: Rate of intracellular glutamine consumption for metabolism 
• Glcint: Intracellular glucose concentration 
• Glnint: Intracellular glutamine concentration 
• UDP-GlcNAc: Intracellular uridine diphosphate N-acetylglucosamine concentration 
• UDP-Glc: Intracellular concentration of uridine diphosphate glucose concentration 
• GDP-Man: Intracellular concentration of guanosine diphosphate mannose 
• UDP-GalNAc: Intracellular uridine diphosphate N-acetylgalactosamine concentration 
• CMP-Neu5Ac: Intracellular cytosine monophosphate N-acetylneuraminic acid concentration 
• UDP-Gal: Intracellular uridine diphosphate galactose concentration 
• GDP-Fuc: Intracellular guanosine diphosphate fucose concentration 
• rUDPGlcNAc: UDP-GlcNAc synthesis rate from glucose and glutamine 
• rUDPGlc: UDP-Glc synthesis rate from glucose 
• rGDPMan: GDP-Man synthesis rate from glucose 
• rUDPGalNAc: UDP-GalNAc synthesis rate from UDP-GlcNAc 
• rCMPNeu5Ac: CMP-Neu5Ac synthesis from UDP-GlcNAc 
• rUDPGal: UDP-Gal synthesis rate from UDP-Glc 
• rGDPFuc: GDP-Fuc synthesis rate from GDP-Man 
• µmax: Maximum specific growth rate 
• kd,max,glc: Maximum specific death rate for glucose depletion 
• kd,max,gln: Maximum specific death rate for glutamine depletion 
• KM,glc; Monod constant for glucose 
• KM,gln; Monod constant for glutamine 
• Kd,glc; Inverse saturation constant for glucose depletion 
• Kd,gln; Inverse saturation constant for glutamine depletion 
• YX/Glc: Yield coefficient of viable cells from glucose 
• YX/Gln: Yield coefficient of viable cells from glutamine 
• YLact/Glc: Yield coefficient of lactate from glucose 
• YAmm/Gln: Yield coefficient of ammonia from glutamine 
• YmAb/Xv: Yield coefficient of mAb from viable cells 
• : Glucose transport rate coefficient (from extracellular to intracellular) 
• : Glutamine transport rate coefficient (from extracellular to intracellular) 
• 	, : Maximum glucose consumption rate for metabolism 
• 	, : Maximum glutamine consumption rate for metabolism 
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• ,	 : Menten coefficient for metabolic glucose consumption 
• ,	 : Menten coefficient for metabolic glutamine consumption 
• : Turnover rate for UDP-GlcNAc synthesis 
• : Turnover rate for UDP-Glc synthesis 
• : Turnover rate for GDP-Man synthesis 
• : Turnover rate for UDP-GalNAc synthesis 
•  : Turnover rate for CMP-Neu5Ac synthesis 
• : Turnover rate for UDP-Gal synthesis 
•  : Turnover rate for GDP-Fuc synthesis 
• ,: Glucose Menten coefficient for UDP-GlcNAc synthesis 
• ,: Glutamine Menten coefficient for UDP-GlcNAc synthesis 
• : Menten coefficient for UDP-Glc synthesis 
• : Menten coefficient for GDP-Man synthesis 
• : Menten coefficient for UDP-GalNAc synthesis 
•  : Menten coefficient for CMP-Neu5Ac synthesis 
• : Menten coefficient for UDP-Gal synthesis 
•  : Menten coefficient for GDP-Fuc synthesis 
•  : Inhibition coefficient for CMP-Neu5Ac synthesis from UDP-GlcNAc 
•  : Inhibition coefficient for GDP-Fuc synthesis from GDP-Man 
• , : Inhibition coefficient for CMP-Neu5Ac transport from UDP-GlcNAc 
• ,: Maximum consumption rate of UDP-GalNAc 
• ,: Menten coefficient for UDP-GalNAc consumption 
• ,: Saturation coefficient for UDP-GlcNAc consumption in glycosylation 
• ,: Saturation coefficient for UDP-Glc consumption in glycosylation 
• ,: Saturation coefficient for GDP-Man consumption in glycosylation 
• ,: Saturation coefficient for CMP-Neu5Ac consumption in glycosylation 
• ,: Saturation coefficient for UDP-Gal consumption in glycosylation 
• ,: Saturation coefficient for GDP-Fuc consumption in glycosylation 
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Chapter 1  
Introduction 
The market for monoclonal antibodies (mAbs) has expanded remarkably over the past fifteen 
years. Between 2009 and 2010, it grew approximately 10% and achieved worldwide sales of 
over $43 billion.1, 2 As of June 2011, there were 28 mAbs approved in the EU and US, of which 
42% are prescribed for the treatment of several types of cancer – including colorectal and 
breast cancer – and another 32% for autoimmune disorders, such as rheumatoid arthritis, 
psoriasis, lupus erythematosus and Crohn’s disease. The remaining 26% are indicated for other 
conditions such as osteoporosis, transplant rejection, bacterial infections, asthma and wet age-
related macular degeneration.1, 2 
Commercial success of mAbs is expected to continue, with their sales projected to account for 
nearly half of the world’s top 100 drugs by 2018.2 Considering this very promising outlook, 
pharmaceutical companies have continued driving new mAb candidates through the 
development pipeline, with approximately 350 currently undergoing clinical studies, of which 
25 were in phase III trials as of November 2011.3 Among these are so-called next-generation 
mAbs such as bi-specific antibodies, antibody-drug conjugates, glycoengineered antibodies and 
antibody fragments, all of which intend to replicate the success achieved by their first-
generation counterparts.4-6 
Despite the promising trends for mAbs, “big” – or innovative – pharmaceutical companies 
have been facing an increasingly challenging environment. From 2004 to 2011, large 
pharmaceutical companies lost approximately $112 billion in sales due to patent expiration of 
several high-profile drugs, and this trend is expected to continue with an estimated $148 billion 
to be lost in the next six years.2 While these losses and a struggling global economy have 
resulted in a relatively bleak outlook for overall growth of innovative pharmaceutical 
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companies, the generics market has been growing at a rapid pace, precisely due to patent 
expirations.2 In response, innovative pharmaceutical companies continue searching for new 
products which will replace the blockbuster drugs that have lost patent protection.2, 7 However, 
industry analysts argue that the cost and relatively low throughput of drug development and 
approval are the major obstacles that are preventing this replacement from occurring.8, 9 Recent 
estimates put the cost of taking a new drug to market at  approximately $1.3 billion,8, 10, 11 and 
although figures in this range have been questioned,12, 13 most reports suggest that 
approximately 60% of the cost for taking a new drug to market arises from the clinical stages of 
drug development.8, 10, 11, 13-15 
Within this context, it has been proposed that two areas are crucial for improving R&D 
productivity: firstly, reduction of attrition rates, i.e. reducing the probability of products failing 
at late clinical phases; and secondly, reduction of the time it takes for drug candidates to go 
through different clinical stages.8, 9, 16 A fundamental target for reducing attrition rates and 
development cycle time is product quality assurance. More specifically, identification of the key 
quality attributes that impact drug safety and efficacy could assist in identifying which drug 
candidates should not be progressed to further clinical trials, thus aiding in attrition 
predictability. In addition, understanding the mechanisms by which manufacturing conditions 
impact product quality would potentially reduce drug development cycle time by allowing 
process optimization to occur simultaneously with scale-up and clinical trials. Considering this, 
regulatory agencies and industry experts proposed implementation of the Quality by Design 
(QbD) paradigm for development of all new drug products in the pipeline. Fundamentally, QbD 
aims to build quality into the product at every stage of development by making use of 
quantitative mechanistic relationships between process inputs and the different features that 
impact product quality. 
QbD has been successfully implemented in small molecule therapeutics (SMT) manufacture 
on several occasions.17-21 Its implementation, however, has been considerably more challenging 
in the field of biological pharmaceuticals. This has largely been due to the size and complexity of 
biological molecules. Figure 1 compares the scale of a monoclonal antibody with three SMTs 
which are, on average, 500 times smaller than the mAb. Compounding the effect of size is three-
dimensional structure. In all cases, the structure of each molecule defines its safety and efficacy 
as therapeutics, although it is clear that variation in structure is more likely to occur within a 
large molecule than in smaller ones. In addition, SMTs are generally produced by well-defined 
and characterised chemical processes, whereas mAbs are produced by mammalian cells in 
culture, a process that is inherently more complex and is not yet fully understood. 
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Figure 1. Comparison of an IgG-mAb with small molecule therapeutics 
Crystal structure of an IgG1 mAb22 (A), molecular structure of 3 SMTs which are indicated for 
autoimmune disorders and cancer: Fluorouracil (B), Methotrexate (C) and Tofacitinib (D). 
Molecular complexity of the mAb and incomplete understanding of the bioprocesses 
employed for its manufacture highlights the importance of elucidating the mechanisms that 
relate bioprocess conditions with the quality features of mAbs, and thus also underlines the 
difficulties associated with implementing QbD for the development of these drugs. Knowledge 
gained on the interplay between bioprocess conditions and mAb quality is currently playing a 
critical role for the development of new mAbs in the pipeline and is considered of paramount 
importance in the context of the currently struggling pharmaceutical market.23 
When considering QbD for mAb development and manufacture, it is necessary to 
understand which of their molecular features impact their safety and therapeutic efficacy. 
Broadly, a fully functional mAb consists of a properly folded protein backbone which has been 
modified by the addition of functional groups and other side-chains. These additions to the 
peptide backbone are commonly referred to as post-translational modifications (PTMs), and 
although fragmentation, carboxylation, amidation and sulfation are PTMs commonly associated 
with currently marketed biologics, glycosylation is considered to be the most  prevalent and 
complex one.24 More specifically, all commercially available mAbs are based on the gamma 
immunoglobulin (IgG) isotype, which contains a consensus asparagine-linked (N-linked) 
glycosylation site on the Cγ2 domains of its crystallizable fragment (Fc). In turn, the nature and 
distribution of glycan structures bound to this fragment have been reported to greatly influence 
the immunogenicity, serum half-life and therapeutic mechanism of mAbs,25-27 thus defining 
these glycan distributions as critical for mAb quality in the QbD context.  Furthermore, it has 
been widely reported that bioprocess conditions employed for mAb manufacture (e.g. nutrient 
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availability, dissolved oxygen, pH, temperature, stirring speed and culture medium 
supplementation) influence the composition and distribution of the glycans bound to mAbs.28, 29 
Despite the wealth of publications describing the mechanisms underlying the influence of 
certain bioprocess conditions on protein glycosylation, few have been fully quantitative. Finally, 
authors have suggested that quantitative, mechanistic mathematical models will be central to 
implementing QbD to biopharmaceutical process development,29, 30 and the case of mAb 
glycosylation should be no different. 
Given the commercial importance of mAbs, the current climate in the pharmaceutical sector 
and the ensuing need for quantitative mechanistic mathematical models describing drug quality 
as a function of manufacturing processes and conditions, with this work we propose the 
definition of a mathematical model that attempts to mechanistically describe the glycosylation 
profiles of mAbs as a function of nutrient availability during cell culture. 
The first objective, therefore, was to develop a mathematical model that represents the 
glycosylation process which occurs in the Golgi apparatus. Because none of the three previously 
published models for Golgi glycosylation have the ability to represent the effect of extracellular 
culture conditions on the glycosylation process,31-33 our model includes transport of nucleotide 
sugars (NSDs) from the cytosol to the Golgi apparatus. NSDs are metabolic products which are 
synthesized from extracellular nutrients and consumed in the glycosylation reactions in the 
Golgi apparatus. Accordingly, these metabolites were considered as crucial for drawing 
mechanistic links between nutrient availability, cell metabolism and mAb glycosylation. 
A second mathematical model was developed to describe cell culture dynamics. This model 
was based on Monod kinetics, but was expanded to include intracellular accumulation of 
glucose, glutamine and seven nucleotide sugars. The purpose of this model is to mechanistically 
link extracellular nutrient availability, cell growth, mAb productivity, intracellular NSD 
availability and the Golgi glycosylation process. A conceptual description of the objectives of this 
work is presented in Figure 2. 
Experimentally, mAb-producing mammalian cells were grown under batch conditions and 
typical data (viable cell density, extracellular glucose, glutamine, lactate and ammonia; as well 
as mAb titre) were collected. In addition, methods for extracting and quantifying the 
intracellular pools of nucleotide sugars were developed and optimised with the aim of obtaining 
time-profiles for their availability throughout cell culture. Finally, the glycan composition of the 
produced mAb was monitored under batch operation with MALDI-TOF mass spectrometry. The 
collected experimental data was subsequently used to estimate the unknown parameters of the 
mathematical models. 
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Figure 2. Overall strategy for linking nutrient availability with mAb Fc N-glycosylation 
A model that describes cell growth, mAb productivity and NSD metabolism as a function of glucose 
and glutamine availability will be coupled to a model for N-linked glycosylation in the Golgi 
apparatus. The coupled model will be able to represent mAb Fc N-glycosylation as a function of 
glucose and glutamine availability throughout cell culture. 
The culmination of this work is a single, combined mathematical model that quantitatively 
and mechanistically relates cell culture dynamics, intracellular metabolite accumulation and 
mAb glycosylation. The aim of this coupled model is to assist in predicting mAb glycosylation-
associated quality, and thus aid in the development, manufacture and approval of next-
generation mAbs under the QbD scope. 
This thesis will first present an overview of the current market for mAbs, and the 
increasingly challenging environment the companies that are producing them are facing. This 
will be followed by a review of the relevant literature that has described protein N-linked 
glycosylation, the impact it has on mAb structure and function, and the interplay between 
bioprocess conditions and protein glycosylation. Subsequently, a description of Quality by 
Design and the application of its principles in the context of mAb glycosylation-associated 
quality and bioprocessing will be presented. The thesis will continue with a description of 
mathematical models, their construction, their underlying assumptions, as well as the 
optimisation strategies developed to estimate their unknown parameters. A description of the 
experimental methods employed throughout the project will be presented with special 
emphasis on the development and optimization of the NSD extraction and quantification 
protocols that were established through this work. Both modelling and experimental results will 
then be presented and compared in order to assess and establish the validity of assumptions 
that were made and experimental procedures that were established or followed. Finally, the 
thesis will conclude by presenting the main findings of the work along with recommendations 
for future paths in this line of research. 
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Chapter 2  
Literature Review 
2.1.  Pharmaceutical Quality by Design 
As was discussed in the introduction to this thesis, Quality by Design (QbD) was proposed along 
with other strategies as a means for pharmaceutical companies to improve their drug 
development throughput by building quality into the product at every stage of development and 
manufacture. This section will review the underlying concepts of QbD applied to drug 
development and manufacture, contrast these concepts with the current state of affairs in the 
industry and highlight the advantages associated with adopting the QbD paradigm for drug 
development and manufacture. 
2.1.1. Current state of pharmaceutical process development 
Drug development begins by identifying molecules that have the biochemical potential to treat 
illnesses. Pharmaceutical companies then select drug candidates based on their 
manufacturability and potential profitability for optimization and, eventually, are progressed to 
preclinical and clinical studies so that their safety and therapeutic efficacy is assessed. 
Concurrently, manufacturing is scaled up so that sufficient material is available throughout all 
stages of product development. Also throughout these phases, data concerning drug safety, 
efficacy and manufacture is reviewed for approval by the corresponding regulatory agencies. 
Approval requires that the drug product is shown to be produced consistently, that it is safe and 
finally, that it is efficacious for its indication. Despite decades of advances in drug 
manufacturing, pharmaceutical process development and approval is still extremely lengthy, 
highly expensive and uncertain.34 
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Pharmaceutical companies have largely relied on the Quality by Testing (QbT) approach.34 
Under QbT, the ranges for drug substance properties that yield acceptable safety and efficacy, 
also known as product quality attributes, are associated with a set of process inputs in terms of 
process parameters and raw materials during the preclinical and clinical stages of development. 
In turn, process inputs that have empirically shown to yield acceptable product quality are 
defined and often maintained unchanged after phase II clinical trials so that manufacturers 
avoid costs associated with additional testing for regulatory compliance.35 From this point on, 
the product is tested for quality compliance after manufacturing runs with these pre-defined 
process inputs.34-37 This approach relies solely on empirical knowledge, excluding mechanistic 
knowledge of how process inputs are linked with product quality, and thus, uncouples the end-
quality of the product from the manufacturing process.  
There are several drawbacks of the QbT approach.29, 35, 38 The first is that development and 
approval of pharmaceutical processes has historically been extremely time-consuming and 
costly. It has been estimated that drug approval takes between 7 to 10 years9, 39 and costs $1.2 
to $1.8 bn per approved drug when the risk of failure is included.8, 40 These issues are correlated 
and may be attributed to the limited understanding between product quality characteristics, 
therapeutic mechanisms, and the effect process inputs have on product quality. 
Secondly, process control is not established by mechanistic links between process inputs 
and product quality, rendering the process susceptible to generating off-spec products. In such 
cases, identification of the source(s) of failure is difficult. 
Additionally, the range of process conditions approved under QbT is tightly defined and 
input disturbances outside this space require validation, which equates to further delays and 
expense. This discourages pharmaceutical companies from optimising processes or 
implementing innovative technologies. Finally, manufacturing processes developed and 
approved under QbT generate a limited amount of knowledge because mechanistic links 
between process inputs and product quality are largely disregarded. This restricts knowledge 
transfer between processes and products. Furthermore, this lack of generated mechanistic 
knowledge increases the likelihood of suboptimal process performance. 
Small molecules and protein therapeutics currently undergo the same QbT development and 
approval process and suffer the same caveats. In the QbT context, bioprocess inputs are 
empirically defined so that the protein quality characteristics, such as e.g. aggregation, folding, 
methylation and glycosylation, lie within acceptable ranges for safety and therapeutic efficacy. 
As occurs with small molecules, QbT disjoins therapeutic protein quality from the bioprocess,  
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leading to inadequate understanding of the relationship between process inputs and product 
quality and thus limiting the potential for bioprocess optimization. 
The inefficiencies of QbT have led to significant investments in drug discovery rather than 
process understanding and optimization. This, in turn, has translated into reduced cost-
effectiveness, lower number of novel manufacturing processes and an overall drop in number 
and quality of innovative drugs.8, 35 The issues discussed above, as well as the need for 
increasing drug development throughput at lower cost, have led the regulatory bodies and 
pharmaceutical companies to propose the introduction of Quality by Design principles to the 
manufacture of all new drugs – including therapeutic proteins – along the development 
pipeline.34, 38, 41 
2.1.2. Implementation of QbD to pharmaceutical process 
development 
Pharmaceutical QbD is a conceptual framework for the development and approval of 
pharmaceutical manufacturing processes that aims to build quality – particularly with respect 
to safety and therapeutic efficacy – into the product at every stage of process development.29, 37, 
38 Application of QbD principles to process development is outlined in the Process Analytical 
Technology (PAT) guideline “PAT – A Framework for Innovative Pharmaceutical Manufacturing 
and Quality Assurance42” by the US Federal Drug Administration (USFDA) and in the guidance 
documents “ICH Q8 Pharmaceutical Development,37” “ICH Q9 Quality Risk Management43” and 
“ICH Q10 Pharmaceutical Quality Systems44” from the International Conference on 
Harmonization (ICH), which is an association constituted by the USFDA, the European 
Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) 
and several experts from the pharmaceutical industry. 
QbD implementation is an information-driven process where all available knowledge on the 
drug product including, but not limited to, its therapeutic mechanisms, its manufacturing 
process and potential sources of variability is used to define a range of manufacturing 
conditions that will ultimately ensure in vivo product safety and efficacy. More specifically, the 
ICH guidelines 37, 43, 45 require the definition of the quality target product profile, identification of 
the critical quality attributes (CQAs) of the drug product, identification of process inputs that 
affect product CQAs, Selection of the appropriate manufacturing process, and definition of a 
control strategy. These steps are discussed in detail below. 
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Definition of the quality target product profile (QTPP) 
The QTPP is the set of quality characteristics that ensure that the drug product is safe and 
efficacious. Considerations to define the QTPP include the route of administration, dosage form, 
delivery systems, dosage strength, sterility, purity and stability.37 
Identification of the critical quality attributes (CQAs) of the drug product 
A CQA is defined in ICH Q8 as “a physical, chemical, biological, or microbiological property or 
characteristic that should be within an appropriate limit, range, or distribution to ensure the 
desired product quality” 37. As the definition implies, identification of CQAs requires thorough 
physicochemical and biological characterization of the drug product and in-depth knowledge of 
the properties that have a higher influence on its safety and efficacy. 
Identification of process inputs that affect product CQAs 
Once CQAs are identified, it is necessary to determine not only which process inputs (raw 
materials and process conditions) impact CQAs, but also how these inputs interact to affect the 
CQAs. It is possible that the required knowledge may not be available for certain processes 
(particularly novel ones) and should be established through the combination of prior 
knowledge, mechanistic modelling, experimentation and, finally, a risk assessment so that the 
influence of material attributes and process conditions on CQAs is ranked according to 
likelihood and extent of impact. For this purpose, under QbD, there is special emphasis on 
design of experiments (DoE) so that the interaction between individual process inputs and their 
impact on product CQAs is taken into consideration. Crucially, all elements involved in this 
section directly couple manufacturing process conditions with the CQAs in a robust, systematic 
and information-driven manner. 
Selection of the appropriate manufacturing process 
The aforementioned risk assessment will dictate a multi-dimensional design space of allowable 
process input values. ICH Q8 defines the design space as “an established multidimensional 
combination and interaction of material attributes and/or process parameters demonstrated to 
provide assurance of quality.”37 Guided by the design space, the manufacturing process 
conditions that ensure product quality can be identified. The selected process must be robust 
such that the likelihood of the CQAs being within the range that ensures safety and efficacy is 
maximised. 
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Definition of a control strategy 
With the appropriate manufacturing process in place, a risk mitigation strategy can be 
established. This involves monitoring and controlling raw material specifications such that no 
impact is observed on the drug product’s CQAs. In addition, the process parameters that 
influence the CQAs are controlled, ideally through online measurements and robust control 
systems, at every stage of the manufacturing process so that the desired product quality is met. 
An enabling tool for QbD implementation is process analytical technology (PAT). PAT is 
defined by the USFDA and the ICH as “a system for designing, analyzing and controlling 
manufacturing through timely measurements of CQAs and performance attributes of raw and 
in-process materials and processes with the goal of ensuring final product quality.42” The 
elements of PAT concerning process design and control have been presented in the description 
of QbD above. However, PAT also concerns the “timely measurement of CQAs and performance 
attributes”42 throughout the implementation of QbD to manufacturing process development. 
Experimental methods for accurately identifying and measuring the physical, chemical and 
biological properties of drug products are essential for defining QTPPs and CQAs early in 
process development. Further along in the implementation of QbD, it is also necessary to 
accurately measure the material attributes and process parameters that affect product CQAs. 
Finally, once the manufacturing process is established, appropriate analytical technologies are 
necessary to monitor process parameters ideally online (or at line) so that process metrics can 
be used for process control. Analytical methods therefore constitute a core element throughout 
process development under the QbD scope.46 
The three major regulatory bodies (USFDA, EMA and PMDA) are encouraging 
implementation of the QbD approach for the development of all new drugs in the pipeline.19, 34, 
36, 38 QbD is expected to reduce process approval time and costs, limit regulatory intervention 
and encourage optimization and innovation by building processes around the mechanistic 
relationships between inputs and product quality. Because these relationships should be based 
on mechanistic knowledge, process outputs are expected to be more predictable and to require 
less regulation. This, in turn, would considerably reduce approval time and development costs. 
In addition, the more ample design space created through QbD would allow inputs to vary more 
without the need for additional approval. Predictability would also translate into more robust 
control systems that would decrease the likelihood of failed batches. Finally, the knowledge 
generated along with the broader design space and more flexible regulatory approval procedure 
would encourage process optimization and could potentially contribute to the development of 
novel processes as well as the discovery and design of next generation drugs. 
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The QbD framework has already been implemented in the manufacture of small-molecule 
therapeutics (SMTs) with relative ease. However, the implementation of QbD to protein 
therapeutics (PTs) has met more resistance. This can be attributed to the fact that the physical 
and chemical processes underlying the manufacture of SMTs is better understood and the 
mechanisms relating process inputs with SMT quality are easier to define. In contrast, the 
cellular mechanisms by which PTs are produced are less well understood, and the structural 
complexity of PTs makes their isolation, separation, purification and overall quality control 
significantly more challenging. Despite this, the regulatory agencies and several authors believe 
that sufficient knowledge is available or can be gained through current experimental and 
modelling methodologies to elucidate mechanistic relations between bioprocesses and PT 
quality, thus allowing for implementation of QbD principles to the development of therapeutic 
protein manufacturing processes in the near future.34, 38 
Implementation of the QbD paradigm in biologics should increase knowledge on the 
therapeutic mechanisms of biotherapeutics considerably. This could lead to the improvement of 
existing products and may contribute to the discovery and development of new biologics. It will 
also enable more robust process control, process optimization and, potentially, development of 
novel and efficient manufacturing platforms Implied in this is the considerable reduction in 
approval times which would heavily reduce costs of product and process development and 
eventually translate into lower costs for healthcare providers and patients. 
2.2. Monoclonal antibodies: structure and function 
Antibodies, which are more formally named immunoglobulins (Igs), are the biomolecules 
that mediate humoral adaptative immune response in vertebrates. Immunoglobulins are 
glycoproteins that are produced by a type of white blood cells named B-lymphocytes. Being 
glycoproteins, Igs consist of a polypeptide backbone (protein backbone) that has 
oligosaccharide structures (glycans) covalently bound to it. Most mammalian Igs are formed by 
four different polypeptide chains covalently bound together by disulphide bridges. The four 
constituting chains are two identical light chains and two identical heavy chains. Each chain is 
composed of separate structural domains. The light chains consist of two domains –a constant 
domain (CL), which defines either the kappa (κ) or lambda (λ) isotype, and a variable domain 
(VL), which dictates the antibody’s affinity for its antigen. The heavy chains also contain a set of 
constant structural domains (CH) and a single variable domain (VH), which serves the same 
purpose as their VL counterpart. The constant domains of the heavy chains define five different 
isotypes, which are IgA, IgD, IgE, IgG and IgM. IgA, IgD, IgE and IgG heavy chains consist of three 
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constant structural domains, while IgM heavy chains contain four constant domains. Each of 
these domains, regardless of it being constant or variable, has a three dimensional structure 
that is defined by intermolecular forces and disulphide bonds. Figure 3 shows the domain 
structure and intra and inter chain disulphide bonding within immunoglobulins. 
 
Figure 3. Generalised domain organisation in antibody molecules 
On the left we have the generalised domain organisation of antibodies which contain only four 
heavy chain domains (IgA, IgD and IgG). On the right we have the organisation of IgM, which 
contains five heavy chain domains and has no hinge region. The sense of the polypeptide chains is 
represented shown by the NH4+ and COO- annotations. The disulphide bonds which generate each 
separate domain and which also bind the separate chains to each other are presented in red. The 
constant domains can be seen in blue and the variable domains are presented in green. 
Monoclonal antibodies are immunoglobulins that are produced by the clones of a single cell 
that has been immortalised (it has the ability to reproduce indefinitely in vitro). The original 
method by which B-lymphocytes were immortalised was hybridisation. The hybridoma 
technology consists in fusing a B-lymphocyte that produces a desired antibody with a tumorous 
B-lymphocyte.47 Since the advent of this technology, focus was set on generating a new class of 
drugs that could bind, with very high specificity, to pathogenic targets within patients. From the 
first mAbs that were generated to avoid transplant rejection, a vast number of them are 
currently approved by regulatory bodies for the treatment of immunological disorders, 
infectious diseases and cancer. As of June, 2011, 28 mAbs have been approved by the U.S. Food 
and Drug Administration (USFDA) or the European Medicines Agency (EMEA).1, 2 Table 1 shows 
the currently approved mAbs, their antibody isotype, the antigens they bind to and the category 
of illnesses for which they are currently prescribed. 
Table 1 shows that all approved mAbs are based on the IgG isotype. For this reason, this 
review will focus on the structure of IgG and the mechanisms by which it functions. IgG has the 
same basic structure shown in Figure 3, but can be seen in more detail in Figure 4. It has two 
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heavy chains, and two light chains. Its gamma (γ) heavy chain is composed of four structural 
domains, which are named Cγ1, Cγ2, Cγ3 and VH. The IgG light chains contain two domains which 
are named CL and VH, and are responsible for antigen binding. 
 
Table 1. Global market for mAbs in 20111, 2, 48 
 
Generic name US trade name Company Antibody Format 
Therapeutical 
Category 
2011 Global 
Sales 
($ billion) 
Infliximab Remicade Centocor Chimeric, IgG1κ, anti-TNF Immunological $ 9.00 
Adalimumab Humira Abbott Humanized, IgG1κ, anti-TNFa Immunological $ 8.20 
Rituximab Rituxan 
Biogen IDEC and 
Genentech/Roche 
Chimeric, IgG1κ, anti-CD20 Cancer $ 6.80 
Bevacizumab Avastin Genentech/Roche Humanized, IgG1κ, anti-VEGF Cancer $ 6.00 
Trastuzumab Herceptin Genentech/Roche Humanized, IgG1κ, anti-HER2 Cancer $ 5.90 
Ranibizumab Lucentis Genentech/Roche Humanized, IgG1κ Fab, anti-VEGF Ophthalmic $ 3.80 
Cetuximab Erbitux ImClone Systems 
Chimeric, IgG1κ, anti-EGF 
receptor 
Cancer $ 1.90 
Natalizumab Tysabri Biogen Idec 
Humanized, IgG4κ, anti-a4-
integrin 
Immunological $ 1.50 
Palivizumab Synagis MedImmune Humanized, IgG1κ, anti-RSV Anti-infective $ 1.00 
Abciximab ReoPro Centocor Chimeric, IgG1κ, anti-GPIIb/IIIa Hemostasis 
$ 3.60 
Alemtuzumab Campath Genzyme Humanized, IgG1κ, anti-CD52 Cancer 
Basiliximab Simulect Novartis/Cerimon Chimeric, IgG1κ, anti-CD25 Immunological 
Basiliximab Simulect Novartis Chimeric, IgG1κ, anti-CD25 Immunological 
Belimumab Benlysta 
Human Genome 
Sciences/GlaxoSmithKline 
Human, IgG1λ, anti-BLyS Immunological 
Canakinumab Ilaris Novartis Human, IgG1κ, anti-IL1β Immunological 
Catumaxomab Removab Fresnius/Trion 
Trispecific, mouse IgG2a/rat 
IgG2b, anti-EpCAM and CD3 
Cancer 
Certolizumab 
pegol 
Cimzia UCB 
Humanized, pegylated IgG1κ-
derived Fab, anti-TNF-α 
Immunological 
Denosumab Prolia/XGEVA 
Amgen/GlaxoSmithKline/Daiichi-
Sankyo/AstraZeneca 
Human, IgG2κ, anti-RANKL Cancer 
Eculizumab Soliris Alexion 
Humanized, IgG2/4κ, anti-
complement-5 
Immunological 
Golimumab Simponi 
Johnson & Johnson/Merck & 
Co./Mitsubishi Tanabe Pharma 
Human, IgG1κ, anti-TNF-α Immunological 
Ibritumomab 
tiuxetan 
Zevalin Biogen Idec 
Murine, IgG1κ, anti-CD20 
radiolabeled (Y-90) 
Cancer 
Ipilimumab Yervoy Bristo-Myers Squibb/Medarex Human IgG1κ, anti-CTLA4 Cancer 
Muromonab-
CD3 
Orthoclone 
OKT3 
Johnson &Johnson Murine, IgG2α, anti-CD3 Immunological 
Ofatumumab Arzerra GlaxoSmithKline/Genmab Human, IgG2κ, anti-CD20 Cancer 
Omalizumab Xolair Genentech/Roche Humanized, IgG1κ, anti-IgE Immunological 
Panitumumab Vectibix Amgen Human, IgG2κ, anti-EGF receptor Cancer 
Tocilizumab Actemra Roche/Chugai Humanized, IgG1κ, anti-IL-6R Immunological 
Tositumomab-
I131 
Bexxar Corixa 
Murine, IgG2αλ, anti-CD20; 
radiolabeled (I-131) 
Cancer 
Ustekinumab Stelara Centocor/Johnson & Johnson Human, IgG1κ, anti-IL12/23 Immunological 
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Figure 4. Structure of IgG 
Figure 4A shows the spatial arrangement of IgG. The chains are identical; hence, they are arranged 
such that they are rotated on their z axis and situated one in front of the other. The chains that can 
be seen between the Cγ2 domains (  and ) represent the consensus glycosylation site of IgG. 
Figure 4B presents the ribbon structure of IgG, obtained from crystallographic data.22 The 
separate domains are presented in different colours. Additionally, the secondary structure (α-
helices and β-sheets) can be seen in panel B. The antigen binding fragment (Fab) and the constant 
or crystallisable fragment (Fc) are also shown 
The mechanism of action of monoclonal antibodies is directly a function of their structure. 
The variable regions within their heavy and light chains bind with very high specificity to the 
antibody’s respective antigen, while the constant domains determine the manner in which the 
antigen-bound immunoglobulin will either neutralize the antigen or activate an immune 
response within the host organism to remove it. The IgG isotype has been selected as the base 
for therapeutic mAbs because of its ability to generate immune effector functions such as 
antibody-dependent cellular cytotoxicity (ADCC)49-51 and complement-dependent cellular 
cytotoxicity (CDC).52, 53 These mechanisms are schematically shown in Figure 5.  
Additionally, IgG-based mAbs have been shown to modulate immune response in patients.54-
56 Immune response modulation is mediated by FcγRII-B2 receptors which are expressed on the 
membrane of Macrophages, neutrophils and eosinophils. The purpose of these receptors is to 
adjust the concentrations at which immune complexes (antigen/antibody complexes) activate 
other cells of the immune system.57 Anthony and collaborators55 proposed a model in which 
IgGs with specific oligosaccharide structures trigger up-regulation of the synthesis of FcγRII-B2 
receptors. This implies that IgGs with certain oligosaccharide structures have the ability to 
regulate the concentrations at which they will trigger immune responses. Further research on 
the mechanisms by which this occurs has been reviewed recently by Nimmerjahn and 
Ravetch.56 
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Figure 5. Cytotoxic effector functions of mAbs23 
Antibody-dependent cellular cytotoxicity (ADCC): The constant fragment of the mAb binds to the 
FcγRΙΙΙ receptors which are present on the surface of natural killer (NK) cells and to the FcγRII-A 
receptors on the surface of neutrophils. These immune system cells recognise clusters of mAbs 
bound to the antigenic epitopes of whole-cell immunological threats. NK and neutrophil cells react 
by secreting granulocytes, which consist of a cocktail of cell lytic agents that eventually lead the 
immunological threat towards apoptosis, also known as cell death.57 
Complement dependent cellular cytotoxicity (CDC): This mechanism is also used by the immune 
system to eliminate whole-cell pathogens. The Fc of antigen-bound mAbs binds to the C1q 
component of the complement complex. This interaction initiates the complement cascade which 
eventually generates the membrane attack complex, and this ultimately destroys the pathogen’s 
membrane, thus removing it.57 
Considering the QbD guidelines described in previous sections, knowledge of the effects 
therapeutic products are meant to elicit in patients is crucial. The therapeutic indication of all 
currently commercialized mAbs is presented in Table 1. For treatment of cancer, mAbs are 
expected to generate either ADCC and/or CDC to lyse or neutralise cancer cells. The same effect 
is desired when mAbs are prescribed for anti-infective purposes. In the case of immunological 
disorders, monoclonal antibodies are expected to modulate immune response. Structural 
integrity of the antigen-binding (Fab) and constant (Fc) fragments of all mAbs is intrinsically 
necessary for their therapeutic efficacy. If the structure of their Fab is compromised, they will 
not bind with sufficient specificity or affinity to their antigen. If their Fc is structurally flawed, 
the mAbs will be unable to elicit effector functions, and thus, the host organism will be unable to 
remove the immunological threat. 
mAb
Target cell
CDC
ADCC
Effector cells
(e.g. NK cells/neutrophils)
C1q
Complement 
cascade activation
Lysis
LysisAntigen
FcγR
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Under QbD, the structural integrity of mAbs is defined as a critical quality attribute because 
it defines the therapeutic mechanism these products are meant to elicit in patients. Moreover, 
the considerations mentioned in this section provide an outline of which product properties are 
to be monitored and controlled to ensure that it retains the appropriate safety and therapeutic 
properties for the treatment it is prescribed for. 
2.3. Protein Glycosylation 
Protein glycosylation is the post-translational modification by which oligosaccharide structures 
covalently bind to the polypeptide backbone of a protein. There are two types of protein 
glycosylation: serine/threonine-linked glycosylation (O-linked) and asparagine-linked 
glycosylation (N-linked). O-linked glycosylation is seldom seen in antibodies,58, 59 and therefore, 
focus will only be set upon N-linked glycosylation in this review. Asparagine-linked 
glycosylation is a process that begins in the endoplasmic reticulum and concludes in the Golgi 
apparatus. The overall process has been well described by several authors.60, 61 A schematic 
description of N-linked glycosylation is presented in Figure 6. 
The end product of the N-glycosylation process is a properly folded protein with an 
oligosaccharide chain bound to it. N-linked oligosaccharides can be of the high mannose, hybrid 
or complex types. Despite their classification, N-linked oligosaccharides contain a common core 
structure which consists of three mannose and two GlcNAc residues (Man3GlcNAc2). The two 
GlcNAc residues form the base that is bound to the asparagine residue of the protein backbone. 
The first of the mannose residues is attached to the second GlcNAc of the base. Bound to this 
initial mannose residue are the two other mannose residues, one joined through an α-1,3 
linkage and the other one attached through an α-1,6 bond. These mannose residues give rise to 
the two arms that characterise all N-linked glycans. A detailed representation of the core 
oligosaccharide structure can be seen in Figure 7. 
As their name implies, high mannose oligosaccharide structures only contain mannose 
residues bound to the core. For the purposes of this review, we shall consider that high 
mannose oligosaccharides contain up to six mannose structures apart from the core mannoses, 
and their specific configuration, including individual bond structure, can be seen in Figure 7. 
Complex-type oligosaccharides are characterised by having branches (antennae) stemming 
from the core structure. Depending on the degree of processing, available enzymes and protein-
related stearic constraints, complex oligosaccharides can have two, three or four antennae. In 
turn, each antenna can contain GlcNAc, galactose and sialic acid residues. 
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Figure 6. Protein N-linked Glycosylation Process23 
Step 1: The precursor oligosaccharide with a simplified formula of GlcNAc2Man8Gluc3 is 
transferred onto the asparagine residue within the consensus amino acid sequon Asn-X-Ser or 
Asn-X-Thr (where X is any amino acid except proline) of the nascent polypeptide chain. Step 2: The 
polypeptide chain acquires its secondary, tertiary and quaternary structure by means of intra and 
intermolecular interactions and disulphide bonding. It is worth mentioning that the glucose ( ) 
residues participate in the proper folding of the amino acid backbone as quality control markers. 
All three glucose residues must be removed so that the properly folded protein can be secreted to 
the Golgi apparatus. Step 3: The glycoprotein is transported by means of vesicles to the Golgi 
apparatus. Steps 4 - 6: The oligosaccharide structure bound to the polypeptide backbone is 
modified by a series of sugar trimming and addition reactions. The trimming reactions remove 
mannose ( ) residues from the oligosaccharide. The sugar-transfer reactions add N-
acetylglucosamine (GlcNAc) ( ), fucose ( ), galactose ( ) and N-acetylneuraminic acid (sialic 
acid or Neu5Ac) ( ) residues to the oligosaccharide chain. All of these reactions are catalysed by 
enzymes whose concentration varies from one compartment of the Golgi apparatus to the other.62, 
63 Step 7: Once the oligosaccharide is processed within the Golgi apparatus, the cell secretes the 
glycoprotein to the extracellular medium. 
 
Additionally, complex-type oligosaccharides can contain a fucose residue bound to the 
GlcNAc that is attached to the asparagine of the protein backbone. Since it is bound directly onto 
the core of the oligosaccharide, this monosaccharide residue is commonly referred to as core 
fucose. The structure of complex oligosaccharides can also be seen in Figure 7. Hybrid-type 
oligosaccharides are a combination of high mannose and complex type oligosaccharides. The α-
1,6 arm of the core has mannose residues attached to it as occurs in high-mannose-type 
oligosaccharides. The α-1,3 arm of hybrid-type oligosaccharides contains monosaccharides that 
correspond to the complex-type. Again, the structure for hybrid-type glycans can be seen Figure 
7. 
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Figure 7. Types of N-linked oligosaccharide structures 
Panel A shows a high mannose oligosaccharide, panel B shows a hybrid oligosaccharide and panel 
C shows a complex tetraantennary oligosaccharide with core fucosylation. The configuration of 
the bonds is also presented. The greek letter α or β represents the type of glycosidic bond and the 
numbers represent the carbon of the monosaccharides which form the bond. The core structure of 
simplified formula Man3GlcNAc2 is common for all structures and is shown inside the dashed 
boxes. 
Two levels of glycoprotein heterogeneity are associated with glycosylation. The first is 
termed macroheterogeneity and denotes the variation resulting from presence or absence of 
oligosaccharide structures at specific sequons on the amino acid backbone of the protein. 
Macroheterogeneity arises from perturbations in the synthesis of the precursor oligosaccharide 
or it not being adequately added to the nascent polypeptide chain during translation. The 
second type of glycosylation-associated variability occurs due to different levels of 
oligosaccharide processing within the Golgi apparatus and is named microheterogeneity. 
Microheterogeneity occurs due to variations in the sugar trimming and addition reactions that 
occur within the Golgi apparatus. Concentration of substrates (nucleotide sugar donors), 
enzyme availability and residence time of the glycoprotein within the Golgi apparatus all 
influence the extent with which these reactions occur. There are five types of sugar trimming 
and addition reactions in the Golgi apparatus depending on the enzymes that catalyse them and 
the substrates involved. These reactions can be seen in Figure 8. 
There are two families of mannosidases (ManI and ManII) in the Golgi, and their purpose is 
to catalyse the removal of mannose residues from the N-linked precursor oligosaccharide. There 
are five types of N-acetylglucosamine transferases (GnTI, GnTII, GnTIII, GnTIV and GnTV). These 
enzymes use uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) as substrate and add N-
acetylglucosamine (GlcNAc) residues to the glycopeptide oligosaccharide. Galactosyltransferase 
(GalT) is the enzyme which adds galactose (Gal) residues to the glycan by using uridine 
diphosphate galactose (UDP-Gal) as its substrate. The final type of enzyme that participates in 
the processing reactions within the Golgi apparatus is sialyltransferase (SiaT). This enzyme uses 
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cytosine monophosphate N-acetylneuraminic acid (denoted as either CMP-Neu5Ac or CMP-SA) 
as substrate and adds sialic acid residues (Neu5Ac or SA) to the asparagine-bound 
oligosaccharide.64, 65 
 
Figure 8. Oligosaccharide processing reactions of the Golgi apparatus29 
The oligosaccharide structures are trimmed by mannosidase reactions. Also, monosaccharides are 
added to the oligosaccharide by action of specific enzymes. The substrates for each of these 
reactions (UDP-GlcNAc, GDP-Fuc, UDP-Gal and CMP-SA), and the by-products (UDP, GDP and CMP) 
can be seen in this figure. 
2.3.1. Nucleotide sugar metabolism 
The substrates for the sugar addition reactions described in the previous section are the 
protein-bound oligosaccharide chain and the nucleotide sugar donors (NSD). As substrates for 
these reactions, their availability within the cell can affect both the macro and 
microheterogeneity of N-linked oligosaccharides. The availability and concentration of 
nucleotide sugars in the cell’s cytoplasm determines the rate at which the precursor 
oligosaccharide is synthesised on the membrane of the endoplasmic reticulum. If nucleotide 
sugar availability in the cytoplasm is low, the rate at which the precursor oligosaccharide is 
produced will also be low. When this occurs, the precursor oligosaccharide may be available in 
insufficient quantities for it to be added onto the N-glycosylation site(s) of the protein, thus 
affecting glycoprotein macroheterogeneity. Moreover, the concentration of nucleotide sugars 
within the Golgi apparatus determines the extent of processing reactions therein, thus affecting 
glycoprotein microheterogeneity as well. Mammalian cells are able to produce all of the 
required nucleotide sugars through metabolism by using simple carbon sources, such as glucose 
and glutamine, as inputs. Figure 9 presents an overview of the metabolic network that is used 
by mammalian cells to produce NSDs. The metabolic synthesis of nucleotide sugars is closely 
related to central carbon metabolism and energetic state of the cells.  In Figure 9, we see that 
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the nucleotide sugar metabolism consists of a series of enzyme-catalysed reactions whereby 
extracellular components, such as glucose, galactose, mannose and others, are sequentially 
modified to produce the NSDs. An interesting feature of the metabolic pathway is that all NSDs 
can be produced from a single carbon source, such as glucose, and an organic nitrogen source 
(such as glutamine) and that the entire pathway is highly interrelated. 
 
Figure 9. Nucleotide sugar metabolism in mammalian cells66, 67 
The solid arrows represent reactions while the dashed arrows represent transport into the cell 
(glucose, galactose, fructose, mannose, GlcN, fucose, ManNAc) and from the cytosol towards the 
endoplasmic reticulum or Golgi apparatus (UDP-GlcNAc, GDP-Fuc, UDP-Gal, CMP-Neu5Ac, UDP-
GlcA, UDP-GalNAc). The numbers in red enumerate the number of components in the pathway. 
2.4. Effects of glycosylation on mAb structure and function 
All IgG-based mAbs present a conserved N-linked glycosylation site at asparagine 297 of the Cγ2 
domains of their heavy chains. Numerous reports both for polyclonal and monoclonal 
antibodies have shown that the oligosaccharides bound to this site have a profound effect on the 
antibody Fc 3D structure and effector functions.25-27 Additionally, the variable region of IgG-
based mAbs may also contain glycosylated N-linked sequons. It has been found that in many 
cases where this occurs, the oligosaccharide structures of these sites influence the affinity of the 
mAb for its respective antigen.59, 68-71 However, the presence of oligosaccharides in these 
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fragments is relatively uncommon – between 15 and 20% of human polyclonal IgG contain Fab 
glycans.72, 73 Hence, this review will mainly focus on glycosylation of the Fc fragments of mAbs. 
Given this tight glycosylation-structure/function relationship, it is clear that adequate 
glycosylation of IgG-based mAbs is essential towards their use as therapeutics. The following 
section will review some of the efforts that have been made to analyze the impact mAb 
oligosaccharide profiles have on their structure and function. 
 
Figure 10. Common oligosaccharide structures on the Fc of mAbs 
The most common glycans on the Fc of mAbs are complex, biantennary structures with varying 
degrees of fucosylation, galactosylation, and sialylation.74-76 
Both heavy chains of the mAb are in close proximity to each other due to disulphide bonding 
and intermolecular interactions. This spatial constraint reduces the affinity of the 
glycosyltransferase enzymes, which are responsible for the addition of sugar residues to the 
growing oligosaccharide chain, for their substrates.77, 78 It is for this reason that the Fc 
oligosaccharides of mAbs are not as diverse as for other glycoproteins. This does not mean, 
however, that there is not a high degree of heterogeneity in these structures. Many studies have 
reported that the most common oligosaccharide structures bound to the Fc of monoclonal 
antibodies are of the complex, bi-antennary type with varying degrees of core fucosylation, 
bisecting GlcNAc, galactosylation and sialylation. The most commonly observed oligosaccharide 
structures on the Fc of IgG-based mAbs74-76 are schematically shown in Figure 10. 
Given the distribution of oligosaccharides bound to the Fc of mAbs, many research groups 
have focused on the influence these structures have on mAb function both in vivo and in vitro. 
Many anti-cancer mAbs rely on their ability to generate ADCC for the removal of cancerous 
cells.27, 49, 51 One of the findings that has attracted substantial interest by drug developers is that 
absence of core fucosylation of the oligosaccharide structures can increase ADCC dramatically –
up to 50 fold.79-82 Capitalizing on these findings, groups have developed methods for reducing or 
completely inhibiting fucosylation of mAbs. 
Mannose N-Acetylglucosamine (GlcNAc) Fucose
Galactose Sialic Acid
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The early efforts to increase ADCC by glycan engineering were based on over-expressing 
genes for GnTIII, which is the sugar-transfer enzyme that adds bisecting GlcNAc to the core 
mannose of the oligosaccharide.83 At that point it was thought that the presence of bisecting 
GlcNAc on IgG1-based mAbs contributed to enhanced ADCC. However, it was later observed that 
the addition of bisecting GlcNAc residues increased ADCC by competing with the addition of 
fucose to the oligosaccharide structures.81 Additional attempts involving over-expression of 
competing enzymes to reduce oligosaccharide fucosylation were made when GnTIII and 
mannosidase II (ManII) were over-expressed simultaneously to yield low-fucose Fc 
oligosaccharides.84 The other tendency has been to either silence85, 86 or knock out87, 88 the 
fucosyltransferase genes in mAb-producing cell lines. 
It is worth noting that there is a risk in genetically modifying cell-lines. It is possible that 
extensive engineering of the endogenous (native) glycosylation pathways in cells could lead to 
negatively impacting their growth profile or protein productivity. With this in mind, additional 
strategies based on disrupting other pathways involved in N-linked glycan biosynthesis have 
been developed. Reduction in core fucosylation of mAbs has been achieved by supplementing 
culture medium with fucose analogues that inhibit the activity of GDP-mannose dehydratase. 
This enzyme is responsible for synthesizing GDP-fucose which, in turn, is the direct precursor 
for glycan core fucosylation; thus, inhibition of its activity leads to reduced fucose content on 
mAb Fc glycans produced under these conditions.89 A similar strategy that has been employed is 
to add castanospermine (CS) to culture medium. CS is a mannosidase inhibitor and, as such, 
prevents cleavage of mannoses from early glycoproteins, thus yielding lower fucosylation.90 
Although fucosylation is prevented with the CS strategy, high mannose structures are produced. 
It has been widely reported that mAbs with high mannose glycans have reduced serum half-life 
in patients, an effect likely due to recognition by the mannose receptor of macrophages.91-93 
Given the synthesis of undesirable high mannose glycans, applicability of the CS strategy is yet 
to be confirmed. 
Other interesting findings have revealed that mAb Fc glycans also influence CDC induction 
either by binding to the C1q component of the complement94, 95 or by interaction with the 
mannose binding lectin (MBL).96, 97 Specifically, it has been shown that absence of galactose on 
mAb Fc glycans yields lower affinity of this fragment for the C1q component of the complement 
cascade.25, 98 It has also been reported that non-galactosylated Fc glycans interact with the MBL, 
and can thus activate the complement cascade.96, 97 Similarly to the glycosylation engineering 
attempts made to increase ADCC, close attention should be given to glycosylation profiles of 
mAbs when their therapeutic mechanism relies on CDC. 
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In contrast to glycans suitable for eliciting cytotoxic effector functions, the oligosaccharide 
structures of mAbs used for the treatment of autoimmune disorders should modulate the 
immune response of patients. Studies on therapeutic intravenous IgG (IVIG) have found that the 
presence of terminal sialic acid residues on the oligosaccharides of their Fc fragments has great 
influence on their anti-inflammatory effect.54-56 IVIG must be administered in high doses (1-2 
g/kg) to achieve anti-inflammatory effects. This has been found to correlate with the fraction of 
IVIG that contains α2,6-bound terminal sialic acid residues on their Fc oligosaccharides.54 Again, 
certain cell lines have been engineered to ensure that sialic acid addition to glycoproteins is 
adequate.99-101 
Viewing the information presented in this section under the QbD scope, it is possible to 
consider different glycan profiles as integral components of the quality target product profile 
(QTPP) of mAbs. Following the definition of QTPP, the ideal glycosylation profile of an ADCC-
based therapeutic mAb would contain no core fucosylation. Similarly, a mAb whose therapeutic 
function relies on CDC would be fully galactosylated and a mAb developed for immune response 
modulation would be sialylated. Furthermore, given the importance Fc glycosylation has on 
mAb safety and therapeutic efficacy, the composition and distribution of these carbohydrate 
structures must be considered critical quality attributes (CQAs) of these molecules.  Defining 
glycans as CQAs of mAbs implies that their composition and distribution must be monitored and 
controlled within ranges that ensure product safety and therapeutic efficacy throughout process 
development and manufacture. 
2.5. Effects of bioprocess conditions on protein 
glycosylation 
Having defined Fc glycosylation as a CQA of mAbs, the next step in QbD is to determine which 
manufacturing process inputs affect the CQAs and – mechanistically – how this occurs. 
Monoclonal antibodies are produced by culturing mammalian cells, and as is common for these 
processes, nutrient availability, dissolved oxygen, supplements, temperature, operation 
schedule and culture modes can all influence product quality. The following section will present 
the extent at which these process inputs have been reported to influence the composition and 
distribution of N-linked carbohydrates on therapeutic glycoproteins. It will also provide 
mechanistic descriptions of how these inputs have been proposed to impact glycan composition 
and distribution. Other reviews on these topics are available.28, 29, 102 
2.5. EFFECTS OF BIOPROCESS CONDITIONS ON PROTEIN GLYCOSYLATION 24 
 
 
2.5.1. Nutrient availability 
Several studies have demonstrated that carbon source and its availability has great influence on 
therapeutic protein glycosylation.103 The impact of carbon source availability has been observed 
to affect both the site occupancy (macroheterogeneity) and glycan profile (microheterogeneity) 
of glycoproteins. Experimental findings indicate that when monosaccharides other than glucose 
are used as the main source of carbon for cell growth, the glycoform is affected.104 For example, 
Tachibana et al.105 observed differential glycosylation on the Fab of a monoclonal antibody due 
to substitution of glucose by fructose, mannose and galactose. The effects of carbon source on 
protein glycosylation are likely due to the differential efficiency with which cells channel 
monosaccharide inputs through the nucleotide sugar pathway. This, in turn, explains the effects 
that complete carbon source replacement has on both macro and microheterogeneity, as 
reviewed by Goochee & Monica.103 However, quantitative information on the effect of carbon 
source on intracellular nucleotide sugar pools and protein N-glycosylation is still lacking, and 
few direct links have been established. 
Studies on the impact of carbon availability on protein glycosylation have mainly involved 
glucose as the primary carbon source and glucosamine as a supplement. Hayter and 
collaborators106 found that when glucose concentrations varied from 0.3 mM to 0.8 mM within a 
chemostat, the fraction of fully glycosylated interferon gamma (IFN-γ) went from around 50% 
to 70%, while the proportion of non-glycosylated IFN-γ went from 20% to below 5%. However, 
it was not until key research by Nyberg and collaborators107 that the decrease in site occupancy 
of IFN-γ under glucose and glucosamine starvation was explained. They found that site 
occupancy issues occurred most likely due to low biosynthesis of UTP and glucosamine-
phosphate, which are both substrates for the production of UDP-GlcNAc. In turn, UDP-GlcNAc is 
a fundamental substrate for the production of the precursor oligosaccharide on the membrane 
of the endoplasmic reticulum. If UDP-GlcNAc is not available, the precursor oligosaccharide 
cannot be synthesized, and hence, the first step of N-glycosylation cannot proceed. 
The findings by Nyberg et al.107 were complemented when Wong et al.108 observed that 
despite controlling glucose and glutamine concentrations to low values (0.7 mM of glucose and 
0.1 mM of glutamine) within a fed batch system, no site occupancy issues arose. Through their 
findings, this group concluded that only extreme glucose starvation (concentrations below 0.35 
mM) reduced protein productivity and generated site occupancy issues. However, they did 
observe changes in the microheterogeneity of their model glycoprotein. These consisted in 
lower sialylation and increased production of high mannose oligosaccharide structures. These 
negatively affect IgG effector functions,91, 94 as well as increasing mAb clearance rates from 
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human sera, which further reduces their therapeutic efficacy.91, 92, 109 An additional 
consideration comes from the fact that highly sialylated oligosaccharides on the Fc of mAbs 
increases their anti-inflammatory capacity.54, 56 It is advantageous for mAbs relying on 
inflammatory responses (ADCC and CDC) to contain low levels of sialylation, whereas for anti-
inflammatory mAbs high proportions of sialylated Fc oligosaccharides are desired in order to 
increase their therapeutic efficacy. 
Both Nyberg et al.107 and Wong et al.108 proposed that the effect of nutrient limitations on 
protein glycosylation was most likely due to a decline in intracellular availability of UDP-GlcNAc. 
This can be explained through the glycosylation process within the Golgi apparatus and 
nucleotide sugar metabolism. The initial steps of N-glycan processing are sequential trimming 
reactions whereby mannose residues are cleaved from the Man8GlcNAc2 oligosaccharide to 
yield Man5GlcNAc2, as can be seen in Figure 7. At this point, the first sugar transfer reaction 
occurs, which is the GnTI (N-acetylglucosaminyltransferase I) catalysed addition of a GlcNAc 
residue to the α-1,3 branch of the core oligosaccharide. The substrates for this reaction are the 
oligosaccharide chain bound to the protein and UDP-GlcNAc. If this reaction does not occur, the 
subsequent reactions of glycan processing in Golgi cannot proceed, and the resulting 
oligosaccharide structure will be of the high mannose variety. 
The reduction in sialylation can be explained by the biosynthetic pathway of CMP-Neu5Ac, 
which is the substrate required for addition of sialic acid (Neu5Ac). The primary substrate for 
this pathway is ManNAc, which is, in turn, produced through the enzymatic modification of 
UDP-GlcNAc. Again, if low levels of UDP-GlcNAc are available within the cell, very little ManNAc 
will be produced through UDP-GlcNAc, and thus very low levels of CMP-Neu5Ac will be 
available as substrates within the Golgi apparatus. Furthermore, it has been shown that addition 
of ManNAc to cell culture media has considerably increased the sialylation of produced 
glycoproteins.110 Contradictorily, no such effects were observed when UDP-GlcNAc was added 
to the medium, but this has been attributed to the fact that high cytosolic UDP-GlcNAc 
concentration limits the transfer of CMP-Neu5Ac into the Golgi apparatus.111 These internal 
control loops give evidence of the sophisticated levels of intracellular organization surrounding 
the protein glycosylation processes. 
2.5.2. Dissolved Oxygen 
Another process parameter linked to mAb glycosylation is dissolved oxygen availability. The 
observed effects of dissolved oxygen tension appear to vary depending on glycoprotein and cell 
line. High values of dissolved oxygen tension (DOT) (100% DOT) have been reported to 
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decrease the sialic acid content of an erythropoietin-antibody crystallisable fragment fusion 
protein (EPO-Fc) produced in Chinese hamster ovary cells (CHO),112 whereas Chotigeat and 
collaborators113 observed increased sialylation of human follicle stimulation hormone (hHFS) 
expressed in the same cell line at a dissolved oxygen tension (DOT) of 90%. Moreover, 
Gawlitzek et al.114 and Trummer et al.112 observed that reduced dissolved oxygen (0% to 10% 
DOT) had no observable impact on sialylation.  
Table 2. Effect of dissolved oxygen tension (DOT) on protein N-glycosylation29 
Additionally, it has been reported that mice, when grown under hypoxic conditions, produce 
transferrin with increased core fucosylation and IgG with reduced core fucose residues.116 High 
values of dissolved oxygen have also been reported to increase the galactose content of mAb 
glycans.115 This group observed that higher galactosylation occurred at a DOT of 100% and was 
significantly lower at DOT of 10%. The extent of galactosylation impacts the effector functions 
generated by mAbs94 and has even been described as possibly being the optimal mAb glycoform 
for FcγR binding.26 As mentioned earlier, FcγR binding is fundamental for eliciting effector 
functions, and thus is crucial for effectiveness of the mAb as a therapeutic. 
Despite the efforts that have been made to understand the interplay between dissolved 
oxygen and glycosylation, the mechanisms by which this occurs have yet to be defined.102 The 
main hypothesis as to why galactosylation increases with dissolved oxygen concentrations is 
that the intracellular concentration of uridine diphosphate galactose (UDP-Gal) increases with 
dissolved oxygen concentrations. Tentatively, it could be possible to relate increased UDP-Gal 
concentrations at high dissolved oxygen values through nucleotide sugar metabolism. Kunkel 
and collaborators115 found that high values for dissolved oxygen generated shifts in the energy 
metabolism of the cultured cells, and that these shifts included higher flux of glucose through 
the glycolysis pathway, of which the first intermediary is glucose-6P. Glucose-6P serves as an 
early precursor of UDP-Gal biosynthesis, and the increase in its production could, at least in 
part, account for the higher availability of UDP-Gal for oligosaccharide processing within Golgi. 
PRODUCT CELL LINE DOT EFFECT 
Human follicle 
stimulating hormone 
(hFSH) 
CHO 10 - 90% Maximum sialylation at 90% 
DOT113 
Interleukin-2-N-
glycosylation variant 
BHK-21 0 and 100% No effect on glycosylation at 0% 
DOT114 
IgG1 mAb Murine hybridoma 
CC9C10 
0, 50 and 100% Galactosylation increases with 
DOT115 
EPO-Fc CHO 10, 30, 50, 70, 90 
and 100% 
No effect observed from 10 to 90%. 
Loss of sialylation at 100% DOT112 
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2.5.3. Ammonia and pH 
The effect ammonia concentration and pH have on protein glycosylation is closely related. 
Ammonia concentration and pH have been reported to have a synergic effect on protein N-
glycosylation macroheterogeneity. Borys and collaborators117 found that when increasing 
ammonia concentration from 0 to 9 mM, the fraction of heavily glycosylated mouse placental 
lactogen-I (mPL-I) went from 90% to 25% at a pH of 8.0, from 90% to 65% at a pH of 7.6 and 
from 90% to 80% at a pH of 7.2. 
Increasing concentrations of ammonia (from 1 mM to 15 mM of NH4Cl) have been observed 
to reduce the galactosylation and sialylation of a tumour necrosis factor-IgG fusion protein up to 
40%.118 It was concluded that accumulation of NH4+ affects N-glycosylation by increasing the pH 
of the Golgi compartments to levels at which the GalT (β1,4-galactosyltransferase) and the SiaT 
(α1,3-sialyltransferase) enzymes have lower activities. It has also been reported that high pH 
values cause mislocalization of the ManII, GnTI, GalT and SiaT glycosyltransferase enzymes 
along the Golgi apparatus.119, 120 This mislocalization, in turn, has been associated with lower 
galactosylation and sialylation of N-linked glycans.120Additional findings by Gawlitzek et al.121 
showed that ammonia concentrations of 15 mM increased branching on the N-glycans of a 
recombinant interleukin-2 produced in BHK-21 cells. This was observed to correspond with an 
increase in availability of UDP-GlcNAc and UDP-GalNAc. Both reports by Gawlitzek and 
collaborators118, 121 are consistent given that there is an inverse relationship between UDP-Gal 
and UDP-GlcNAc. The more UTP that is consumed within the cell to produce UDP-GlcNAc, the 
less there is to produce UDP-Gal. 
Borys and collaborators117 observed that glycosylation was relatively unaffected in a pH 
range between 6.9 and 8.2 at low ammonia concentrations. However, they did find decreased 
site occupancy at pH values outside that range. Yoon et al.122 found that the sialic acid content 
decreases from 68% to 40% between a pH range of 6.8 and 7.8. This is likely due to decreased 
GalT and SiaT activities at high Golgi pH values reported by Gawlitzek et al.118 The relationship 
between galactosylation and sialylation with pH has also been observed by Muthing et al.123 This 
group found that culture medium pH values of 7.4 yielded the highest proportion of fully 
galactosylated oligosaccharides in a murine IgG3 monoclonal antibody, whereas the lowest 
levels of sialylation occurred at a pH of 6.9. These results are also consistent and possibly due to 
decreased GalT and SiaT activities at high pH,118 but also may be due to glycosyltransferase 
mislocalization in Golgi.120 
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2.5.4. Cell culture viability, growth phase and temperature 
The manner in which temperature affects protein N-glycosylation has been related to cell 
viability and cell growth stage.124-126 These research groups have proposed that decreased 
temperatures maintain cell viability over longer periods of time, and that protein glycosylation 
occurs more efficiently under these high-viability conditions. This is consistent with previous 
research that has shown that the genes involved in the synthesis of the precursor 
oligosaccharide on the membrane of the endoplasmic reticulum are up-regulated during the 
transition between growth stage 0 (G0) and growth stage 1 (G1).127 
Additionally, Ahn and collaborators (2008) found that at temperatures below 32°C, 
branching and sialic acid content of EPO produced in CHO cells decreased when compared to 
the glycoforms produced at 37°C. This correlates with previous observations where the 
intracellular pool of UDP-GlcNAc and UDP-GalNAc were found to decrease at lower 
temperatures.128 This implies that there is an optimum temperature for N-linked glycosylation 
where production of the precursor oligosaccharide is the highest permitted by availability of 
UDP-GlcNAc. 
2.5.5. Serum and lipid supplements 
The effect of lipid supplements on N-linked glycosylation has been reported by Jenkins and 
collaborators.129 This group observed that by supplementing the culture medium with a mixture 
of bovine serum albumin (BSA) and lipids, site occupancy increased greatly, when compared to 
their control experiments. They proposed that this increase in site occupancy was either due to 
absence of possibly toxic oxidised lipids which are found in conventional BSA preparations or 
due to the availability of additional lipids which favour glycosylation. Jenkins et al.129 also 
observed that the duration of the growth phase of the culture increased when a lipid 
supplement was added to the medium during the late log phase of the culture. Similarly to 
temperature, a prolonged growth phase could also account for increased N-glycosylation site 
occupancy. 
Another cell culture factor that has been observed to affect N-linked glycosylation is the use 
of chemically defined or serum-supplemented culture media. The desire to avoid animal-
derived components in cell culture media has led several research groups to analyse the effects 
of supplements on N-glycosylation of therapeutic mAbs. Lifely and collaborators79 produced the 
IgG-based mAb CAPMPATH-1H by culturing CHO cells in either serum supplemented or serum 
free media. They found that the major oligosaccharides bound to CAMPATH-1H in both cultures 
were the same; however, they also found that the product derived from serum free media had 
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less mono and bi-galactosylated species. Lifely et al.79 observed that the relative amount of 
sialylated species was higher for the serum free culture than for its non-supplemented 
counterpart. Gawlitzek et al.114 produced recombinant interleukin-2 in BHK cells in absence or 
presence of fetal calf serum, and found that the serum free cultures increased the core 
fucosylation and sialylation levels on the glycan structures of their product. The latter is 
consistent with the findings by Lifely and collaborators.79 An additional study quantified the 
effect of serum supplementation, serum-free preparations and chemically-defined media on the 
oligosaccharide profiles of a mAb produced by hybridoma cell lines.130 They observed that 
serum-supplemented cultures produced broader distributions of glycans when compared to the 
serum-free and chemically-defined media. They also observed clear differences in the 
oligosaccharide profiles derived from each of their culture media. They found higher 
galactosylation when they used serum-supplemented and chemically-defined media compared 
to when they used serum-free media. Moreover, they observed reduction of sialylation but 
increases in the amount of core fucosylation in serum-free and chemically-defined media. As 
seen above, the effects of serum supplementation on the oligosaccharide profiles of 
glycoproteins has been reported to be consistent throughout. However, because some of the 
components of serum preparations are unknown, the mechanisms by which these effects occur 
are not fully understood. 
2.5.6. pCO2 and osmolality 
The effect of CO2 partial pressure (pCO2) and osmolality of culture media on the oligosaccharide 
moieties of a mAb have been reported.131 They observed that the macroheterogeneity of an 
IgG2-based mAb was unaffected at elevated values of pCO2 (up to 250mmHg) and osmolality 
(up to 476 mOsm/kg). They also found that, while controlling osmolality at 320 mOsm/kg, 
elevating pCO2 increased mAb galactosylation, but at controlled pCO2 (either at 40 mmHg or 195 
mmHg) high osmotic stress (435 mOsm/kg) negatively impacted galactose content by 5% and 
25% respectively. They concluded by proposing that the reduction in galactosylation was due to 
increased pH of the Golgi apparatus. As mentioned previously, other research groups have 
proposed that the GalT (β1,4-galactosyltransferase) enzyme has reduced activity at high Golgi 
pH values.118, 132 Elevated pH of the Golgi apparatus due to elevated pCO2 and hyperosmotic 
stress may be the underlying reason for the effects observed by Schmelzer & Miller.131 However, 
these authors mention that measurements of Golgi pH under these conditions are still lacking. 
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2.5.7. Stirring speed 
Another very important process parameter is stirring speed. Adequate stirring within cell 
culture environments ensures that all cells receive equal amounts of nutrients, oxygen and heat. 
However, excessive stirring can cause the cells in culture to become stressed, and thus affect 
their viability, mAb productivity and mAb quality (including glycosylation). Only the effect of 
shear stress on site occupancy has been investigated.133 This group found that while increasing 
stirring speed from 40 to 200 rpm (with corresponding Reynold’s number (Re) values of 
1.87x103 and 9.31x103), the fraction of underglycosylated Tissue-Type Plasminogen Activator 
(tPA) increased from 31% to 72%. 
They proposed that at high stirring rates (high shear stress), cells respond by up-regulating 
membrane synthesis, increasing the rigidity of their membranes by additional synthesis of 
cholesterol and overall increase in protein synthesis, all at the expense of lower doubling rates. 
Of these, the factor to which they attribute lower site occupancy is the higher rate of protein 
synthesis. They concluded that at higher protein synthesis rates, the retention time of 
glycoproteins within the endoplasmic reticulum decreases, and because of this, N-glycan site 
occupancy is negatively affected. 
2.5.8. Culture modes and operation schedule 
Much of the research that has aimed to elucidate the effects of process conditions have been 
carried out in different cell culture systems. These culture systems have mainly been batch 
bioreactors,79, 107, 110, 112, 117, 118, 124, 129, 131-136 continuous bioreactors107, 114, 121, 126, 137 and fed-batch 
bioreactors.107, 108, 124, 136, 138 Additionally, more complex systems have also been used, such as 
hollow fibre bioreactors,79 biphasic bioreactors139 and microcarrier-immobilised cells in 
fluidised bed bioreactors.114 It is more suitable to discuss the effects batch cultures, perfusion 
cultures and fed-batch systems have on product N-glycosylation because these are the culture 
modes that predominate in the biopharmaceutical industry and because the more complex 
culture systems have been used for research purposes. 
The relationship between product N-glycosylation and cell culture mode can directly be 
linked through the metabolic effects presented previously in this section. Each of these three 
culture modes implies different cell growth and viability, nutrient consumption and metabolite 
production profiles. In a simple batch system, N-glycosylation issues arising from cell growth 
stage, cell culture time, nutrient availability and metabolite production would all be expected to 
occur, although they could be relatively offset by selecting optimal batch times or by reducing 
temperature to ensure a favourable growth stage for protein productivity and glycosylation.125, 
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126, 137 In a fed batch reactor, nutrient availability issues would be resolved, but the rest of the 
drawbacks would still be present. For these systems, accumulation of metabolic by-products 
and the effects of cell culture time on N-glycosylation would be predominant. However, these 
issues could be addressed through the same means as for normal batch systems. The major 
advantages for batch and fed batch systems are their simplicity, their flexibility to be used for 
the manufacture of several different products and their relatively high yields and final product 
concentrations.140 Contrastingly, continuous bioreactors offer more control over most of the cell 
culture conditions. Nutrient depletion is addressed by continuous addition of culture media; 
metabolic by-product accumulation is resolved by continuous removal of cell culture medium, 
and cell culture age, cell viability and cell growth stage can all be manipulated by the dilution 
rate of the continuous system and cell recirculation. For example, Nyberg et al.107 reported that 
low dilution rates reduce N-glycosylation site occupancy due to nutrient limitations. Ahn and 
collaborators126 also observed the effect of dilution rates on the microheterogeneity of a mAb. 
They found that galactosylation decreased with lower dilution rates (from 0.2 to 0.3 d-1) and 
proposed that this effect occurred because the concentration of metabolites, such as NH4+, 
inhibited mAb galactosylation as had been previously described.118, 132 Moreover, Ahn et al.126 
observed an increase in galactosylation at higher dilution rates (between 0.5 and 0.8 d-1) which 
could be explained by higher nutrient availability, a cell growth stage more favourable for N-
glycosylation or lack of inhibitory metabolite (NH4+) effects under those conditions. 
2.5.9. Cell line 
The choice of production cell line also has a significant effect on the microheterogeneity of mAb 
Fc glycosylation. The expression of glycosyltransferase enzymes and glycosidases varies from 
one cell line to another.141 Since these enzymes catalyse the monosaccharide trimming and 
addition reactions that occur in Golgi, their concentration and distribution along the secretory 
pathway determine the extent of oligosaccharide processing and overall glycan distribution of 
secreted proteins. The cell lines which are more commonly used for the production of mAbs are 
CHO and NS0, although other cell lines, such as Sp/0, Y0 and human lymphoma clones, have also 
been employed to a lesser extent. As the most common hosts for mAb production, the 
glycosylation profiles produced by NS0 and CHO have been compared frequently.45, 79, 142-144 All 
these studies have observed that while CHO cells produce bi -galactosylated glycans where each 
galactose residue has a β−1,4 bond with the preceding GlcNAc on each antenna of the 
oligosaccharide (row 3, Table 3), NS0 cell lines generate bi-galactosylated structures with two 
galactose residues on one of the antenna. This occurs because murine-derived cell lines encode 
genes for glycosyltransferase enzymes which can add galactose residues with an α-1,3 
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glycosydic bond to a preceding galactose residue (row 4, Table 3). Significance of these α-1,3-
bound galactose residues is highlighted by a report that found these motifs produced 
anaphylactic reactions in patients.145 Beck and collaborators143 also found that despite CHO and 
NS0 generating the same predominating oligosaccharide structures, the relative abundance of 
these three is different in both cell lines (rows 1 to 3, Table 3) 
Table 3. Differences between mAb glycosylation profiles between the CHO and NS0143 
Raju et al.141 carried out a study in which they compared the serum IgG oligosaccharide 
structures of several species including human, rat, mouse and guinea pig. They found clear 
species-specific differences in the type of sialic acid residues on the oligosaccharides. They 
observed that human oligosaccharides only contained N-acetyl neuraminic acid (NANA), while 
mouse glycans contained N-glycolylneuraminic acid (NGNA) residues and rat glycans contained 
both NANA and NGNA. Additionally, this group found that the proportion of monogalactosylated 
isomers varied considerably from species to species. They attributed these differences to a 
species-dependent specificity of the β1,4-galactosyltransferase enzymes for either one or the 
other antenna on the complex oligosaccharide structures. 
Lifely and collaborators79 (1995) also used the Y0 cell line to produce a version of the 
CAMPATH mAb. They found that this cell line introduced bisecting GlcNAc to the central 
mannose of the core oligosaccharide structure. Stadlmann et al.45 compared the glycoforms of 
commercial mAbs produced in these expression systems and found similar discrepancies 
between the oligosaccharide profiles produced by CHO and NS0. This group also measured the 
oligosaccharide profiles of an anti-HIV mAb generated by a human lymphoma cell line, and they 
observed that its oligosaccharides were more heavily galactosylated and sialylated. In addition, 
this group also determined the IgG Fc glycosylation patterns of guinea pigs and observed that 
the predominating oligosaccharides were mono and di-sialylated structures with bisecting 
GlcNAc. 
NAME STRUCTURE CHO NS0 
G0F 
 
61% 15% 
G1F 
 
36% 53% 
G2F 
 
3% 26% 
G2F (α-1,3) 
 
No α-1,3 Gal bonds are 
produced 
This bond is produced 
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Another promising tendency in the biopharmaceutical sector has been to explore the 
production of biological therapeutics in more robust expression systems, such as bacterial, 
yeast, insect or plant cells. From the preceding paragraph, which mentions glycosylation pattern 
variation among different mammalian cell lines, it can be inferred that the differences should 
increase as the evolutionary distance of the production cell lines diverges from mammals. 
Interestingly, a form of N-linked glycosylation has been described in bacteria of the 
Campylobacter genus.146-148 However, the N-linked carbohydrates produced by these bacteria 
are relatively simple (only three constituting monosaccharide species).146-149 Speculatively, it is 
possible that higher complexity of glycan structures is achievable exclusively in eukaryotes 
given that they have internal compartmentalisation (i.e., presence of the Golgi apparatus).  
Accordingly, native yeast cells are capable of glycosylating proteins; however, they lack 
many of the transferase enzymes of the Golgi apparatus, and thus generally produce only high 
mannose oligosaccharide structures.101, 150, 151 Plant cells express most of the required enzymes; 
however, they have additional transferases that can add non-mammalian sugars such as xylose, 
mannose and fucose to complex oligosaccharides.152 Finally, certain insect cell lines also contain 
many of the glycosyl transferase enzymes necessary to produce glycoforms similar to those 
found in mammalian systems.153-155 However, many differences have been found between the 
resulting glycoforms produced by these and mammalian cell lines. Most insect cell lines lack 
critical enzymes which participate in the biosynthetic pathway of the nucleotide-sugar 
precursor CMP-SA (cytosine mono phosphate sialic acid). Because of this, these cell lines are 
incapable of adding sialic acid residues to N-linked oligosaccharides.154 
Insect cell lines have also been reported to lack certain transport proteins of nucleotide 
sugars (the co-substrates of the sugar-addition reactions within the Golgi apparatus) on the 
surface of the Golgi membrane. This reduces the concentration of co-substrates of the sugar 
addition reactions which, in turn, results in the synthesis of incompletely processed 
oligosaccharide structures by these cell lines.156 Additionally, the low activity or absence of 
certain glucosyl transferase enzymes (such as GnTII with ~1% of the activity of mammalian 
GnTII) in the Golgi apparatus,157 along with the presence of enzymes which limit (such as 
GlcNAcase) or impede the synthesis of human-type glycoforms has also been reported within 
insect cell lines.158 
Despite the broad differences between the glycosylation patterns of alternative expression 
systems and mammalian cell lines, many promising advances have been achieved. Examples of 
these advances are the production of mammalian-like oligosaccharides in yeast cells,150, 151, 159, 
160 galactosylated oligosaccharides in insect cell lines,161 galactosylated oligosaccharides in 
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plants,162 controlled glycosylation of mAbs in plants152 and optimised glycosylation of mAbs in 
plants.163 
Table 4. Impact of bioprocess inputs on protein N-glycosylation23 
Process 
Condition 
Product/Cell Line: Effect Proposed cause(s) 
Nutrient 
availability 
mAb/human hybridoma: change in 
microheterogeneity when glucose is substituted by 
fructose, mannose and galactose 
Differential efficiency with which the 
cells consume the different carbon 
sources105 
IFNγ/CΗΟ:  site occupancy on at glucose<0.3mM  Low biosynthesis of UTP and 
glucosamine 6- phosphate106, 107 
IFNγ/CΗΟ:  sialylation and  high mannose 
glycans at  0.35mM <glucose<0.7mM and 
glutamine at  0.1mM 
Decline of UDP-GlcNAc synthesis108 
Dissolved O2 
(These effects 
depend on cell line 
and product) 
EPO-Fc/CHO: no effect between 10-90% DOT,  
sialylation at 100% DOT 
Mechanism not defined112 
hFSH/CHO: maximum sialylation at 100%DOT Mechanism not defined113 
IL-2 glycovariant/BHK-21: no effect at 0% DOT Mechanism not defined114 
IgG1 mAb/murine hybridoma CC9C10: 
galactosylation with  DOT 
UDP-Gal increases with DOT due to 
increased flux through glycolysis115 
Ammonia and pH 
(The effect 
between  NH4+ and 
pH is synergic) 
mPL-I/murine:  site occupancy on at 9mM NH4+ Mechanism not defined117 
TNF-IgG/CHO: 40%  in galactosylation and 
sialylation 
pH inhibits GalT and SiaT activities118 
pH causes GnTI, ManII, GalT and SiaT 
to mislocalize in Golgi119, 120 
IL-2/BHK-21:  branching in at 15mM NH4+ 
Concentration of UDP-GlcNAc and 
UDP-GalNAc reduces the concentration 
of UDP-Gal121 
EPO/CHO:  sialylation of at 10mM NH4+ 
Concentration of UDP-GlcNAc 
decreases transport of CMP-Neu5Ac into 
Golgi111, 132 
mPL-I/murine: 28% sialylation at 6.8<pH<7.8 
pH inhibits GalT and SiaT activities. 
pH causes GnTI, ManII, GalT and SiaT 
to mislocalise in Golgi117 
Highest levels of IgG3 mAb/murine hybridoma 
galactosylation at pH=7.4, lowest levels of 
sialylation at pH=6.9 
pH inhibits GalT and SiaT activities. 
pH causes GnTI, ManII, GalT and SiaT 
to mislocalize in Golgi123 
Viability, growth 
phase and 
temperature 
EPO/CHO:  branching at 32°C<T<37°C 
 temperature decreases UDP-GlcNAc 
and UDP-GalNAc concentration126 
Serum and lipid 
supplements 
 
 
IFNγ/CHO:  branching with lipid 
supplementation129 
Mechanisms not understood because 
serum composition is unknown 
IgG1/CHO:  sialylation with serum-free 
medium79 
IL2/BHK-21:  fucosylation and  sialylation 
with serum-free medium114 
mAb/murine hybridomas: broader glycan 
distribution and  galactosylation with BSA 
supplementation130 
pCO2 and 
osmolality 
IgG2/SP2/0: unaffected up to 250mmHg pCO2 
 galactosylation at 320mOsm/kg and high pCO2 
25%  in galactosylation at 195mmHg pCO2 and 
435mOsm/kg 
Osmotic stress induces pH which 
inhibits GalT and SiaT activities and 
causes them to mislocalize131 
Stirring speed tPA/CHO: 72%  site occupancy at 40<S<200rpm 
Shear stress increases protein syhtnesis 
wich reduces ER retention time133 
Culture modes 
I IFNγ/CHO: low dilution rates yield low site 
occupancy 
0.5<D<0.8day-1. 
Concentration of metabolites inhibits 
GalT and SiaT activity and mislocalises 
these compounds107 
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This section has reviewed the bioprocess inputs that have been reported to impact protein 
N-linked glycosylation. It has also discussed many of the mechanism by which these inputs 
influence glycan composition and distribution. A summary of the impact of bioprocess 
conditions on N-linked glycosylation is presented in Table 4. 
In the QbD context, this information should be used to define the design space of allowable 
process inputs that will ensure appropriate product quality. For example, the threshold for 
minimum glutamine availability during cell culture described by Nyberg et al.107 and Wong et 
al.108 can be used to establish a set of feeding strategies that ensure adequate site occupancy and 
antennarity of N-glycans. However, a fundamental consideration while establishing the design 
space under QbD is how combinations of different process inputs impact product quality. If the 
feeding strategies for glutamine were not to consider ammonia accumulation and the negative 
effects this would have on product quality,118 the design space would be too lax and would not 
provide quality assurance. Therefore, all known combinations of process inputs should also be 
used to establish a better constrained design space that will lead to product quality assurance. 
Although the interactions between process inputs and protein glycosylation have been 
reported, several of the underlying mechanisms responsible for these effects are still to be 
described mechanistically (e.g. dissolved oxygen, the synergy between ammonia and pH, serum 
supplementation and shear stress). It is therefore impossible to develop mechanistic 
mathematical models relating such inputs with protein glycosylation. Conversely, the 
mechanisms that have been described to a fuller extent are those which associate nutrient 
availability with protein N-linked glycosylation. More specifically, the mechanisms by which 
glucose and glutamine availability impact glycosylation have been clearly drawn and associated 
with cellular metabolism and the availability of key metabolites (nucleotide sugar donors – 
NSDs) for the glycan processing reactions in Golgi. For this reason, and given our objective of 
developing a mechanistic mathematical model that relates bioprocess conditions with mAb N-
linked glycosylation, glucose and glutamine availability throughout cell culture were defined as 
the process conditions to link with mAb Fc N-linked glycosylation in this work. 
2.6. Previous mathematical models for protein 
glycosylation 
Despite the relevance of N-linked glycosylation, few attempts have been made to model this 
phenomenon. Concretely, four models have been formulated over the past decade of which one 
addresses the attachment of the precursor oligosaccharide to the nascent polypeptide,164 and 
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the other three have focused on the oligosaccharide processing reactions within the Golgi 
apparatus.31-33 In the context of this research project, it has seldom been reported for 
monoclonal antibodies to have considerable macroheterogeneity. Therefore, this review will 
focus on the mathematical models that have been developed to address glycan 
microheterogeneity. 
Umaña & Bailey, 199731 
The first N-glycosylation model was developed by Umaña & Bailey in 1997. This group 
approximated the Golgi apparatus compartments to a series of four continually-stirred tank 
reactors connected in series. Within this framework, they defined a series of 33 
oligosaccharides which participate in 33 reactions catalysed by eight different enzymes. In 
order to define the kinetics for each of the reactions, Umaña & Bailey did a thorough revision of 
the literature available on the properties of the enzymes they considered for their work. The 
purpose of their model was to gain qualitative insight on the distribution of oligosaccharide 
structures represented by the model, and to simulate the effects of over-expression of certain 
enzymes within the system. They found that over-expression of GnT enzymes (III, IV and V) 
generated clear variations on the distribution of oligosaccharide structures. Additionally, they 
observed considerable qualitative oligosaccharide profile changes due to changes in protein 
productivity which, in the case of CSTR reactors, would affect the residence time of the 
glycoprotein within the Golgi compartments. 
Being the first attempt to mathematically model the glycosylation process within the Golgi 
apparatus, and that the purposes of their model were of a more qualitative nature, Umaña & 
Bailey made a series of simplifying assumptions. Among these simplifying assumptions, they 
considered few oligosaccharide structures and reactions and neglected the addition of fucose or 
sialic acid in their model. Additionally, when they developed their model little information on 
the mechanisms by which the enzymes work was available, which led Umaña & Bailey to use 
oversimplified enzyme kinetics. Finally, and likely also due to the aims of their mathematical 
model, they assumed no variation in the availability of nucleotide sugar donors within the 
compartments of the Golgi apparatus. This, while being useful for gaining qualitative knowledge 
on the distribution of oligosaccharides, isolated their system from extracellular conditions, thus 
impeding their model to represent external influences on the calculated oligosaccharide 
structures. 
Krambeck and Betenbaugh, 200532 
Eight years went by until the next mathematical model for protein N-linked glycosylation was 
developed. This second effort was made by Krambeck and Betenbaugh in 2005. They also 
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considered the Golgi apparatus as a series of four CSTRs in series, but their model was more 
ambitious than Umaña & Bailey’s since it considered the addition of core fucose, galactose, poly 
N-lactosamine and sialic acid into their model. The addition of these species increased the 
number of reactions to 22,871 and the number of possible oligosaccharide structures to 7,565. 
Krambeck and Betenbaugh based the kinetic parameters of their model on Umaña & Bailey’s, 
but had to add parameters to account for the additional enzymes and reactions. As part of their 
strategy, this group adjusted enzyme concentrations within the Golgi apparatus to match 
obtained glycosylation profiles with experimental data. Once this was done, they increased 
protein productivity and observed the differences in the oligosaccharide profiles and to what 
these differences were due to. Finally, they evaluated which metabolic engineering strategies 
could be implemented to ensure that, despite increased productivity, oligosaccharide profiles of 
their protein would remain unchanged. Given the sheer size and complexity of their model, 
Krambeck and Betenbaugh also included assumptions into their modelling framework. They 
considered that all kinetic mechanisms were the same for all oligosaccharide processing 
enzymes. However, they improved the reaction rate expressions by adding competitive 
inhibition terms which account for different substrates competing for a single enzyme. Again, 
since the aims of this mathematical model were to assess possible genetic engineering strategies 
for adequate glycosylation, this group also assumed the concentration of nucleotide sugar 
donors to be constant throughout the Golgi, uncoupling glycosylation from cellular metabolism. 
Hossler et al., 200733 
The most recent attempt to model protein N-linked glycosylation was published in 2007. Again, 
the aim of this modelling attempt was to gain insight into the physiology of glycoprotein-
producing cells and to evaluate possible cellular engineering techniques to minimise 
glycoprotein microheterogeneity. Based on recent findings supporting the Golgi maturation 
model over the stationary or classical Golgi model,165, 166 Hossler and collaborators modelled the 
system as 4 PFR reactors in series. This group considered 326 glycan species within their model, 
and do not report the number of reactions that participate in their system. Hossler et al. 
obtained kinetic parameters from the same sources the previous two studies had. Despite the 
similarities with the previous two models, this group generated additional insight into the 
modelling of this process by comparing the performance of two models, 4 PFRs and the 4 CSTRs. 
When comparing the results obtained from these models with experimental data, they found 
that the 4 PFRs present results closer to those obtained with the 4 CSTR model, which is further 
supports the Golgi maturation model. An additional strategy this group adopted was to optimise 
the proportion of terminally-processed oligosaccharide structures by adjusting the enzyme 
concentration and distribution along the different compartments of the Golgi apparatus and the 
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concentration of nucleotide sugar donors within each compartment. Finally, this group 
performed a sensitivity analysis on their model in order to assess which of its variables had 
higher impact on the calculated oligosaccharide profiles. Hossler et al. considered that all 
enzymes function with the same kinetic mechanism, and also included competitive inhibition 
terms into their enzyme catalysed reaction rate expressions. This group also assumed a 
constant concentration for nucleotide sugar donors within the compartments of the Golgi 
apparatus, which prevented accounting for metabolic effects on protein N-linked glycosylation. 
The modelling efforts presented above have all contributed towards understanding the N-
linked glycosylation process within the Golgi apparatus. However, because the objective of these 
research groups was to assess possible cell engineering strategies with their models, they do not 
consider cellular metabolism, and therefore, uncouple the glycosylation process from 
bioprocess conditions. However, it is clear from preceding sections of this thesis that a variety of 
bioprocess inputs influence protein N-linked glycosylation. In light of these limitations, the 
objective of this work was to bridge the gap and produce a mathematical model that 
mechanistically and quantitatively links nutrient availability with the glycosylation associated 
quality of mAbs by including cell culture dynamics and cellular metabolism. 
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2.7. Techniques for mAb glycosylation analysis 
A crucial element required for all steps of QbD implementation is process analytical technology 
(PAT). As was discussed previously, PAT is “a system for designing, analysing and controlling 
manufacturing through timely measurements of CQAs and performance attributes of raw and 
in-process materials and processes with the goal of ensuring final product quality.”167 In order 
to implement QbD for the development of processes that integrate N-glycosylation quality into 
the mAb product, accurate and high-throughput methods to determine the glycosylation-
associated CQAs of mAbs are fundamental. In line with this perspective, the need for rapid 
acquisition of information throughout the development of manufacturing processes has led to 
the adaptation, optimization and development of novel techniques for the analysis of 
glycoproteins and their corresponding oligosaccharides. This section will briefly discuss the 
techniques that have been used to determine, on a qualitative and quantitative basis, the 
oligosaccharide structures of mAbs. For further background, two reviews on the overall strategy 
for glycan preparation and analysis are available.168, 169 Broadly, there are three levels of 
information pertaining to the oligosaccharides of glycoproteins: 
Level 1: Identification of glycosylation sites (macroheterogeneity) 
This first level of investigation identifies the possible glycosylation sites of the mAb. In the case 
of IgG-based mAbs, the general procedure of glycosylation site identification is simpler than for 
other glycoproteins which have higher degrees of macroheterogeneity. As described earlier, 
each IgG-based mAb molecule contains two conserved N-linked glycosylation sites on its Fc 
fragment – located on the Cγ2 domains of the Fc fragment (Figure 4). 
The other possible N-linked glycosylation sites (appropriate Asn-X-Ser or Asn–X–Thr 
sequons) on the IgG molecule may occur on the variable regions of its Fab fragments. It has been 
estimated that between 10–20% of all IgGs contain Asn–X-Ser or Asn–X–Thr sequons in the 
variable regions of their Fabs.72, 73 Figure 11 presents two ways in which the protein backbone 
of mAb molecules can be cleaved. If N-glycosylation sites were to be found on the variable 
regions of the mAb, these could be identified by these digests. Reduction and acidification45, 170 
and papain digestion143, 171 have been performed on mAbs to analyze their macroheterogeneity. 
Additional glycosylation sites may appear in three arrangements:  on the variable region of the 
light chain (VL domain), on the variable region of the heavy chains (VH domain) or on both. For 
the two first cases, mAb digestion with papain yields two Fab fragments and a single Fc 
fragment. Isolating each of these permits distinguishing the source of the oligosaccharide chains 
(whether they belong to the variable regions or to the constant region). For the third case 
,which is less common, the mAb would have to be sequentially digested first by papain, and then 
2.7. TECHNIQUES FOR MAB GLYCOSYLATION ANALYSIS 40 
 
 
by chemical means to determine which oligosaccharide structures are present on each peptide 
fragment. 
 
Figure 11. Cleavage of the peptide backbone of mAbs29 
Reduction and acidification yield four peptide chains – two heavy chains and two light chains (A). 
Papain digestion produces three fragments – two Fab and one Fc (B). 
Another attractive strategy for finding additional glycosylation sites on IgG-based mAb 
samples is to perform collision induced dissociation (CID) experiments through mass 
spectrometry.45, 171 This method consists in randomly fragmenting glycoproteins while they are 
inside an ion trap (IT) cell of an MS instrument through bombardment with ions. The resulting 
mass spectrum of the fragmented sample yields information on the glycosylation sites of the 
molecule. 
Level 2: Glycan profiling (microheterogeneity) 
The second level of mAb glycoform characterization is to detect and quantify the different 
oligosaccharide structures bound to each of its glycosylation sites (mAb microheterogeneity due 
to glycosylation). Once the possible glycosylation sites have been identified and separated, the 
glycans are ready for analysis. At this point, two strategies can be used. The first investigates 
glycopeptides, which requires the protein backbone to be cleaved usually with trypsin to yield 
low molecular weight glycopeptides, which are then analyzed by the techniques described later 
in this section.45, 58, 144, 172 The second strategy is to remove the oligosaccharides from the protein 
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backbone. This can be achieved by chemical means (e.g. hydrazinolysis); however, enzymatic 
cleavage is more frequently used. The most common enzyme employed for this task is Peptide 
N-glycosidase F (PNGase F), which is known to have broad specificity and releases all N-linked 
glycans from the peptide backbone of the IgG-based mAbs. The released oligosaccharides or 
glycopeptides are then ready to be analyzed by any of the different techniques presented below. 
The objective of the analytical techniques is to identify which oligosaccharide structures are 
present and their abundance within the mixture. 
Level 3: Glycan structural analysis 
The third and most detailed level of mAb glycosylation is structural analysis. Given that the 
linkages between the constituting monosaccharides of glycans may vary, these must also be 
characterized to obtain the intramolecular structures of the oligosaccharides bound to mAbs. In 
order to generate structural information, a series of sequential enzyme-catalyzed reactions that 
remove monosaccharides from the oligosaccharide, must be performed.59, 78, 79, 109, 130, 142, 173 The 
key to finding the types of bonds that occur between the different monosaccharides are the 
enzymes that are used. Certain glycosidases have such high specificity that they will be able to 
cleave an α-1,3 glycosidic bond, but not an α-1,6. If the sequence of the reactions is planned 
properly, and the products (both monosaccharides and oligosaccharides) are quantified 
accurately by any of the analytical techniques presented below, the bond structure of the 
original glycan can be obtained. An additional strategy that has been used to analyze the 
structure of mAb glycans has been CID.45, 58, 144, 174-176 Similarly to glycopeptides, cleaved 
oligosaccharides can be ionized, trapped and collided with ions to generate oligosaccharide 
fragments. On these fragments, so-called parent ion experiments can be performed to obtain 
structural details on the linkages of the glycans. 
So far, only general strategies for glycosylation analysis have been discussed. In the next 
section, the specific analytical techniques that have been used for the analysis of mAb glycans 
are discussed. We categorise these analytical techniques into two groups: mass spectrometric 
techniques; and separation-based techniques. A brief overview of the individual analytical 
techniques will be presented in the following sections. 
2.7.1. Mass Spectrometry (MS) 
Mass spectrometric techniques are characterized by the three main phenomena by which they 
function. MS is based on a) ionizing the molecules which compose the sample, b) separating 
them as a function of their mass to charge ratio, and c) detecting and quantifying them. The 
detection modules of current MS systems have been optimized for sensitivity and accuracy, and 
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hence do not have much impact on the quality of data. For this reason, this section will only 
address the most commonly used ionization and separation methods used in MS-based 
analytical techniques for mAb glycan characterization. 
Ionization Techniques 
The purified and, in some cases, derivatized glycan or glycopeptide sample must be ionized for 
analysis by MS. Weak ionization techniques should be used for the analysis of oligosaccharide 
structures because they are complex and fragile. The two main ionization techniques used for 
the characterization of mAb oligosaccharides are: 
Matrix Assisted Laser Desorption Ionisation (MALDI) 
This method is commonly used to ionize glycans that have been cleaved from the protein 
backbone of the mAb. Prior to ionization by this method, it is common for the cleaved 
oligosaccharides to be derivatized by permethylation.142, 174 This derivatization of the 
oligosaccharide structures presents considerable advantages, namely that it avoids 
fragmentation of the sample during the ionization process, it allows for quantification of both 
neutral and charged (sialic acid-containing) oligosaccharide species simultaneously and 
improves the detection sensitivity of molecular ions.177 Once the oligosaccharides are prepared, 
they are embedded into a low molecular weight, UV absorbing crystalline matrix, which, in the 
case of glycans is usually 2,5-dihydroxybenzoic acid (2,5-DHB). A pulsed laser is focused onto 
the sample/matrix mixture where most of the energy from the laser pulse is absorbed by the 
matrix, and enough energy is transmitted to the sample molecules to ionize them. The process 
by which the ionized sample is released from the matrix is still not fully understood, but is 
believed to be similar to flash evaporation. MALDI is known as a low energy ionization method 
because it causes little or no fragmentation while producing singly charged ions. 
Electrospray Ionisation (ESI) 
This ionization method can be applied to released oligosaccharides, but has also been used for 
analysis of glycopeptides. The sample, while in solution, is injected into a narrow capillary. 
Pressure is applied to the injection end of the capillary so that its content is dispersed as an 
aerosol of small droplets. The tip of the sprayer is generally coated with gold and a high voltage 
is applied to it so that when the sample is sprayed charge is conferred to the droplets. Once this 
occurs, the aerosol of highly charged droplets is passed through a drying gas to aid solvent 
evaporation. The charged droplets become smaller until the sample molecules are solvent-free 
and charged. This ionization method is also low energy, but in contrast to MALDI, it may 
generate multiply charged ions. 
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Mass Analysers 
Once the oligosaccharides are ionized, they are transferred towards the mass analyzer of the 
instrument. The mass analyzers separate the species within the sample according to their mass 
to charge ratio. The most common mass analyzers used for mAb glycan characterization have 
been: 
Quadrupole (Q) Mass Analyzers 
Quadrupole mass analyzers, which are also named quadrupole mass filters, have low resolution, 
and because of this, two or more of them are used in series or are also used in conjunction with 
other mass analyzers to obtain higher resolving power. In the specific case of mAb glycan 
characterization, several quadrupole mass filters are arranged in series to perform CID 
(MS/MS) experiments or are also coupled in tandem arrangements to TOF mass analyzers.45, 144, 
178-180 Q mass filters use a quadrupolar electrical field, which consists of both radio frequency 
(RF) and direct current (DC) components to separate ions. At given field intensities, ions with 
certain m/z ratios become resonant and are thus trapped within the field, while other ions with 
different m/z ratios do not resonate and escape the field. The quadrupolar electrical field can be 
manipulated by changing the magnitudes of its RF component. When coupled to TOF mass 
analyzers, quadrupole mass filters are used as sieves in which the ions with a desired range of 
m/z are condensed and sent towards the TOF analyzer while all other ions outside the set range 
leave the field and never reach the TOF system. 
Time of Flight (TOF) Mass Analyzers 
These analyzers are the most commonly used for the characterization of mAb glycans. Linear 
TOF analyzers consist of an electrical field-free tunnel through which the ionized species travel 
at a given velocity. In turn, the velocity of each charged molecule that travels through the TOF 
analyzer is a direct function of their mass and charge. For example, if a mixture contains two 
different oligosaccharide structures A and B with molecular weights of 1,400 g/mol and 1,600 
g/mol respectively, and both are singly charged, their mass to charge ratio m/z will be 1,400 
and 1,600. Within the TOF analyzer, the velocity of A will be higher to that of B because it has 
lower mass, and will reach the detector in less time than B. A contrasting example would occur 
if A is singly charged, but B is doubly charged. The m/z value for A would remain as 1,400, but 
the one for B would be 1,600/2 = 800. In this case, B would have higher velocity along the TOF 
tube and reach the detector earlier than A. Linear TOF systems have poor resolution and mass 
accuracy. The modern TOF analyzers contain systems called reflectrons which can reverse the 
flight path of ions. Reflectrons increase the flight distances within the TOF analyzer, thus 
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increasing resolution, and they also correct kinetic energy distribution effects, which greatly 
improves mass accuracy as well. 
2.7.2. Separation-based methods for glycan analysis of mAbs 
The separation techniques for oligosaccharide analysis are somewhat analogous to MS 
techniques in the sense that the components of the sample mixture are separated and later 
quantified. However, the principle by which the sample components are separated does not 
depend on the m/z ratio. Instead, different properties of the sample components (such as size, 
polarity and ionic interactions) are used to differentially separate them so that they can be 
detected. Additionally, the means by which glycans are detected by these techniques influences 
the accuracy and sensitivity of the method. There are four predominating separation-based 
techniques that have been used for mAb glycan characterization: 
High Performance Anion Exchange Chromatography coupled to Pulsed Amperometric 
Detection (HPAEC-PAD) 
In HPAEC-PAD, which is a type of adsorption liquid chromatography, the sample molecules are 
differentially adsorbed onto a positively charged solid matrix by ionic interactions. Alkaline 
buffer is added to the sample to ensure that its pH is higher than the pKa of the oligosaccharides 
which are to be separated, thus conferring them a net negative charge. The high pH sample is 
then loaded into the column leaving the negatively charged analytes to interact with the 
positively charged column matrix. The elution step consists of injecting a solution of so-called 
gradient ions onto the column so that the oligosaccharide molecules are differentially desorbed 
from the matrix. This differential desorption of the oligosaccharides from the matrix gives them 
different elution times, thus permitting them to be separated for detection. Pulsed 
amperometric detection is based on measuring the current generated by oxidation or reduction 
reactions on the surface of an electrode.181  
This detection method is highly sensitive, but in order to directly measure concentration of 
oligosaccharides, reference compounds must be used to generate calibration curves. This is 
because the current that is produced by a single mole of analyte varies from compound to 
compound, and is not proportional to their concentration within the sample mixture. For 
example, two OH groups of galactose can be oxidized under the detection conditions, but only 
one OH of mannose is oxidized. Therefore higher response would be measured for galactose 
than mannose even when they appear at the same concentration. This problem can be 
overcome by producing calibration curves for each of the compounds that are being analyzed. 
When PAD is used to detect complex oligosaccharides, it may be difficult to produce the 
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calibration curves due to lack of reference compounds. In these cases, only relative 
quantification is possible.182 
RP and HILIC Liquid Chromatography (LC) 
Liquid chromatography techniques separate the components of a mixture based on the 
differential partition of components, due to hydrophilic and hydrophobic interactions, between 
a mobile phase and a stationary phase. In the context of mAb separation and quantification, 
detection is usually made by photometric detectors which measure either UV absorption or 
fluorescence. This section shall first discuss the different separation modes that are used in LC 
and will conclude with a brief overview of how oligosaccharides are detected when analyzed by 
these methods. 
Reversed-phase high performance liquid chromatography (RP-HPLC) 
Reversed-phase liquid chromatography refers to when the mobile phase is polar (hydrophilic) 
and the stationary phase is non-polar (hydrophobic). Depending on the polarity of the different 
analytes within the mixture, they interact more strongly with either phase and thus are 
separated for eventual detection and quantification. In RP-HPLC, the dissolved sample is 
injected at high pressure (~1,500 psi) into a column packed with non-polar media (commonly, 
C18) octadecylsilyl columns). It is worth noting that oligosaccharide structures, being composed 
of monosaccharide (carbohydrate) units, tend to be quite polar due to the large amount of 
hydroxyl groups that are substituted along their carbon backbone. If these hydroxyl groups 
were to be left intact, the oligosaccharide structures would interact very weakly with the non-
polar stationary phase and elute almost immediately with the polar mobile phase, yielding little 
or no separation. Because of this, oligosaccharides that are to be separated by RP-HPLC, are 
generally derivatized by permethylation. This process substitutes the hydrogen on the hydroxyl 
group of the constituting carbohydrates with methyl groups, thus reducing their polarity and 
greatly increasing stability (especially of sialylated oligosaccharides if MS analysis will be done 
on the effluent of the LC system). By reducing their polarity, permethylation increases 
interaction of the oligosaccharides with the non-polar (hydrophobic) stationary phase, and thus, 
their separation is more efficient. Once the oligosaccharide molecules are separated by HPLC, 
they are usually detected by conventional UV absorption methods. 
Hydrophilic interaction liquid chromatography (HILIC-HPLC or HILIC-UPLC) 
Hydrophilic interaction chromatography is neither normal phase (NP) nor reverse phase (RP) 
chromatography. NP chromatography is the opposite of RP because in it, the mobile phase is 
non-polar and the stationary phase is polar. In contrast to both, hydrophilic interaction 
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chromatography uses a relatively polar mobile phase (acetonitrile) and a polar stationary phase 
(e.g. silica derivatized with amide groups). Instead of having the analytes separate as a result of 
their differential partition between polar and non-polar media, HILIC separates compounds as a 
function of their differential capacity of producing hydrogen bonds with the polar media of the 
stationary phase. HILIC techniques for the characterization of oligosaccharides have been 
established for conventional HPLC systems (1,500 psi, column packed with particles between 3 
and 5 µm). However, the advent of new technologies for producing columns packed with 
smaller particles (1 to 2 µm) has permitted systems which operate at much higher pressures 
(14,000 psi). At these pressures, the process is named ultra performance liquid chromatography 
(UPLC). UPLC systems have improved resolution, speed and sensitivity compared to their lower 
pressure counterpart, HPLC.183 Additionally, new UPLC columns for glycan analysis are being 
developed and tested. These columns have been used to completely separate and quantify mAb 
glycans (including structural isomers) in 30 minutes183 which is a considerable gain compared 
to the 50 minute run time recently achieved by rapid resolution RP-HPLC.184 
As was mentioned earlier, when LC techniques are used to analyze oligosaccharides, an 
important factor is detection and quantification. Mass spectrometry can only yield relative 
quantification of oligosaccharides (e.g. fraction of species A with respect to the most abundant 
species detected), and in some cases PAD detectors have the same limitation. In contrast, 
detection and quantification in LC is commonly done either by UV absorbance or fluorescence, 
and both of these photometric methods ensures direct quantification of the analyzed molecules 
as long as the measured signal falls into the linear range of the detectors.  
Paradoxically, carbohydrates have no chromophores (usually conjugated double bonds), 
and thus are undetectable by UV or fluorescence photometers. The strategy that has been 
developed to overcome this issue is to label oligosaccharides (or their constituting 
carbohydrates) with UV-absorbing molecules. In the specific case of N-linked glycans, 
derivatization techniques have been developed through which a single oligosaccharide is bound 
with a single label molecule, and these methods have focused on reductive amination chemistry. 
The GlcNAc residue at the base of free complex oligosaccharides contains an exposed reducing 
carbonyl group. The carbon on this reducing group is reacted, under reducing conditions, with 
the amino group of the label molecule, thus generating a stable, secondary amine. These types of 
reactions ensure that each oligosaccharide is bound to a single label. As expected, the most 
commonly used labels for glycan quantification contain primary amine groups and are: 2-
aminobenzamide (2-AB), 2-aminobenzoic acid (2-AA), 3-(acetylamino)-6-aminoacridine (AA-
Ac), 2-aminopyridine (AP), 8-aminopyrene-1,3,6-trisulfonate (APTS) and 1,2-diamino-4,5-
methylenedioxybenzene dihydrochloride (DMB).185, 186 
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Table 5. Commonly used UV and fluorescent labels for quantification of glycans29 
Table 5 shows the structures of these commonly used labels along with the maximum of 
their spectral peaks both for absorbance and fluorescence. The labels can then be detected by 
common spectrophotometers or by fluorescence inducing spectrophotometers. These labels 
allow oligosaccharides to be detected with sensitivities 500 to 1,000 times higher than the non-
labeled glycans.187 Analytical technique sensitivity is crucial for the implementation of QbD to 
mAb manufacturing processes because a) in these processes, the amount of material that is to 
be analyzed is limited and b) higher sensitivity of the analytical method allows monitoring of 
oligosaccharides that are present in lower abundances, and thus be included in the development 
of the manufacturing process. 
Capillary electrophoresis with laser induced fluorescence (CE-LIF) 
This method is quite different from the liquid chromatography techniques described above. The 
principle by which capillary electrophoresis separates the components of a mixture is by their 
size to charge ratio. The sample, while dissolved in an appropriate buffer, is fed into a capillary, 
which has an electrical potential applied to its ends. The voltage induces the components of the 
sample to migrate at rates which depend on their charge and size. In many cases, the capillary is 
filled with a gel which enhances separation resolution by sieving the components as a function 
of their size. Detection in CE systems is quite similar, if not identical, to fluorescence detection in 
LC methods. Therefore, when analyzed by this technique, it is necessary for the oligosaccharides 
NAME FORMULA ABSORBANCE/FLUORESCENCE 
2-aminobenzoic acid (2-AA) 
 
UV: 217, 247 and 335 nm 
λexc: 360 nm 
λem: 425 nm 
2-aminobenzamide (2-AB) 
 
UV: 213 and 248 nm 
λexc: 330 nm 
λem: 420 nm 
3-(acetylamino)-6-aminoacridine 
(AA-Ac) 
 
UV: 272, 377 and 432 nm 
λexc: 382 or 445 nm 
λem: 520 nm 
2-aminopyridine (AP) 
 
UV: 240 nm 
λexc: 310 nm 
λem: 380 nm 
 
8-aminopyrene-1,3,6-trisulfonate 
(APTS) 
 
λexc: 315 nm 
λem: 512 nm 
1,2-diamino-4,5-
methylenedioxybenzene 
dihydrochloride (DMB)  
λexc: 373 nm 
λem: 448 nm 
O
OH
NH2
O
NH2
NH2
NHAcNH2N
N NH2
S O-
O
O
S
O-
O O
S
O-
O O
H2N
O
OH2N
H2N
2.7. TECHNIQUES FOR MAB GLYCOSYLATION ANALYSIS 48 
 
 
to be labeled with fluorescent molecules as well. A commonly used label for CE-LIF is APTS.178, 
188, 189 CE-LIF has high resolving power in smaller time frames given the nature of the 
separation, and similarly to LC methods, this technique is also very sensitive given its use of 
fluorescent labels. 
Fluorophore-assisted carbohydrate electrophoresis (FACE) 
FACE is a gel-based analytical technique developed for the separation and quantification of 
carbohydrates and structures. The mechanism by which FACE separates carbohydrates is by 
their charge and size. (165).190 The principle by which this technique works is similar to CE, and 
also requires labeling with fluorescent compounds. However, FACE usually entails fluorescent 
labeling with compounds that are charged, such as ANTS or APTS, to ensure that the species is 
charged for adequate migration through the gel. FACE, over time, has been replaced by other 
techniques, such as CE-LIF and LC because they have been found to have higher resolving 
power, more reproducible detection and higher throughputs due to their automation. The 
replacement of FACE by CE and other techniques can be inferred from Table 6. The three cases 
in which FACE has been used for mAb oligosaccharide characterization were Kunkel et al.,115 
Leibiger et al.,59 and Saba et al.175 
2.7.3. Combination of analytical techniques (LC-MS and CE-MS) 
A very important advantage of separation-based analytical techniques in the context of mAb 
glycan characterization is that they can be coupled to MS via an ESI interface. An underlying 
issue of all non-MS oligosaccharide characterization methods is the identification of all 
separated species. As mentioned previously, the amount and purity of standard 
oligosaccharides is scarce, thus when employing a single technique for oligosaccharide 
characterization, there is a relative degree of uncertainty concerning both absolute 
quantification and identification of the oligosaccharide structure. The manner in which these 
limitations have been overcome is by combining two or more of these techniques. In mAb 
glycan analysis (and usually for all other glycoprotein characterization), the most common 
example of this combination has been the on-line connection of liquid chromatography or 
capillary electrophoresis techniques to mass spectrometry through an ESI interface. This 
combination of analytical techniques permits separation and absolute quantification of 
oligosaccharide species by LC or CE (through fluorescence or absorption) and identification (or 
identity confirmation) of each species which has been separated by mass spectrometry. 
Examples of the combination of these techniques towards the characterization of mAb glycans 
are CE–LIF–ESI–MS189, 191 and RP–HPLC–ESI–MS.45, 75, 142-144, 172, 175, 178, 180, 190, 192, 193 
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2.7.4. Multimethodological approach 
The need for obtaining all three levels of glycan information has led to the proposal of 
multimethodological approaches for glycoprotein oligosaccharide characterization (168). In 
these approaches, a combination of analytical techniques is performed for the full 
characterization of oligosaccharides. 
Level 1, which corresponds to the determination of glycosylation sites of the glycoprotein 
(macroheterogeneity), can be covered by generating glycoprotein digests (as shown in Figure 
11) and feeding the digests into a tandem CE–MS or LC–MS system. These systems not only have 
the resolution necessary to distinguish the mass of the protein backbone to which the 
oligosaccharide is bound, but they can also determine differences as to which oligosaccharide 
structure is bound to each fragment of protein backbone. 
Level 2, which concerns the oligosaccharide structures and concentrations (glycan profile), 
can be covered by applying HPAEC, CE–LIF or LC–fluorescence/absorbance for the separation 
and quantification of each oligosaccharide species. These techniques are coupled to MS in order 
to identify the oligosaccharide species. Additionally, these results (both the quantification and 
the identification of the oligosaccharide profiles) can be confirmed by monosaccharide 
composition analysis, which consists in cleaving all the glycosidic bonds within the 
oligosaccharide, thus producing a pool of monosaccharides which can then be analyzed by CE–
LIF, LC–fluorescence/absorbance, HPAEC–PAD, MALDI–TOF or ESI–MS. The concentrations of 
monosaccharides and their relative proportions within the pool should match their 
stoichiometric abundance within the oligosaccharides which were measured previously. 
Finally, Level 3, which corresponds to oligosaccharide structural analysis and linkage 
characterization, can be obtained by sequential glycosidase digestions of the oligosaccharides, 
and identifying and quantifying the products of each digest by CE–LIF, LC–
fluorescence/absorbance, HPAEC–PAD, MALDI–TOF or ESI–MS. Another approach for obtaining 
level 3 information is by performing fragmentation analyses with MALDI–Ion Trap–MS or ESI–
Ion Trap–MS. Ion traps are similar to quadrupole mass analyzers since they can be tuned to 
retain oligosaccharide ions with a set m/z range. However, they are designed to trap said ions 
instead of sieving them as the quadrupole mass analyzer does. Once the charged oligosaccharide 
ions are trapped, they can be fragmented by collision with other ions. The manner in which the 
ionized gycans are fragmented yields structural information on the original oligosaccharide 
structure. Table 6 presents the techniques for mAb glycosylation analysis that have been used 
over the past fifteen years. 
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Table 6. Analytical techniques for mAb glycosylation29 
YEAR MAB FORMAT 
PRODUCTION CELL 
LINE 
OLIGOSACCHARIDE CHARACTERISATION REFERENCE 
1993 Chimeric IgG1, IgG2, IgG3 and IgG4 CHO and mouse J558L HPAEC-PAD for relative glycan quantification 
Neutral oligosaccharides labelled with 2-AP for RP-HPLC for quantification 
(134) 
1994 Human IgG1 NS0 HPAEC-PAD for relative glycan quantification (138) 
1995 CAMPATH-H1: Humanized IgG1κ, anti-
CDw52 
CHO, Y0 and NS0 HPAEC-PAD for relative glycan quantification 
sequential exoglycosidase treatment and MALDI-TOF-MS for structural analysis 
(79) 
1997 CAMPATH-H1: Humanized IgG1κ, anti-
CDw52 
CHO and NS0 Permethylated glycans were directly injected into ESI-Q-MS for CID structural 
characterisation 
MALDI-TOF-MS for glycan identification and relative quantification 
exoglycosidase treatment and MALDI-TOF-MS for structural analysis 
(142) 
1998 Murine IgG2b C3H/SW cell line RP-HPLC-ESI-Ion Trap-MS/MS for glycopeptides identification and relative 
quantification 
(58) 
1998 Murine IgG1 CC9C10 cell line ANTS-labelling for FACE 
HPAEC-PAD for relative glycan quantification 
(115) 
1999 Human CBGA1 IgG1λ Human-mouse 
hybridoma 
ANTS-labelling for FACE 
HPAEC-PAD for relative glycan quantification 
exoglycosidase treatment-HPAEC-PAD for structural analysis 
(59) 
1999 Chimeric IgG1κ (Rituximab) CHO APTS-labelling and CE-LIF for glycan quantification (194) 
1999 Chimeric IgG1 CHO MALDI-TOF-MS for glycan identification and relative quantification (83) 
2000 Chimeric IgG1-TNFR (immunoadhesin 
tumor necrosis factor) fusion protein 
CHO MALDI-TOF-MS for glycan identification and relative quantification 
HPAEC-PAD for relative monosaccharide quantification 
OPD (O-Phenylenediamine)-labelling and RP-HPLC for Neu5Ac quantification 
(118) 
2000 Murine IgG1κ Sp2/0 HPAEC-PAD for relative glycan quantification (195) 
2000 Chimeric IgG1 CHO 2-AB labelling and NP-HPLC for glycan quantification 
Exoglycosidase treatment and NP-HPLC for structural analysis 
(109) 
2001 Murine IgG1 (MGR48) Tobacco plants MALDI-TOF-MS for glycan identification and relative quantification (196) 
2001 Humanized IgG1 NS0 MALDI-TOF-MS for glycan identification and relative quantification 
Permethylated glycans and RP-HPLC-ESI-Q-TOF-MS/MS with CID for structural 
analysis 
(174) 
2001 Humanized IgG1 GSNS0 2-AB labelled for NP-HPLC for glycan quantification 
Exoglycosidase treatment and NP-HPLC for structural analysis 
(78) 
2002 Murine IgG1κ Sp2/0 (CC9C10) APTS-labelling for FACE 
HPAEC-PAD for relative glycan quantification 
PMP-derivatised for MALDI-TOF-MS for glycan identification 
NP-HPLC-ESI-Q-TOF-MS/MS for structural analysis 
(175) 
2004 Murine IgG1 Murine hybridoma 2-AB labelling and NP-HPLC for glycan quantification 
Exoglycosidase treatment and NP-HPLC for structural analysis 
(173) 
2004 Murine IgG1κ Tobacco plants, Sp2/0 2-AB labelling and NP-HPLC for glycan quantification 
Exoglycosidase treatment and NP-HPLC for structural analysis 
(154) 
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2005 Murine IgG1κ  N/A APTS-labelling and CE-LIF for intact oligosaccharide and free monosaccharide 
quantification 
MALDI-TOF-MS for glycan identification 
RP-HPLC-ESI-Q-TOF-MS for site occupancy analysis 
(178) 
2005 Humanized IgG1κ (7H2HM and A2CHM) 7H2HM produced in 
CHO and A2CHM 
produced in NS0cell 
lines 
MALDI-TOF-MS for glycopeptide identification and relative quantification 
RP-HPLC-ESI-TOF-MS for glycopeptide structural analysis and relative quantification 
Papain digestion and hydrophobic interaction LC for site occupancy analysis 
(143) 
2006 Human IgG1κ Aquatic plant Lemna 
minor 
2-AA labelling and NP-HPLC-ESI-Q-TOF-MS for glycan quantification and 
identification 
HPAEC-PAD for relative monosaccharide composition 
MALDI-Q-TOF-MS for glycan identification 
(163) 
2006 Humanized IgG1k (trastuzumab), Chimeric 
IgG1k (rituximab) and humanized IgGk 
(palivizumab) 
CHO and NS0 2-AA labelling and CE-LIF for glycan quantification 
Oligosaccharide fractions separated by RP-HPLC and MALDI-Q-TOF-MS/MS for 
structural analysis 
(176) 
2006 Murine IgG1 Murine hybridoma HPAEC-PAD for relative glycan quantification (136) 
2006 Recombinant IgG N/A RP-HPLC-ESI-Q-TOF-MS/MS for intact mAb structural analysis 
MALDI-TOF-MS for glycan identification 
2-AA labelling and HPAEC-PAD for relative glycan quantification 
(180) 
2007 Human IgG1κ Human myeloma cell 
lines 
RP-HPLC-ESI-TOF-MS with orthogonal acceleration for glycoprotein structural 
analysis 
2-AP labelling and NP-HPLC for glycan quantification 
(75) 
2007 IgG1 and IgG2 CHO 2-AB labelling and RP-HPLC-ESI-Q-TOF-MS for quantification and on-line glycan 
identification 
RP-HPLC-ESI-IT-MS for structural analysis 
(192) 
2007 Murine IgG1 BCF2 hybridoma APTS labelling and CE-LIF for glycan quantification 
Exoglycosidase treatment and CE-LIF for structural analysis 
(130) 
2007 Chimeric IgG1κ (Cetuximab) Sp2/0 2-AA labelling and NP-HPLC for glycan quantification 
MALDI-Q-TOF-MS for glycan identification 
MALDI-Q-TOF-MS/MS for structural analysis 
(179) 
2008 Chimeric IgG1κ (rituximab), humanized 
IgG1κ (omalizumab, trastuzumab, anti-
HIV) expressed in CHO, Chimeric IgGκ 
(cetuximab, infliximab) expressed in Sp/0, 
humanized IgG1κ (daclizumab) expressed 
in NS0 and anti-HIV IgG1κ expressed in 
human cell line 
CHO, Sp/0, NS0 and 
human cell lines 
RP-HPLC-ESI-Q-TOF-MS/MS for glycopeptide structural analysis and relative 
quantification 
Borohydrate-reduced and Porous graphitic carbon (PGC)-HPLC-ESI-Q-TOF-MS for 
glycan identification 
2-AB labelling and NP-HPLC for quantification 
(45) 
2008 N/A CHO Papain digestion of mAbs and RP-HPLC-ESI-Q-TOF-MS/MS for glycopeptide 
identification, site occupancy and relative quantification 
(171) 
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2008 Humanized IgG1κ (A2CHM, A3BHM) and 
murine IgG1κ (7C10) 
NS0, CHO and murine 
hybridoma 
RP-HPLC-ESI-TOF-MS for relative  glycoprotein identification and relative 
quantification 
ESI-IT-MS/MS for glycan structural analysis 
Nano-RP-HPLC-ESI-IT-MS/MS for glycopeptide structural analysis and relative 
quantification 
(144) 
2008 IgG1 N/A APTS labelling and CE-LIF-ESI-TOF-MS for glycan quantification and identification (189) 
2008 IgG1κ Mouse hybridoma Intact mAb and RP-UPLC-ESI-Q-Ion Mobility (IM)-TOF for glycoprotein identification 
and relative quantification 
Reduced mAb and RP-UPLC-ESI-Q-IM-TOF for site occupancy, glycoprotein 
identification and relative quantification 
Nano-RP-HPLC-ESI-Dual Ion Trap-MS/MS for glycopeptide structural analysis 
(170) 
2009 Human IgG1κ NA HPAEC-PAD for relative monosaccharide quantification 
HPAEC-PAD for relative glycan quantification 
APTS labelling and CE-LIF for glycan quantification 
RP-HPLC-ESI-IT-MS for glycan identification and relative quantification 
RP-HPLC-ESI-IT-MS for glycopeptide identification and relative quantification 
(172) 
2009 N/A N/A 3-AA-Ac labelling for NP-UPLC-ESI-TOF-MS for glycan quantification and 
identification (30 min) 
(183) 
2009 Humanized IgG1κ (trastuzumab), Chimeric 
IgG1κ (rituximab) and humanized IgGκ 
(palivizumab) 
CHO and NS0 9-fluorenylmethyl chloroformate (Fmoc-Cl) labelling and CE-LIF-ESI-IT-MS/MS for 
glycan quantification, identification and structural analysis 
(191) 
2009 IgG1, IgG2, IgG3 and IgG4 CHO 2-AB labelling and RP-HPLC-ESI-Q-TOF-MS for glycan quantification and 
identification (45 min) 
(184) 
2009 Humanized IgG1κ (trastuzumab) CHO Intact mAb and RP-UPLC-ESI-Q-Ion Mobility (IM)-TOF for glycoprotein identification 
and relative quantification 
Reduced mAb and RP-UPLC-ESI-Q-IM-TOF for site occupancy, glycoprotein 
identification and relative quantification 
Nano-RP-HPLC-ESI-Dual Ion Trap-MS/MS for glycopeptide structural analysis 
(197) 
2010 Human IgGs (HA78 anti-hepatitis A; 2G12 
anti-HIV) 
Arabidopsis thaliana RP-HPLC-ESI-Q-TOF-MS/MS for glycopeptide structural analysis and relative 
quantification 
Borohydrate-reduced and Porous graphitic carbon (PGC)-HPLC-ESI-Q-TOF-MS for 
glycan identification 
2-AB labelling and NP-HPLC for quantification 
(198) 
2011 N/A N/A Zwitterionic-HILIC-HPLC-ESI-Q-TOF of unlabelled glycans for relative quantification 
and identification 
HILIC-HPLC-ESI-Q-TOF of 2-AB labelled glycans for quantification and identification 
(199) 
2011 Monoclonal human IgG1; monoclonal 
mouse IgG1; polyvalent  human IgG 
(Redimune©); 16 licenced mAbs 
Human; mouse 
myeloma; CHO; NS0; 
Sp2/0 
APTS labelling and CE-LIF for glycan quantification (200) 
2012 Humanized anti-EGFR IgG1 NS0 2-AB labelling and NP-HPLC-ESI-Q-TOF for glycan quantification and identification 
Exoglycosidase  treatment for glycan structural analysis 
MALDI-TOF-MS for glycan identification 
(201) 
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There have also been multiplexed analysis methods where parallel use of analytical 
techniques greatly improves N-glycan profiling.202, 203 These methods have relied on performing 
parallel lectin microarrays and mass spectrometry to identify specific glycoforms of different 
proteins at high-throughput.202 An interesting example of glycan analysis using multiplexed 
analytical techniques was reported recently by Mittermayr et al.203 This group found that when 
using HILIC-UPLC in parallel with CE-LIF, complete structural annotation of the glycans bound 
to human polyclonal antibodies was performed in less than 20 minutes. They attributed the 
short time in glycan structure annotation to the convenient orthogonality of both analytical 
techniques. 
2.7.5. Glycosylation databases 
The techniques described in the previous section produce rather complex datasets. Because of 
this, a major challenge underlying glycan analysis is data interpretation. As was mentioned in 
previous sections of this thesis, MS generates spectra where observed peaks correspond to 
different mass to charge ratios (m/z). By knowing – or in some cases, assuming – the possible 
molecular ion charges (z) produced by the ionisation method, the peaks can be assigned to a 
molecular weight (MW). The obtained MWs must then be compared to glycans that have either 
been previously observed or that are feasibly produced by known glycan biosynthetic 
pathways.204 
Similarly, glycan data generated with the separation-based methods described in the 
previous sections must also be interpreted. The peaks generated by these methods must be 
assigned to a glycan structure. Because separation efficiency may vary on a day-to-day basis and 
is also heavily dependent on the analytical equipment itself, peak assignment is challenging. In 
order to address this issue, methods where the retention times of observed peaks are correlated 
with those obtained for an internal standard (2-AB labelled dextran ladder), have been 
developed.205, 206 This methodology allows for accurate assignment of glycan species, the 
product of sequential glycosidase digestions and – rather importantly – has made results 
generated with different equipment comparable.168, 206 
Underlying the interpretation of glycan analysis data is the need of detailed databases 
where all possible (or previously observed) glycan species are reported in such a way that 
measured glycan data can be readily compared and interpreted. In addition to the databases, 
software that annotates experimental data by comparing it to the available glycan profiles from 
databases is also necessary. Several glycan databases and glycan analysis software tools have 
been developed and made available for glycan data interpretation. Currently available glycan 
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databases and software have been reviewed recently,207, 208 and therefore, this section will 
briefly summarise the most relevant ones to this thesis. 
CCSD (CarbBank)( http://www.glycome-db.org/getDownloadPage.action?page=carbbank)209 
This was the first carbohydrate database and was established in the early 1990s. Its latest 
release contains >50,000 records which link carbohydrate structure, the organism that 
synthesised it, along with the analytical methods that were used to determine the structure. 
Maintenance and additions to the database were discontinued in 1997, but it is still available as 
part of newer carbohydrate databases. 
GlycomeDB (http://www.glycome-db.org/)210, 211 
This is the latest glycan database, and links all the major publicly-available databases. This 
compiled database contains over 35,000 unique glycans along with taxonomic annotations. 
GlycomeDB database is updated weekly by retrieving new data that has been uploaded to its 
associated databases. 
KEGG Glycan (http://www.genome.jp/kegg/glycan/)212, 213 
This database provides data on glycan structures and associates them with the metabolic 
pathways involved in their biosynthesis. This database includes >10,000 glycan structures and 
is able to associate each of them with the necessary genome, transcriptome and proteome 
required for their synthesis. 
GlycoBase 3.0 (http://glycobase.nibrt.ie/glycobase/show_nibrt.action)214 
This database contains experimental HPLC and UPLC elution times for >380 2AB-labelled N-
glycans with respect to the dextran ladder internal standard. As was mentioned previously, the 
normalisation of the retention time with respect to the dextran ladder eliminates day-to-day 
and equipment-associated variation. 
GlycoWorkBench (http://code.google.com/p/glycoworkbench/)204, 215 
This is an open source software package that has been developed to assign peaks obtained 
through MS glycan analysis. GlycoWorkBench links to the CarbBank, GlycomeDB and 
Glycosciences.de databases to search for all the experimentally reported glycans that have a 
given molecular weight. Based on the glycoprotein-producing organism and the glycoprotein 
itself, the user selects the most feasible glycan structure associated with the measured 
molecular weight.  
2.7. TECHNIQUES FOR MAB GLYCOSYLATION ANALYSIS 55 
 
 
Glycosciences.de (http://www.glycosciences.de/)216, 217 
This is a web-based application for glycosciences in general. It is constituted both by glycan 
databases as well as tools for glycome analysis. Its main database is derived from CCSD and 
SugaBase. Based on these, Glycosciences.de contains glycan structure, experimental NMR, MS 
and crystallographic data along with taxonomy. The main software tools available within 
Glycosciences.de include applications that calculate the main fragments that would be 
generated in CID-MS spectra (GlycoFragment), applications that calculate the possible torsion 
angles of glycans (GlyTorsion) and software that analyses the presence of amino acids in the 
vicinity of carbohydrate residues (GlyVicinity). 
With the bioinformatics tools presented in this section, many of the difficulties associated 
with the complex data produced by glycan analysis can be overcome. Depending on the 
analytical method that is selected for glycan analysis, different databases would be used in 
order to identify which glycans are present – and in what proportions – in a given sample. 
Without the availability of these tools, glycan analysis would be cumbersome and less reliable. 
2.7.6. High throughput methods 
An important element of PAT within the QbD perspective is timeliness of the measurements. 
Ideally, product CQA measurements should be taken on-line to obtain dynamic datasets and 
ensure optimal control over the process. In the case of small molecule therapeutics, on-line 
measurement of product CQAs has been achieved with relative success.218-220 In contrast, on-line 
measurement for process inputs and CQAs of biologics is challenging, and is even more so in the 
case of glycosylation-associated CQAs. Although much progress has been made in reducing 
runtime of N-glycan analysis,183 sample preparation prior to the analytical techniques remains a 
bottleneck for on-line monitoring of these CQAs. Moreover, if glycan analysis is to be used on-
line or at-line to inform manufacturing operations, fast, small-scale, accurate and, preferably, 
automated methods would be required. Initial attempts were based on microtitre plate assays 
where capture, reduction, tryptic digestion and fractionation of N-linked glycopeptides were 
performed prior to MALDI-TOF MS glycan analysis.221 Although this methodology required 
small volumes, it was still laborious and lengthy.  
More successful methods for high throughput preparation of N-glycans have been reviewed 
recently.222 This review discusses two methods that rely on HILIC UPLC for quantification of 2-
AB labelled N-linked glycans with subsequent structural elucidation of these species performed 
by sequential exoglycosidase treatment and weak anion exchange (WAX) HPLC. In the context 
of small-scale high-throughput sample preparation, two of the methods reviewed by Doherty et 
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al.222 In these methods, all steps required for sample preparation (isolation, reduction and 
alkylation, glycan release, labelling and purification) are performed in a 96 well plate format 
and have been fully automated with the use of liquid-handling robotic systems.205, 223 
Automated, small-scale approaches for sample preparation and subsequent analysis of mAb 
N-glycans represent the forefront in developing on-line monitoring of glycan-associated mAb 
QCAs in the QbD context. These methods, combined with highly sensitive and high-throughput 
analytical techniques, are continuously contributing to a fuller understanding of the mechanistic 
relationships between bioprocess inputs and mAb glycosylation-associated quality. In addition, 
these high-throughput methods should eventually allow for improved bioprocess control and 
aid in building glycosylation-associated quality into mAbs throughout process development and 
manufacture. 
  
GOLGI N-LINKED GLYCOSYLATION MODEL 57 
 
 
Chapter 3  
Golgi N-linked glycosylation model 
3.1. Definition of the mathematical model 
This chapter will present the definition of a dynamic mathematical model which intends to 
mechanistically describe the process of mAb Fc glycosylation. The four models that have been 
previously developed to represent N-linked glycosylation have been reviewed in section 2.6 of 
this thesis. All previous models have generated a great deal of insight into the N-linked 
glycosylation process. However, throughout this chapter, we hope to show that further 
considerations that were included into this model yield enhanced performance over previous 
ones, and that these additional features contribute to a fuller mechanistic description of the N-
linked glycosylation of mAbs. 
The three main elements of the mathematical model presented herein are: 
i) The Golgi apparatus functions under the so-called cisternal maturation regime; 
ii)  The rate expressions for the enzymatic reactions that occur within the Golgi 
apparatus have been derived from the kinetic mechanisms that have been reported 
for each enzyme; 
iii) The protein-mediated transport of NSDs into the Golgi apparatus has been included 
to provide a link between cellular metabolism and the Golgi glycosylation process. 
These elements are presented in more detail in the following sections. 
In addition, the model presented in this section assumes that the first step of the N-linked 
glycosylation process of mAbs is completed successfully, and therefore, has been developed to 
only represent the glycosylation reactions which occur in the Golgi apparatus. As was 
mentioned previously, the close proximity of both Cγ2 domains in IgG molecules limits the space 
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available for the oligosaccharide structures, which in turn, limits their branching and 
complexity.77 Previous reports show that the oligosaccharide bound to the Fc of mAbs are 
limited to complex, bi-antennary structures that are usually core-fucosylated, and have varying 
degrees of galactosylation and low levels of sialylation.76, 224 For these reasons, the reaction 
scheme for mAb Fc glycosylation has been reduced to the one presented in Figure 12. The 
structure and constituting monosaccharide linkages of the oligosaccharides considered in this 
model are presented in Figure 7. 
 
Figure 12. mAb Fc N-linked glycosylation reaction scheme225 
The scheme begins with a Man9 oligosaccharide which is acted upon by ManI. Once Man5 is 
produced, GnTI adds GlcNAc to the α-1,3 arm of the core oligosaccharide structure. After this step, 
the reaction scheme diverges to 77 species generated by 95 possible reactions which are catalysed 
by eight different enzymes. Finally, the scheme converges to produce a fully processed 
biantennary oligosaccharide. 
3.2. Cisternal maturation and material balances 
Most of the current experimental information surrounding the Golgi apparatus favours the 
cisternal maturation model over the previously accepted static Golgi model.165, 166, 226, 227 
Cisternal maturation postulates that the Golgi compartments are synthesized from components 
of the endoplasmic reticulum and transit towards the secretory components of the cell.228, 229 
During their movement, Golgi-resident proteins are recycled from subsequent compartments to 
preceding ones through retrograde transport mediated by COPI coated vesicles.226, 227 Based on 
cisternal maturation, the Golgi apparatus has been modelled as a single PFR, as illustrated in 
Figure 13. 
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Figure 13. Cisternal maturation of the Golgi apparatus viewed as a PFR225 
A single cisterna is produced from components of the endoplasmic reticulum (tER) and enters the 
Golgi space, which is defined herein as an imaginary tube (dotted line). The cisterna transits 
through the Golgi space, and while this occurs, its resident proteins (TPs and glycosylation 
enzymes) are transported to preceeding compartments as depicted by the vesicles shown at the 
top. Once the compartment reaches the end of the tube, its contents are transferred to carriers 
that are responsible for secreting the glycoprotein to the extracellular environment.  
Although the compartments are discrete sections, their movement along the z axis is 
continuous, thus making it possible to consider the system as a single, continuous PFR. 
Assuming no axial dispersion within the compartment, constant flow of cargo through the 
complex (constant linear velocity), and constant diameter of the Golgi compartments, the time-
dependent material balance for the components inside the PFR are shown in equations 1, 2 and 
3. 
• Oligosaccharide balances:  
 ! " #, $ 4&'()  * +,-./
.1.
/23  …Eq. 1 
• NSD balances: 
456! " #6, $ 4&'() 456* +,-6,/./
.1.
/23  …Eq. 2 
• By-product balances: 
76! " $#6, $ 4&'() 76* +,-6,/./
.1.
/23  …Eq. 3 
An integral element of the cisternal maturation model is that the resident proteins of the 
Golgi apparatus (glycosylation enzymes and transport proteins) are recycled from subsequent 
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compartments to preceding ones.226, 227 In the present model, this has been incorporated by 
defining enzyme concentration profiles along the length, z, as three parameter normal functions 
(Equations 4 and 5): 
• Enzymes: 8/9*: " 8/,;<=>?@A@B,CDEFB G>  …Eq. 4 
• Transport proteins: H469*: " H46,;<=>I@A@J,CDEFJ K> …Eq. 5 
 
Figure 14. Definition of Golgi resident protein concentration profiles 
The Golgi resident protein concentration profiles are defined by three parameters (Ej,MAX, zj,MAX and 
ωj). Ej,MAX represents the peak concentration of the resident protein, zj,MAX corresponds to the 
location of the peak concentration along the Golgi space and ωj represents the breadth of the 
concentration. 
These functions represent the inherent behaviour of enzyme concentration when recycling 
is considered: there would be a stage during which the enzyme accumulates while it is being fed 
into a given compartment from the subsequent one. The enzyme concentration would then 
reach a transitory peak concentration after which the enzyme would begin to be transferred to 
preceding compartments, thus generating a decline stage. The stages of Golgi resident protein 
accumulation and depletion, as well as a description of each of the three parameters that define 
Eqs. 4 and 5, are presented in Figure 14. 
3.3. Enzyme kinetics 
The previous models for N-linked glycosylation considered simplified enzyme kinetics, where 
only competitive inhibition was considered. Moreover, all previous models considered the same 
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kinetic mechanism for all of the enzyme-catalyzed reactions. The kinetic expressions in the 
present model were expanded by considering the structural and kinetic mechanisms by which 
these enzymes act. Table 7 shows that three kinetic mechanisms prevail among the enzymes 
involved in mAb N-linked glycosylation. Each reaction mechanism defines how the substrate(s) 
bind to the enzyme, and which step of the process is the catalytic one. Additionally, but not 
independently to the catalytic mechanism, different types of inhibitory effects may occur within 
these systems. Given that many different oligosaccharides can be modified by the same enzyme, 
it is reasonable to assume that competitive inhibition occurs. Moreover, product inhibition has 
been reported for many of these reactions.230-232 The reaction rates are presented as equations 6 
through 8. The full derivation is included in Appendix I. 
Table 7. Kinetics of N-linked glycosylation enzymes 
Kinetic Mechanism Reaction Mechanism Enzymes 
Michaelis Menten with 
competitive and product 
inhibition 
 
ManI233, 234 
ManII235 
Sequential-order Bi-Bi 
with competitive and 
product inhibition 
 
GnTI236 
GnTII237 
GalT231 
Random-order Bi-Bi with 
competitive and product 
inhibition 
 
FucT230 
GnTIII232 
SiaT238 
 
Michaelis-Menten kinetics: 
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Sequential-order Bi-Bi kinetics 
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Random-order Bi-Bi kinetics 
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…Eq. 8 
3.4. Nucleotide sugar donor transport 
NSDs (UDP-GlcNAc, GDP-Fuc, UDP-Gal and CMP-Neu5Ac) are the co-substrates for the sugar 
addition reactions of N-linked glycosylation and their availability inside the Golgi cisternae has 
been reported to affect the N-linked glycosylation process.78, 107, 108, 162 NSDs are synthesized in 
the cytosol of cells (with the exception of CMP-Neu5Ac, which is produced in the nucleus) and 
their transfer into the Golgi apparatus is mediated by transport proteins (TPs). All four TPs 
considered in this paper, act by an anti-port mechanism whereby the NSDs are transported into 
the Golgi cisternae while their dephosphorylated nucleotide component (which accumulates in 
the Golgi lumen through the glycosylation reactions) is transported out of the cisternae.239 For 
example, the TP for UDP-GlcNAc removes a single uridine monophopsphate (UMP) molecule for 
every UDP-GlcNAc molecule it introduces into Golgi.240 The same occurs for all other transport 
proteins considered in this work.241-243 These transport mechanisms have also been 
characterized quantitatively. In all cases, transport has been found to follow saturation kinetics, 
which depends on the concentration of the NSD on the cytosolic side of Golgi and on the 
respective dephosphorylated nucleotide concentration on the luminal side.241-243 
To generate a first link between cellular metabolism and N-linked glycosylation, the 
transport of NSDs has been included into our model. Using the information presented above, 
and considering that the interaction between transport substrates and the TP is analogous to 
enzyme-substrate interactions, the expression describing transport of NSDs into the Golgi 
apparatus is defined as equation 9. The derivation of this equation is presented in Appendix II. 
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3.5. Golgi glycosylation parameter values 
The overall cell volume considered in this work is 2,500 µm3.244 Combining this with structural 
information of the Golgi apparatus reported by Ladinsky et al.,245 the volume of the Golgi 
apparatus was calculated as 25 µm3. Assuming only four compartments and using an aspect 
ratio (diameter:thickness) of 60 to 1 (approximated from Ladinsky et al.245), the obtained 
internal diameter of the tube presented in Figure 13 is 7.82 µm. The overall length of the tube 
(length of the Golgi stack) is calculated as 0.52 µm. With this information, the surface area of a 
single compartment was calculated as 990 µm2. The specific protein productivity was taken as 
387 pmol (106 cell)-1 day-1.246 This value falls within the range reported by Bibila and 
Robinson.247 When considering that each mAb molecule contains two N-linked glycosylation 
sites, the glycan productivity for this system is 773 pmol (106 cell)-1 day-1, which also lies within 
the range of 100 to 1,500 pmol (106 cell)-1 day-1 used in previous models.31-33  
Umaña and Bailey estimated the residence time of proteins within the Golgi apparatus as 22 
min.,31 which seems reasonable considering that Hirschberg and Lippincott-Schwartz248 
reported an ER/Golgi residence time of 40 min with a protein flux equivalent to 574 pmol 
(106cell)-1 day-1. The volumetric flowrate (q) through the Golgi space was defined as 1.12 µm3 
min-1 and the concentration of glycoprotein that is transferred from the endoplasmic reticulum 
to the Golgi apparatus (i.e. the concentration of glycoprotein at z = 0) was defined as 600 µM of 
glycoprotein. The ensuing concentration of glycan entering the Golgi apparatus is 1,200 µM.  
Enzyme kinetic parameters and NSD transport parameters are presented in Table 8 and Table 9, 
respectively. Details for the calculation of these parameter values are presented in Appendix III. 
3.5.1. Parameter estimation for enzyme concentration profiles 
The localization of the enzymes along the length of Golgi (z) is based on experimental 
information.62 This group determined the distribution of ManII, GnTI, GalT and SiaT by immuno-
labeling cryo-sections of HeLa cells, but left the distribution of GnTII and FucT unknown. This 
methodology generated a series of “snap-shots” of enzyme distribution related to the static 
compartment model of Golgi. The mathematical model presented herein attempts to 
dynamically describe cisternal maturation of Golgi, for this reason, the data presented by 
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Rabouille et al.62 were further detailed by an optimization-based approach. The parameters that 
define enzyme distribution were estimated by finding the minimum amount of total enzyme 
(the integral of enzyme concentration over the length of Golgi) necessary to achieve full 
oligosaccharide processing, including 50% sialylation. 
Table 8. Enzyme turnover and dissociation constants 
Enzyme turnover rates 
Enzyme 
Vmax 
(µmol mg-1 min-1) Organisms 
MW 
(g/mol) 
kf 
(min-1) 
ManI 3.677 Human, purified.249 230,000250 888 
ManII 6.750 Rat liver, purified.234 285,000234 1,924 
GnTI 19.80 Rabbit liver, purified.251 51,600252 1,022 
GnTII 27.50 Rat liver, purified.237 200,000237 1,406 
GnTIII 5.52 Rat liver, purified.253 114,000253 629 
FucT 4.37 
Porcine brain, 
purified.254 
66,530254 291 
GalT 19.80 Rat liver, purified.255 44,040256 872 
SiaT 8.20 Rat, purified.257 59,930258 491 
Enzyme Dissociation constants 
Enzyme Substrate Kd,i (µM) Kd,k 
(µM) Notes and References 
ManI 
Man9 60.5 ---- Estimated.233 
Man8 110.0 ---- Human, purified.249 
Man7 30.8 ---- Estimated.233 
Man6 74.1 ---- Estimated.233 
ManII 
Man5 200.0 ---- 
Purified human 
adenocarcinoma.259 
Man4 100.0 ---- Estimated.32 
FucT 
CoreGlcNAc2 25.0 
46.0 
Porcine brain, purified.254 
α-1,6 arm occupied 1.2 Estimated.32  
GnTI Man5 260.0 170.0 CHO, purified.260 
GnTII CoreGlcNAc1 190.0 960.0 Rat liver, purified.237 
GnTIII CoreGlcNAc2 21.0 420.0 
Rat GnTIII expressed in insect 
cells.232 
GalT 
CoreGlcNAc2 (α-1,3 arm) 430.0 
65.0 Rat liver, purified.261 CoreGlcNAc2 (α-1,6 arm) 130.0 
CoreGlcNAc2Gal1 (α-1,6 arm) 6,280.0 
SiaT Asialo glycoprotein 330.0 50.0 Rat expressed in COS-1 cells.262 
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Table 9. Transport protein parameters 
Transport protein 
Vmax 
(pmol mgprot-1 min-1) 
kT, k 
(min-1) 
LMN,OPQR (µM) 
TP1 (UDP-GlcNAc/UMP) 915.0 1,084 7.13240 
TP2 (GDP-Fuc/GMP) 1.4 230 7.5243 
TP3 (UDP-Gal/UMP) 22.0 689 2.4242 
TP4 (CMP-Neu5Ac/CMP) 335.0 397 1.3241 
Table 10. Intracellular, cytosolic and Golgi NSD concentrations 
NSD 
Total intracellular 
concentration (µM) 
Concentration in 
Golgi lumen (µM) 
Concentration 
in cytosol (µM) 
UDP-GlcNAc 36.7263 1,057 26.4 
GDP-Fuc 20.0264 576 14.4 
UDP-Gal 9.2263 265 6.6 
CMP-SA 33.0110 950 23.7 
  
The parameters that define enzyme distribution were estimated by seeking the minimum 
amount of total enzyme (the integral of enzyme concentration over the length of Golgi) 
necessary to achieve terminal oligosaccharide processing, including 50% sialylation. The 
parameter values were obtained through a multiple-shooting control vector parameterization 
algorithm, which i) chooses the duration of each control interval and the values of the control 
and differential variables at the start of each control interval, ii) solves the dynamic model over 
the time horizon to determine the time variation of all variables in the system and with them, 
obtains the values for the objective function, the constraints and the differences between 
computed values and the ones chosen by the optimiser at the start of each interval. The 
optimiser finally revises the first step and repeats the procedure until the objective function is 
minimised, the constraints are satisfied and the differential variables are continuous at the 
beginning of each control interval.265 
The calculated enzyme concentration profiles along with the estimated parameters that 
define them are presented in Figure 15A. The enzymes appear in a sequential fashion, but 
overlap considerably, which is consistent with previous findings.62, 227 The order in which the 
enzymes appear is related to the reaction sequence itself. For example, the early mannose-
trimming reactions occur at early stages of the reaction scheme, thus ManI appears first. Co-
localization of enzymes was found to have an impact on the reaction kinetics. Specifically, in 
simulations where ManI did not overlap with GnTI, higher overall enzyme concentration was 
necessary to achieve full removal of the mannose residues from the precursor oligosaccharide 
(GnTI pushes the mannose trimming reactions forward and, to an extent avoids product 
inhibition of ManI activity). 
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Figure 15. Resident protein profiles along the Golgi Apparatus225 
A: Calculated glycosylation enzyme concentration profiles along the normalised length of Golgi. B 
and C: Comparison of the optimisation results for enzyme distribution (Opt.) with those reported 
by Rabouille et al.62 (Rep.) D: Calculated TP concentration profiles. The vertical lines in (A) and (D) 
present the regions of the Golgi space. The tables alongside A and D present the parameters that 
were estimated and used to calculate the presented profiles. 
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Similar effects were observed relating FucT with GnTII and GalT with SiaT. The total 
concentration of enzymes (the integral of the presented profiles over the length of Golgi, z) 
ranged between 3.2 µM and 9.1 µM, which is consistent with the glycosylation enzyme 
concentration range of 1 µM to 35 µM estimated through multiplying the membrane-bound 
protein content of 38,000 proteins µm-2 reported by Quinn et al.266 by the molar fraction of Golgi 
glycosylation enzymes reported by Gilchrist et al.267  
A comparison between the estimated enzyme parameters and those reported by Rabouille 
et al.62 is presented in Figure 15B and C. It is clear from Figure 15B that the experimental 
profiles are broader, whereas the simulation profiles are narrower and mainly localized in the 
medial Golgi. This deviation is likely due to the underlying assumptions of the model 
(symmetric enzyme concentration profiles and minimum enzyme required for full 
oligosaccharide processing), but also because of the “snap-shot” representation of the Rabouille 
et al.62 data. In Figure 15C, good agreement can be seen between the experimental and 
estimated profiles. The enzyme profiles presented in Figure 15 also satisfy previously reported 
properties: i) GnTI co-localizes with ManII in the medial Golgi, ii) GnTI, ManII, GalT and SiaT 
coexist in the trans Golgi region, and iii) GalT and SiaT co-localize in the trans Golgi (TG) and the 
trans Golgi network (TGN) regions.62, 120, 227 Hence, it is possible to consider the estimated 
enzyme concentration profiles as representative of the system. 
3.5.2. Parameter estimation for transport protein concentration 
profiles 
The transport protein concentration profiles were also assumed to follow normal functions so 
that the effect of Golgi resident protein recycling would be represented. Low availability of NSDs 
for the Golgi glycosylation reactions has been linked to cell metabolism and not to deficiency of 
their transport into the Golgi107, 118, 268 with the with the exception of Rijcken et al.,111 who 
observed an interesting control mechanism by which UDP-GlcNAc was observed to control 
transport of CMP-Neu5Ac into Golgi. This implies that when NSDs are sufficiently available in 
the cytosol, the transport of NSDs into the Golgi is very close to the rate of accumulation of 
respective by-products which, in turn, is the rate of consumption for each NSD. By assuming 
that the rate of by-product dephosphorylation is much faster than their accumulation, the 
objective function presented as equation 10 was defined and minimized through a multiple-
shooting control vector parameterization algorithm265 to estimate the missing TP parameters. 
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A comparison between the rate of consumption of NSDs and the rate of their transport is 
provided in Appendix IV. Both sets of data overlap showing minimization of the objective 
function presented in equation 10. Results for the parameter estimation are presented in Figure 
15D. It has been previously reported that the UDP-GlcNac TP closely co-localizes with ManII,269 
the UDP-Gal transporter with GalT270 and the CMP-Neu5Ac transporter with SiaT.271 A 
comparison of Figure 15A with Figure 15D shows that these observations are satisfied. In 
addition, the estimated cumulative concentration of transport proteins along the Golgi 
apparatus ranges between 900 µmol µm-2 and 1,700 µmol µm-2 which is well within the total 
membrane-bound protein density of 38,000 reported for the Golgi apparatus of baby hamster 
kidney cells.266 
3.6. Parameter estimation and model simulation 
Most of the enzyme kinetic parameters were obtained through experiments performed using 
free oligosaccharides as substrates (see Table 8). However, Tabas and Kornfeld233 also 
performed kinetic experiments using an immunoglobulin M-derived glycopeptide. Their results 
showed that at low glycopeptide concentrations, the kinetic parameters are similar to those of 
the free oligosaccharide, but at high glycopeptide concentration, the rates diverge, implying a 
change in affinity of the enzyme for the substrate. This evident change in enzyme-glycoprotein 
affinity along with the spatial constraints associated to the mAb Fc oligosaccharides served as 
the basis to consider the dissociation constants as the adjustment criterions when trying to 
match experimentally-obtained mAb Fc oligosaccharide profiles. 
Two recent publications reporting the oligosaccharide profiles of commercial mAbs45, 191 
were used as target data so that unknown kinetic parameters of the model could be estimated. 
The data were introduced into gPROMS version 3.4.0, which is based on a SRQPD sequential 
quadratic programming code.265 Parameter estimation in gPROMS v.3.4.0 is based on the 
maximum likelihood formulation that attempts to determine values for the uncertain physical 
and variance model parameters which maximize the probability that the model will predict the 
values obtained from experimental measurements. 
Parameter estimation was only performed for the dissociation constants of GnTII, FucT and 
GalT because very little or no high mannose, hybrid, bisecting GlcNAc or sialylation were 
3.6. PARAMETER ESTIMATION AND MODEL SIMULATION 69 
 
 
reported by Stadlmann et al.45 and Nakano et al.191 The Kd,i for GnTIII and SiaT were defined as 
1x1012 to represent that the oligosaccharide structures of the mAb Fc are inaccessible for GnTIII 
and SiaT. Also, the dissociation constant for the addition of galactose to the α-1,6 arm of the 
biantennary oligosaccharide when the α-1,3 arm is already occupied (KdiGalTa2B) was defined 
as 50-fold that of KdiGalTa1A based on the previously reported branch specificity of GalT.261 
The estimated parameters are presented in Table 11 and the terminal oligosaccharide profiles 
calculated with these parameters are presented in Figure 18. Additional dynamic results 
showing the oligosaccharide profile distributions along the length of the Golgi apparatus (z) are 
presented in Figure 16. 
Table 11. Estimated dissociation constants with present model225 
Dissociation 
Constant (µM) Herceptin Rituxan Remicade Erbitux Y,ZZ  1,572 1,180 462 366 Y, 711 593 176 145 Y,[ 467 465 169 72 Y,3  143 166 24 5.4 Y,3[  23 105 29 24 Y,)  59 87 149 510 
Deviation from 
experimental data (%) 
1.9 10.4 0.5 2.2 
 
In three cases, the experimental data is reproduced to within 2.5% total deviation. The 
exception is Rituxan, where the net deviation is 10%. The main source for the larger deviation is 
the bi-galactosylated, core fucosylated oligosaccharide 57 shown in Figure 18. Three of the six 
dissociation constants that were estimated correspond to the specificity of GalT for different 
arms of the oligosaccharide. We believe that the higher deviation associated with OS57 in the 
Rituxan data is due to the constraints generated by the relationship between the three GalT 
dissociation constants. If the values for any of the Y, values change, they affect the synthesis 
of more processed oligosaccharides and yield higher deviations associated to species OS31 and 
OS44/45. In reality, each oligosaccharide species should have its own affinity for the different 
enzymes due to enzyme-substrate specificity. We believe that, for the Rituxan data, a deviation 
of 10% is acceptable considering that the number of GalT-associated Y, parameters has been 
reduced from a maximum of 36 given by our reaction scheme (see Figure 12) to only three. 
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Figure 16. Calculated spatial and temporal oligosaccharide profiles within Golgi. 
(A) shows the molar fraction profile of an early oligosaccharide as a function of time and distance 
along the Golgi. (B) corresponds to the profile of an intermediate oligosaccharide and (C) and (D) 
present the profiles of terminal oligosaccahrides. 
3.7. Comparison with previous models 
3.7.1. Effect of kinetic mechanisms 
As mentioned in previous sections, the present model builds on the knowledge generated by 
previous models of the Golgi N-linked glycosylation process. In the three previous models,31-33 
all enzymes involved in the sugar addition reactions of the process were assumed to act with a 
random- order kinetic mechanism.  However, literature suggests that GnTI, GnTII and GalT 
function with a sequential-order kinetic mechanism.231, 237 When comparing the rate 
expressions derived for both mechanisms, we find that there are additional terms in the 
denominator for the random-order kinetic expression (compare the denominator of equations 7 
and 8). These terms correspond to additional enzyme-substrate complexes (EOSi, EOSz and 
EOSi+1) that occur in random-order kinetics, but are absent in sequential-order kinetics. 
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Figure 17. Comparison of present model with previous ones225 
(A) Compares the profiles of sequential-order kinetics (solid lines) with those of random-order 
kinetics (dashed lines) as a function of oligosaccharide concentration at three different NSD 
concentrations (60, 100, and 300mM). (B) Compares oligosaccharide profiles calculated with only 
random-order kinetics (  ) with those calculated with the correct kinetic mechanism for each 
enzyme (  ). 
Figure 17 compares the kinetic mechanisms assumed by previous models (only random-
order) with the mechanisms included in this section (combination of sequential-order and 
random-order kinetics, as shown in T). Figure 17A compares the impact the different 
mechanisms have on the reaction rate values and Figure 17B shows how considering the 
appropriate kinetic mechanisms influence the oligosaccharide profiles calculated by the model. 
From the data, it is clear that the different kinetic mechanisms indeed affect the calculated 
oligosaccharide profiles. In order to assess the impact of the different kinetic mechanisms on 
parameter estimation, the dissociation constants for the mAb-bound oligosaccharides were 
estimated as described in the previous section but with the model containing only random-
order kinetics. Successful reproduction of the commercial mAb oligosaccharide profiles was 
achieved. However, we believe that including the actual kinetic mechanisms for each enzyme 
generates no further complexity in the model, and therefore, should be used to represent the 
Golgi glycosylation process with higher realism. 
3.7.2. Model performance and parameter estimation strategy 
The only previous model that attempted to reproduce experimentally-observed oligosaccharide 
profiles was that of Krambeck and Betenbaugh.32 They attempted to match the oligosaccharide 
profiles for human thrombopoietin by adjusting the total glycosylation enzyme concentration 
while maintaining the corresponding spatial distributions constant. In contrast, Hossler et al.33  
did not attempt to match experimental data given the scope of their work. Instead, they 
estimated the glycosylation enzyme concentrations that would maximize terminally-processed 
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oligosaccharides. Under this methodology, Hossler et al. also assumed enzyme distribution 
along Golgi as constant. 
 
Figure 18. Calculated vs. experimental oligosaccharide profiles225 
Reported data from Nakano et al.191 for Herceptin (A) and Rituxan (B) as well as data from 
Stadlmann et al.45 for Remicade (C) and Erbitux (D) is shown with the dark bars (  ). The 
subsequent bars correspond to results calculated with the present model (  ), the Krambeck & 
Betenbaugh model (  ) and the Hossler et al. model (  ). 
In order to compare the performance of our model with the previous ones, we defined each 
of them, including their underlying assumptions and parameters in gPROMS 3.4.0. The sole 
modification was that the reaction scheme was reduced to the one presented in Figure 12, 
which is specific for mAb Fc oligosaccharides. When simulating both models with their original 
parameters, they both calculated unrealistically high proportions of the bi-galactosylated and 
core fucosylated oligosaccharide 57 (76% for Krambeck and Betenbaugh and 41% for Hossler 
et al.). These values are five and 2.5 times the value of 16.1% reported for Remicade presented 
in Figure 18. The large discrepancies are likely due to the combination of parameters and 
assumptions the previous authors considered and make the results uncomparable with those 
generated by our model. 
In order to produce a more reasonable comparison between the different models, we used 
the strategy proposed by Krambeck and Betenbaugh of estimating the total enzyme 
concentration to match experimental oligosaccharide profiles. So that the results are 
comparable, the same number of parameters was estimated in all cases: six dissociation 
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constants for the current model (as described in previous sections) and the total concentration 
of six glycosylation enzymes for the previous models. This approach was implemented in the 
parameter estimation function of gPROMS version 3.4.0, which has been described in previously 
in this thesis. The estimated parameters, along with the deviations from the experimental data 
are presented in Table 12. 
Table 12. Estimated parameters with previous models225 
It is clear from the data presented in Table 12 that the values obtained for both of the 
previous models are dissimilar. This is very likely due to differences in the kinetic parameters 
assumed by each model. Namely, Hossler and collaborators derived the turnover rate for each 
enzyme by multiplying the reported maximum reaction rate by the molecular weight of the 
monomeric form of each enzyme, while Krambeck and Betenbaugh assumed the molecular 
weight to be that of the entire enzymatic complex. Because of this, the estimated enzyme 
concentrations for the Hossler et al. model are much higher than those estimated for the 
Krambeck & Betenbaugh model.  It is worth noting that due to this assumption by Hossler et al., 
the total amount of resident protein (both with the original enzyme concentrations and the 
estimated ones), present in the Golgi is much higher than the maximum membrane bound 
protein density reported by Quinn et al.,266 thus deeming these concentration profiles 
unfeasible. In contrast, in the current model, the total amount of resident protein in Golgi is 
approximately 60% of the value reported by Quinn et al.266 This, along with the implication of 
resident protein recycling from the Golgi maturation model, suggests that our estimated 
resident protein profiles are more realistic than simple constant concentration profiles for 
resident proteins. 
A comparison of the terminal oligosaccharide profiles calculated with the estimated 
parameters has been included in Figure 18. All but one case (Erbitux profiles calculated with the 
Krambeck and Betenbaugh model) show much larger deviations from the experimental data 
than those obtained with our proposed model and parameter estimation strategy. On average, 
our strategy of estimating dissociation constants yields deviations which are 4.5 times lower 
 K&B Model (µM)  Hossler et al. (µM) 
Enzyme Herceptin Rituxan Remicade Erbitux  Herceptin Rituxan Remicade Erbitux 
ManI 1.21 1.5 1.67 2.06  20.85 19.91 27.34 27.95 
ManII 9.29 6.16 4.07 1.77  6.20 21.88 6.97 9.22 
GnTI 2.54 1.58 9.27 3.98  7.72 9.58 2.35 2.40 
GnTII 0.18 0.23 1.58 0.36  0.30 0.49 0.64 0.42 
FucT 0.82 0.85 0.82 0.81  1.10 1.59 18.89 17.15 
GalT 0.014 0.019 0.021 0.012  8.18 10.62 10.46 6.34 
Deviation from 
experimental 
data (%) 
1.9 10.4 0.5 2.2  1.9 10.4 0.5 2.2 
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than those obtained with the Krambeck and Betenbaugh model and 5.5 times lower than those 
obtained with the Hossler et al. model. The cause of these discrepancies is a combination of 
model structure and the estimation strategy itself (estimating Kd,is versus estimating enzyme 
concentrations). In order to isolate these effects, a second series of parameter estimations were 
performed on the previous models. In this case, the enzyme concentrations were set at the 
original values assumed by each model and the dissociation constants were estimated. When 
estimated for the Krambeck & Betenbaugh model, the Kd,is produced terminal oligosaccharide 
profiles that deviate 5 times more than the current model. The results for the Hossler et al. Kd,i 
estimation deviated 9 times more than those presented in Table 11. In both cases, the deviations 
are higher than those obtained by estimating total enzyme concentration.  
These results suggest that the reason why the current model out-performs the previous 
ones is due to structure and not the estimation strategy. More specifically, the results suggest 
that the definition of the glycosylation enzyme distributions is why the current model out-
performs the previous ones in reproducing experimental oligosaccharide profiles. In order to 
confirm this, a final set of parameter estimations were performed to obtain the distribution of 
glycosylation enzymes that could match experimental data. In this case, the estimations yielded 
results that are comparable with those obtained with the model presented herein (data not 
shown). However, it is worth noting that, in these cases, 24 parameters were estimated: the 
concentration of the six glycosylation enzymes in each of the four Golgi compartments. It is 
possible that good reproduction of the experimental oligosaccharide profiles was achieved due 
to over-fitting. 
This section has compared the performance of the current model with previous ones.  The 
results suggest that the present model along with the methods used to estimate its unknown 
parameters out-performs the previous ones in reproducing experimental mAb Fc 
oligosaccharide profiles. Furthermore, if mathematical models for mAb Fc N-linked 
glycosylation were to be used for bioprocess design, control and optimization following the 
Quality by Design paradigm, it would be necessary for them to represent all the relevant known 
phenomena surrounding the process. In this section, we have shown that our additional 
considerations (appropriate kinetic mechanisms and Golgi protein recycling) have contributed 
to the fidelity of the model while avoiding significant additional complexity. 
3.8. Case study: glycotransferase silencing 
Additional simulations were performed in order to further assess the performance of the model 
against independent sets of data. These simulations were based on the study by Imai-Nishiya 
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and collaborators,86 in which the gene encoding for the FucT enzyme was silenced using small 
interfering RNA (siRNA). As a first step, the dissociation constants for GnTII, FucT and GalT 
were estimated (as described in preceding sections) to match the parental oligosaccharide 
profile. 
 
Figure 19. FucT silencing225 
(A) Shows the experimental86 and calculated glycan profiles prior to FucT silencing. (B) shows 
the glycan profiles after FucT silencing. The experimentally observed glycan profiles ( ) 
are compared with those calculated with the current model ( ), the K&B2005 model ( ) 
and the Hossler 2007 model ( ). 
A comparison between the calculated and parental oligosaccharide profiles is presented as 
Figure 19A, which shows that the profiles obtained through simulation closely match the 
reported ones yielding a net deviation of 3.4%. Next, the concentration of FucT was set to zero 
within the model and a simulation was performed. A comparison of the simulated and reported 
oligosaccharide profiles after FucT silencing is presented in Figure 19B. In this case a slightly 
higher deviation of 4.7% was obtained. The same procedure was performed with the Krambeck 
& Betenbaugh and the Hossler et al. model. The Hossler et al. model had a net deviation of 4.0%, 
which is comparable with the one obtained with the current model. In contrast, the Krambeck & 
Betenbaugh model had a deviation of 17%. Upon setting the FucT concentration to zero, the 
Hossler et al. model calculated oligosaccharide distributions with a 19.3% deviation from the 
experimental ones, while the Krambeck & Betenbaugh model had a 20% deviation. These 
results show that the current model is capable of reproducing the effect of genetic silencing of a 
glycosylation enzyme to a very high degree whereas the previous models seem incapable of 
reproducing the effect accurately. The fact that the current model reproduces this phenomenon 
so effectively makes it useful for exploring cell engineering strategies for the production of 
mAbs with a desired oligosaccharide profile. 
The model for mAb Fc N-linked glycosylation presented in this chapter has approximated 
the Golgi apparatus to a single PFR so that cisternal maturation is represented. Also, a series of 
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optimisation-based strategies have been defined to estimate the unknown parameters that 
define the resident protein concentration profiles within the Golgi apparatus. These 
optimisation strategies have yielded results that are in agreement with previous reports on 
these topics. Further optimisation methods have been implemented to estimate kinetic 
parameters of the system, and with the obtained parameters, the model has shown the 
capability of reproducing the experimentally observed glycosylation profiles of commercial 
mAbs. In addition, this model was compared with previously published ones to observe how its 
novel features contribute to improved representation of mAb N-linked glycosylation. 
Inclusion of the appropriate kinetic mechanisms for the glycosylation enzymes involved in 
the process has been shown to impact model performance considerably. Furthermore, the 
manner in which the resident protein profiles were defined and the subsequent strategy for 
estimating unknown kinetic parameters resulted in an improved reproduction of 
experimentally observed mAb Fc glycan profiles. These promising results were obtained 
without adding significant complexity to the model, when compared to previous ones. 
Finally, this model was shown to replicate the effects of silencing the fucose transferase 
enzyme. Accurate reproduction of this complex perturbation not only gives us confidence in the 
model’s performance, but also leads us to conclude that many of the underlying assumptions 
which were made during its development capture several of the fundamental mechanisms that 
define the N-linked glycosylation process. This, in turn, is consistent with our overall objective 
of representing the mechanistic links between process conditions and mAb Fc glycosylation.  
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Chapter 4  
Culture dynamics and NSD model 
4.1.  Cell culture dynamics model 
The overall goal of this research project is to produce a mathematical model that connects 
nutrient availability with cell growth, mAb productivity, nucleotide sugar metabolism and mAb 
Fc glycosylation. In order to integrate these elements, a model that describes cell culture 
dynamics as a function of glucose and glutamine was developed. This culture dynamics model 
was largely based on Monod-type kinetics, although it was further adapted to account for non-
ideal effects that were observed experimentally. This model has four constituting elements, 
which will be described in the following sections: 
4.1.1. Cell growth and death 
This element of the culture dynamics model is largely based on previous publications from our 
research group.246, 272 Within these models, perfect mixing is assumed, and a total material 
balance can be defined: WUW! " # $ #	  …Eq. 11 
where V is the total cell culture volume within the bioreactor and Fin and Fout are the volumetric 
flowrates in and out of the bioreactor. A balance for viable cells within the bioreactor is defined 
as: WU\]W! " ^U\] $ YU\] $ #	\]  …Eq. 12 
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here, Xv is the concentration of viable cells	`3Xa	]b	cdefghDijfg k, µ is the specific growth rate l3Xa	].mgfn3Xa	].	op q and kd is the specific death rate l3Xa	Y.mgfn3Xa	].	op q. 
The specific growth rate for mammalian cells is frequently defined as a saturation-type 
function which depends on the essential nutrients present during cell culture:273 
^ " ^ ? rst5	u, + rst5	uG? rstv	u, + rstv	uG …Eq. 13 
where µmax is the maximum growth rate in l3Xa	].mgfn3Xa	].	op q, [Glcext] and [Glnext]  are the 
extracellular concentrations of glucose and glutamine, respectively and their units are [mM]. 
KM,glc and KM,gln represent the Monod constant for growth with respect to glucose and glutamine, 
and are expressed in [mM]. 
For this work, the specific death rate was defined as an inverse function of glucose and 
glutamine availability, with the following form: 
Y " Y,, ? Y,Y, + rst5	uG + Y,, ? Y,Y, + rstv	uG …Eq. 14 
kd,max,glc is the maximum death rate under glucose deprivation and kd,max,gln is the maximum death 
rate under glutamine depletion The units of both are l3Xa	Y.mgfn3Xa	].	op q. Kd,glc and Kd,gln are the 
inverse saturation death constants for either component, and are expressed in [mM]. 
Equation 14 represents death of cells as a function of extracellular glucose and glutamine 
depletion. The terms for each nutrient are added because cells may compensate the lack of one 
nutrient with the other. Specifically, cells have been reported to use glutamine as their sole 
source of carbon when they are under glucose deprivation.274, 275 Furthermore, mammalian cells 
also have the ability to recycle organic nitrogen species and survive entirely on glucose.274, 275 
When st5	 ≫ Y,  and stv	 ≫ Y,, the death rate, Y x 0. Inversely, under 
simultaneous glucose and glutamine deprivation, st5	 ≪ Y, and stv	 ≪ Y,, Y x Y,, + Y,,. The more interesting cases are when one of the nutrients is 
depleted while the other one is in excess: when st5	 ≫ Y, and stv	 ≪ Y,, 	Y x Y,,; and when st5	 ≪ Y, and stv	 ≫ Y, , Y x Y,, . Therefore, 
equation 14 describes cell death as a function of depletion of one essential nutrient or the other, 
but also has the capability of describing the compounded effect of depletion of both nutrients. 
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4.1.2. Cell metabolism 
The rates at which nutrients are consumed is directly associated with their uptake by cellular 
metabolism to produce biomass (more live cells), product (mAb) and additional intracellular 
components. A material balance can be performed on the essential nutrients considered 
throughout this thesis (glucose and glutamine): 
WUrst5	uW! " $&\]U + #rst5u $ #	rst5	u …Eq. 15 
WUrstv	uW! " $&\]U + #rstvu $ #	rstv	u …Eq. 16 
In equations 15 and 16, qglc and qgln represent the specific glucose and glutamine uptake 
rates, respectively. The units for these terms are `{|i,if}~3Xa	].	opk and `{|},if}~3Xa	].	opk. The specific 
uptake for glucose and glutamine are defined as: 
& " ^]  + ̅ …Eq. 17 
& " ^]  + ̅ …Eq. 18 
where ]   is the biomass yield coefficient for glucose, expressed in l3Xa 	].mgfn{|i,if}~ q and  ]   is the biomass yield coefficient for glutamine, in units of l3Xa	].mgfn{|},if}~ q. Equations 17 and 
18, are composed of two additive terms. The one on the left corresponds to the amount of 
nutrient that is being consumed to produce biomass, and is therefore proportional to the 
specific growth rate, µ. The second terms, mglc and mgln are the maintenance coefficients for 
glucose and glutamine, respectively. The units for these terms are l{|i,ChjYih||> 		op q and l{|},ChjYih||> 		op q.The additional term ̅ is the average surface area for a single cell in [dm2]. 
Conceptually, these terms represent the amount of glucose and glutamine that is being 
consumed for all other metabolic activity that is not related with cell growth. These terms are 
key for the development of this model and will be discussed further in subsequent sections of 
this chapter. 
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The remaining elements to describe cellular metabolism involve the accumulation of 
metabolites produced by cells in culture. Specifically, the prevalent metabolites produced 
through cell metabolism are ammonia and lactate. The corresponding material balances for 
these species are: 
WUr5!uW! " &	\]U $ #	r5!u …Eq. 19 
WUruW! " &\]U $ #	ru …Eq. 20 
The concentration of each species is given in [mM]. Equations 19 and 20 include terms for 
specific productivity for each of the metabolites, qlact and qamm. The units for these terms are `|Dij,mgfn3Xa	].	op k and `DCC,mgfn3Xa	].	op k. A further description of these terms is: 
&	 " 	  & …Eq. 21 
& "   & …Eq. 22 
The terms 	   and    are the yield coefficients for lactate from glucose and 
ammonia from glutamine, respectively. Equations 21 and 22 express the accumulation of lactate 
and ammonia during cell culture as a function of the total amount of glucose and glutamine that 
is being consumed by the cells.  
4.1.3. mAb production 
The final element regarding extracellular culture dynamics is the one concerning mAb 
accumulation. Although groups have previously described synthesis and secretion of mAbs 
more elaborately,246, 272, 276 for this work, a simpler approach was made: 
WUruW! " &b\]U $ #	ru …Eq. 23 
where qmAb is the specific productivity of antibody in `Cd,mgfn	3Xa	].	opk. Equation 23 shows that mAb 
accumulation is proportional to the viable cell density, Xv. The mAb specific productivity, qmAb 
was, in turn, defined as: 
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&b " b ]  …Eq. 24 
In equation 24, it can be seen that the mAb specific productivity is considered to be constant 
and equal to the yield coefficient, b ] , which is expressed in units of `Cd,mgfn	3Xa	].	opk  . 
Equations 11 through 24 have been defined to capture the extracellular dynamics of cell culture, 
and have included expressions for cell growth and death, as well as nutrient consumption, 
metabolite accumulation and mAb productivity. At this stage, however, these equations have 
not considered mechanistic links between the extracellular environment and what occurs inside 
the cells that are being cultured. The following section will present which elements of the 
equations presented above are used to couple extracellular culture dynamics with intracellular 
accumulation of metabolites. 
4.2. NSD metabolism 
The accumulation of metabolites inside cells may occur through two phenomena. The first one 
is transport of species from the extracellular environment into the cells. These processes may 
occur by purely physical phenomena such as diffusion, but are also commonly mediated by 
biochemical phenomena such as protein-mediated active transport.277 The second way in which 
metabolites may accumulate inside cells is via biochemical synthesis from other nutrients 
supplied in the medium. 
Within the context of this work, it is necessary to describe the accumulation of nucleotide 
sugars (NSDs) within cells so that their availability can be further connected with the 
glycosylation reactions that occur in the Golgi apparatus. From the NSD biosynthetic pathway 
presented in Figure 9 of this thesis, it can be seen that all NSDs can be formed using glucose and 
glutamine as substrates. The initial step towards mechanistically describing the intracellular 
dynamics of NSDs is to define how glucose and glutamine are accumulated inside cells. 
The intracellular accumulation of glucose and glutamine was defined with the following 
equations: 
WUrst5	uW! " ,U $ U,,..1.23  …Eq. 25 
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WUrstv	uW! " ,U $ U , ,..1.23  
…Eq. 26 
In equations 25 and 26, [Glcint] and [Glnint] are the intracellular concentration of glucose and 
glutamine. They are both expressed in [µM] (hence the conversion factor of 1e3). , is the 
average specific area of the cell in lYih||>Yih|| q; U is the average volume of the cell in [dm3]; and rn 
and rm are biochemical reactions where intracellular glucose and glutamine are consumed to 
produce intracellular NSDs. 
Equations 17 and 18 defined two terms that describe the uptake of glucose and glutamine 
that is not destined for biomass production (mglc and mgln). Based on the conceptual meaning of 
these terms, they have been used as the inlets for intracellular glucose and glutamine 
accumulation and were defined as: 
 " ,rst5	u …Eq. 27 
 " ,rstv	u …Eq. 28 
A first-order transport rate expression was defined for both glucose and glutamine based on 
experimental results that will be discussed in subsequent sections of this thesis. In equations 27 
and 28, mglc and mgln have units of l{|i,e}jhg}D|e~hnYih||> 		op q  and l{|},e}jhg}D|e~hnYih||> 		op q , respectively. The 
units for extracellular glucose and glutamine concentration are [mM]. Consequently, the 
dimensions of kT,glc and kT,gln are l {|i,e}jhg}D|e~hnYih||> 	{|i,hEj		opq and l {|},e}jhg}D|e~hnYih||> 	{|},hEj 		opq. 
4.3. NSD reaction network and model reduction 
With equations 25 and 26 describing the intracellular accumulation of glucose and glutamine 
and considering that all NSDs involved in N-linked glycosylation are synthesised using these 
nutrients as substrates, the next step in model development is to define how NSDs accumulate 
intracellularly as a function of glucose and glutamine availability. Figure 9 shows the 
biosynthetic pathway for NSDs in mammalian cells. 
The nucleotide sugar biosynthetic pathway contains 34 components which are produced by 
36 enzyme-catalysed reactions, of which 26 are reversible and 10 are irreversible. All of these 
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components are synthesised from simple carbon and nitrogen sources that are transported 
from the extracellular environment into the cells. These simple carbon sources may be glucose, 
glutamine, galactose, fructose, mannose, N-acetylglucosamine (GlcNAc) and fucose, among 
others. Apart from exceptions where cell culture medium has been supplemented with 
nucleotide sugars,278 N-acetylmannosamine (ManNAc),110 fucose analogues89 and other carbon 
sources,105 the essential carbon and organic nitrogen sources for cell culture are glucose and 
glutamine. As discussed previously in this thesis, glucose and glutamine will be considered 
herein as the only nutrients that lead to NSD biosynthesis. 
A crucial issue when kinetically modelling intracellular biochemical networks is that data 
for the concentration of many of the intermediate species involved in the pathway are unknown. 
Moreover, many of these species are difficult to measure given their low intracellular 
concentration and, in many cases, extremely high turnover.279-281 
Given these difficulties, the metabolic pathway for NSDs was heuristically reduced so that 
unknown species along with uncertain complexity is removed from the final model. The 
considerations behind this heuristic model reduction are: 
1. Glucose and glutamine are considered as the only nutrients that contribute to the 
pathway. 
2. Additional components for NSD synthesis, such as nucleotides (ATP, CTP, GTP and 
UTP) are considered to be in excess and, thus, do not limit accumulation of NSDs. 
The reasoning behind this is that nucleotides are used by cells as energy currency 
and also as substrates for fundamental functions such as DNA and RNA synthesis. 
Elevated cellular requirement for these components lead us to assume that their 
availability throughout cell culture will be in excess with respect to NSDs. 
3. The number of total species has been reduced from 33 to 9 (Glcint, Glnint, UDP-
GlcNAc, UDP-Glc, GDP-Man, UDP-GalNAc, CMP-Neu5Ac, UDP-Gal, GDP-Fuc). This has 
been done because many of the intermediate species along the pathway cannot be 
measured. Each species that is included in the model and is not measured can be 
considered as an unconstrained degree of freedom. These in turn, extend the space 
of possible solutions of the system and potentially reduce model fidelity.279, 280 
4. Implicit in assumption (3) is the reduction of reactions from 35 in the original 
pathway to 7. Each reaction in the reduced set represents the synthesis of NSDs 
either from glucose and glutamine or a preceding NSD in the pathway. Each of these 
reactions is shown by a coloured arrow in Figure 20. One reaction in Figure 20 uses 
glucose and glutamine as substrates to produce UDP-GlcNAc (blue arrow). Another 
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two reactions consume intracellular glucose to produce UDP-Glc (red arrow) and 
GDP-Man (green arrow). The remaining reactions produce peripheral NSDs from 
parent NSDs. UDP-GalNAc (orange arrow) and CMP-Neu5Ac (purple arrow) are 
produced from UDP-GlcNAc. UDP-Gal is produced from UDP-Glc (yellow arrow) and 
GDP-Fucose is produced from GDP-Man (red arrow).  
5. All reported interrelations between the components considered in the reduced 
reaction scheme have been incorporated in the reaction kinetics. This will be 
discussed further in this section.  
6. Reversibility of reactions has been neglected because the flux of material in the 
system is assumed to go from glucose and glutamine towards NSDs. The basis for 
this assumption is that NSDs are continuously transported into the Golgi apparatus, 
thus driving the flux of the pathway in that direction. 
 
Figure 20. Reduced NSD biosynthetic pathway23 
The coloured arrows represent the single reactions that were defined from the inputs (glucose 
and glutamine) to each of the NSDs considered in this work (circled). ( ) represents the single 
UDP-GlcNAc reaction, ( ) for UDP-Glc, ( ) for GDP-Man, ( ) for UDP-GalNAc, ( ) for CMP-Neu5Ac, 
( ) for UDP-Gal and ( ) for GDP-Fuc. 
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Using the assumptions outlined above, and the intracellular glucose and glutamine 
concentrations as defined by equations 25 and 26, the material balances for intracellular NSDs 
are: 
The Fouts in equations 29 through 35 are defined as a function of their consumption in the 
glycosylation reactions which occur in the Golgi apparatus. These reactions are, in turn, a 
function of mAb specific productivity: 
Equation 36 was defined to relate the outlet of each NSD with the glycosylation process in 
the Golgi apparatus and the specific productivity. In equation 36, νk is the stoichiometric 
coefficient of NSDk consumed by attachment to the mAb-bound glycan `,J	Cd k.   is the 
WUr(4st55uW! " U9. $ . $ .: $ #	,  …Eq. 29 
WUr(4st5uW! " U9. $ .: $ #	,  …Eq. 30 
WUrs(4vuW! " U9. $ .: $ #	, …Eq. 31 
WUr(4st5uW! " U9.: $ #	,  …Eq. 32 
WUr4;55uW! " U9.: $ #	, …Eq. 33 
WUr(4stuW! " U9.: $ #	,  …Eq. 34 
WUrs(4#5uW! " U9.: $ #	,  …Eq. 35 
 
#	,6 " 6 I 1	K&b ? r (6u6, + r (6uG …Eq. 36 
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average molecular weight of the mAb in ` Cd	Cdk. qmAb is the specific productivity of mAb, as 
defined previously with equation 24, and has units of `Cd,mgfn	].	op k. The saturation term on the 
right hand side of equation 24 was introduced for the outlet term to be consistent with the Golgi 
NSD transport model defined in equation 9. The saturation constant, Kk,glyc has units of [µM]. 
These expressions, along with their corresponding parameters will be discussed further in 
subsequent sections. 
With equations 29 through 36 describing the material balances of all considered NSDs, the 
following step was to define the kinetics whereby these metabolites are produced. As stated in 
assumption 4 of this section, the number of reactions was reduced so that only the measurable 
components of the system would be considered. Despite the reasons underlying this 
assumption, lumping sequential reactions and their corresponding rates may jeopardise model 
fidelity.279, 280, 282 In an attempt to avoid losing accurate representation of the system’s 
phenomena and following our objective of capturing the mechanistic behaviour of the process, 
different kinetic mechanisms for each lumped reaction were defined as a function of reported 
regulatory behaviour associated with each branch of the pathway. 
4.3.1. Lumped NSD kinetic mechanisms 
The NSD pathway shown in Figure 20 shares the first two enzymatic reactions with glycolysis – 
the fundamental metabolic process whereby mammalian cells produce and store energy from 
glucose.283 From the intermediary fructose-6-phosphate (Fru-6P) on, glycolysis and NSD 
metabolism diverge both with respect to biochemical reactions and metabolites. Because of the 
prevalence of the glycolytic pathway, reactions up to, and including, biosynthesis of Fru-6P have 
been assumed to occur with unregulated saturation kinetics. From Fru-6P on, the different 
lumped reactions diverge to produce all NSDs considered in this work. It was therefore 
necessary to include regulatory features that depend on components considered in the reduced 
metabolic network defined in Figure 20. The mechanism and regulatory effects for the 
intermediary reactions along each lumped pathway was retrieved from the BRaunschweig 
ENzyme Database (BRENDA).284 
UDP-GlcNAc synthesis 
Five enzymes are involved in the synthesis of UDP-GlcNAc from glucose and glutamine. The first 
reaction is catalysed by glutamine-fructose-6-phosphate transaminase (EC 2.6.1.16) and is the 
step where the amine group from glutamine is transferred onto Fru-6P. This reaction is 
reported to have a random-ordered bi-bi mechanism and weak competitive inhibition by UDP-
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GlcNAc. The remaining reactions along this lumped pathway have been reported to have 
ordered ping-pong bi-bi kinetics.284 Ping-pong mechanisms are those where two irreversible 
sequential reactions must occur to generate the final product. In ping-pong kinetics an 
irreversible activation of the enzyme (i.e. by addition of a functional group) must occur before 
the activated enzyme can catalyse the second reaction.285 Being sequential reactions, if the rate 
of one is considered to be much higher than the other, the overall rate expression is reduced to 
simple Michaelis-Menten kinetics. Within this context, and assuming that the substrates for the 
fast reactions within ping-pong kinetics are mediated by metabolites that are assumed to be in 
excess (e.g. nucleotides, as was discussed previously), the kinetics collapse into single substrate 
Michaelis-Menten expressions. In an analogous fashion, the individual reactions along this 
branch are sequential, and thus are lumped into a single reaction rate. For these reasons, the 
overall rate of UDP-GlcNAc synthesis has been defined as a two-substrate, random-ordered rate 
without inhibitory terms: 
where U,  is the maximum turnover rate	`|iicih|| 	op k and ,  and , are the saturation constants with respect to glucose and glutamine respectively. 
UDP-Glc synthesis 
Two sequential reactions are required to synthesise UDP-Glc from glucose-6-P (Glc-6P). The 
first reaction (from Glc-6P to Glc-1P) is catalysed in parallel by three different enzymes. Two 
prevalent mechanisms have been described for these enzymes, which are: ordered, ping-pong 
bi-bi kinetics and single substrate Michaelis-Menten kinetics.284 Making the same assumptions 
described for UDP-GlcNAc synthesis (one reaction is much quicker than the other because its 
substrate is considered to be in excess), this reaction can be simplified to a single substrate 
Michaelis-Menten kinetic expression. 
The second reaction involved in UDP-Glc biosynthesis is from Glc-1P to UDP-Glc. This 
reaction has been reported to occur by sequential order bi-bi kinetics, where the first substrate 
to bind to the enzyme is UTP. Again, assuming that nucleotides are in excess within the system, 
sequential order kinetics may be reduced to single substrate Michaelis-Menten kinetics. 
. " U, ? rst5	u, + rst5	uG? rstv	u, + rstv	uG …Eq. 37 
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Again, two sequential reactions, whose kinetics have been reduced to simple Michaelis-
Menten kinetics, can, in turn, be lumped into a single reaction with the following rate 
expression: 
GDP-Man synthesis 
GDP-Man is produced by three sequential reactions that use Fru-6P as the starting substrate. 
Two of these reactions have been reported to occur by simple Michaelis-Menten kinetics, while 
the remaining one occurs by a ping-pong bi-bi mechanism. Again, under the rationale that has 
been presented for the previous NSDs, these three reactions have been lumped into a single 
substrate Michaelis-Menten kinetic equation: 
UDP-GalNAc and CMPNeu5Ac synthesis 
UDP-GalNAc is produced by a single epimerisation reaction that uses UDP-GlcNAc as a 
substrate. This reaction has been reported to have simple Michaelis-Menten kinetics, and thus 
its rate is defined as: 
In contrast, CMP-Neu5Ac is synthesised by four sequential reactions using UDP-GlcNAc as a 
starting substrate. All reactions down this pathway – except one – have been reported to occur 
with either single substrate Michaelis-Menten kinetics or random-order bi-bi mechanisms. The 
remaining reaction is catalysed by a bifunctional enzyme (EC5.1.3.14) that sequentially converts 
UDP-GlcNAc to ManNAc and ManNAc to ManNAc-6P.286 The ability of catalysing both reactions 
gives this enzyme interesting properties: it has been reported to have allosteric behaviour with 
respect to UDP-GlcNAc and inhibitory allorsterism with respect to CMP-Neu5Ac. Allosterism 
occurs when an enzyme has more than one binding pocket for the substrate(s) and product(s). 
Binding of susbtrates or products induces conformational changes in the enzyme which, in turn, 
may expose additional binding sites (positive cooperativity) or, conversely, reduce the available 
. " U, ? rst5	u, + rst5	uG …Eq. 38 
. " U, ? rst5	u, + rst5	uG …Eq. 39 
. " U, ? r(4st55u, + r(4st55uG …Eq. 40 
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binding sites (negative cooperativity).283 Kinetic studies on this enzyme have found that it has a 
cooperativity coefficient of 0.45 for UDP-GlcNAc and 4.1 for CMP-Neu5Ac.286 The cooperativity 
coefficient below one (negative cooperativity) of UDP-GlcNAc implies that binding of this NSD to 
the enzyme inhibits further substrate binding. This means that excess UDP-GlcNAc inhibits 
formation of ManNAc and thus, further metabolites down this pathway. The competitive 
allosterism exhibited by CMP-Neu5Ac, and its reported cooperativity coefficient above one 
implies that binding of this NSD to the enzyme exposes more sites for further binding (positive 
cooperativity) which, in turn, inhibits enzyme activity even further. From both allosteric effects, 
it is possible to conclude that excess UDP-GlcNAc inhibits eventual synthesis of CMP-Neu5Ac, 
and also that excess CMP-Neu5Ac accumulation strongly inhibits its own synthesis. Because this 
is the most regulated enzyme in the lumped pathway, we have assumed that it is the slowest 
reaction, and thus, its rate controls synthesis of CMP-Neu5Ac from UDP-GlcNAc. Being 
consistent with our attempts to provide mechanistic links between different elements of the 
glycosylation pathway, the rate for this lumped reaction has been defined as: 
UDP-Gal synthesis 
Single reactions are involved in the synthesis of UDP-Gal from UDP-Glc. These have been 
reported to occur in two different ways. The first is by simple epimerisation of UDP-Glc to form 
UDP-Gal. These reactions have been reported to follow single substrate Michaelis-Menten 
kinetics. The other mechanism by which UDP-Gal is produced is through a two substrate ping-
pong reaction. As has been done in previous cases, both of these reactions will be lumped into a 
single one that has simplified Michaelis-Menten kinetics: 
GDP-Fuc synthesis 
Two reactions convert GDP-Man into GDP-Fuc. The first of these reactions converts GDP-Man 
into GDP-4-keto-6-deoxy-D-mannose through a ping-pong bi-bi mechanism. The second 
reaction goes from GDP-4-keto-6-deoxy-D-mannose to GDP-Fuc and occurs through a random-
order bi-bi mechanism. The ping-pong reaction can be reduced to a simple Michaelis-Menten 
expression with the considerations that have previously been discussed in this section. The 
. " U,r(4st55uX., + r(4st55uX. I1 + rue, ¡h¢aiK.3 …Eq. 41 
. " U, ? r(4st5u, + r(4st5uG …Eq. 42 
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second reaction, however, has been reported to be non-competitively inhibited by GDP-Fuc.287 
Assuming that this second reaction is slower than the first, and that its secondary substrate 
(GTP) is assumed to be in excess (as has been the case for all other nucleotides throughout this 
section), the kinetic expression for this lumped pathway reduces to: 
CMP-Neu5Ac transport into Golgi 
A final effect that mechanistically links two of the NSDs considered in this work is the transport 
of CMP-Neu5Ac into the Golgi apparatus. It has widely been reported that the Golgi transporter 
for CMP-Neu5Ac is inhibited by presence of UDP-GlcNAc,111 as was also discussed in section 
2.5.1 of this thesis. In an attempt include this effect within our model, the equation 
corresponding to CMP-Neu5Ac consumption in the Golgi apparatus (Eq. 36) has been modified 
in the following way: 
An important consideration behind the model reduction strategy described throughout this 
section is that, because several sequential reactions have been lumped, all kinetic parameters 
shown in equations 37-43 are unknown and must be estimated from experimental data. 
Subsequent sections of this thesis will discuss how the experimental data was produced, how 
parameter estimation was performed and how the model performs when compared to the 
experimental data. 
 
This chapter has presented a mathematical model for cell culture dynamics which has been 
adapted to include a representation of the intracellular accumulation of nutrients and 
nucleotide sugars. This model has been coupled to the N-linked glycosylation model presented 
in Chapter 3 of this thesis through intracellular NSD availability and mAb productivity. This 
coupled model attempts to capture all reported features that mechanistically relate extracellular 
nutrient availability with the intracellular process of mAb N-linked glycosylation. 
. " U, 	rs(4vu, I1 + ru£¢i,¡D} + ru£¢i,¡D} rue,£¢i + rue,£¢iK …Eq. 43 
#	, " 6 ¤ 3¥	¦ &b 	r4;55u, I1 + ru ¡h¢ai,{|§i + rue,|ii,{|§iK …Eq. 44 
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Chapter 5  
Experimental materials and methods 
5.1. Cell culture 
5.1.1. Cell line and storage 
The cell line used for the experiments of this work is the murine hybridoma HFN 7.1 (CRL-1606 
from ATCC), which produces an anti-human fibronectin IgG1. HFN 7.1 cells were cultured in a 
high glucose-containing (4.5g/L) Dulbecco’s modified Eagle’s medium (DMEM; Gibco, UK) 
supplemented with 10% v/v foetal bovine serum (FBS; Sigma-Aldrich, UK). For storage, 1x107 
cells were suspended in 1mL freeze mix consisting of 95% culture medium and 5% dimethyl 
sulfoxide (DMSO; Sigma-Aldrich, UK), stored in Nalgene® Mr Frosty at -80°C overnight and 
subsequently transferred to liquid nitrogen (-160°C). Thawing the cells from liquid nitrogen 
storage consisted of rapidly agitating the frozen vial in a 37°C water bath for one minute, after 
which, the contents were suspended in 25mL culture medium and set to incubate in a 75cm2 
tissue culture flask (TC-75, Nalgene, UK) for 24 hours. One day post thawing, the contents of the 
TC-75 flask were aspirated and centrifuged at 800rpm for two minutes in a IEC CL30 centrifuge 
(Thermo Scientific, UK). The cell pellet was re-suspended in 25mL of fresh culture medium and 
left to incubate for 48 to 72 hours. 
5.1.2. Cell culture 
Cell culture was performed both in static tissue culture flasks and shake flasks. As mentioned in 
the previous section, the static tissue culture flasks were mainly employed immediately after 
thawing. Cells were cultured in suspension once they achieved acceptable viability and growth 
rates. Suspension cell culture was performed in several working volumes, ranging from 30mL to 
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400mL in appropriately sized Erlenmeyer flasks (Corning, UK and Nalgene, UK). For all cultures, 
the cultures were seeded at 2x105 cells mL-1 and incubated at 5% v/v CO2 and at 37°C in a 
temperature and CO2-controlled incubator (NUAIRE, UK). The rotation speed for all suspension 
cultures was maintained at 125 rpm using an orbital shaker (Stuart SSL1, UK). 
5.1.3. Extracellular metabolite quantification 
Quantification of extracellular glucose, glutamine, lactate and ammonia was performed for all 
cell culture experiments presented in this thesis. Two millilitre samples were drawn from the 
cultures, centrifuged at 800rpm for 5min, and finally the supernatant was decanted and stored 
at -80°C for subsequent analysis. At the time of analysis, the frozen samples were thawed and 
analysed using a Bioprofile 400 system (Nova Biomedical, UK). Briefly, the Bioprofile 400 
system performs automated enzymatic assays on the samples. For glucose, it measures the H2O2 
released during the enzymatic oxidation of glucose in presence of glucose oxidase. Glutamine is 
measured through the production of glutamate by the glutaminase-catalysed hydrolysis of 
glutamine. Lactate is measured through the H2O2 produced by the oxidation of lactate in 
presence of the lactate oxidase enzyme. Ammonia is directly measured by electrochemical 
means. 
5.1.4. mAb quantification 
The titre of mAb produced through cell culture was obtained through an indirect sandwich 
enzyme-linked immunosorbent assay (ELISA). This method was carried out in cell culture 
treated 96-well plates (NUNC, Denmark) using the following protocol previously described by 
Kontoravdi et al.:272 
1. Add 100µL of 1µg/mL anti-human fibronectin antibody from rabbit (Sigma_Aldrich 
F3648) suspended in coating buffer (0.05M sodium bicarbonate, pH 9.6) to each well 
and incubate overnight at 4°C on a level surface. 
2. Block non-specific binding by adding 250µL of blocking buffer (250mL coating buffer 
with 1.25g casein Hammerstein grade) to each well and incubate at room temperature 
for one hour. 
3. Empty the plate and wash three times using washing buffer (phosphate buffered saline 
with 0.05%v/v TWEEN-20). 
4. Add 100 µL of 0.2µg/mL human fibronectin (Chemicon international FC010) suspended 
in PBS to each well. Incubate at room temperature for one hour. 
5.1. CELL CULTURE 93 
 
 
5. Empty the plate and wash three times using washing buffer. 
6. Add 100µL of standards and samples containing HFN 7.1 antibody (Pierce Antibodies 
MA5-12314) suspended in PBS at a dilution of 1:2000 (maximum concentration of mAb 
per well should not exceed 80µg/L) to each well. Incubate at room temperature for one 
hour. 
7. Empty the plate and wash three times using washing buffer. 
8. Add 100µL of 0.64µg/mL anti-mouse Fc antibody from goat (Sigma-Aldrich A0168) 
suspended in PBS to each well. Incubate at room temperature for one hour. 
9. Empty the plate and wash three times using washing buffer. 
10. Dissolve one tablet of 3,3’,5,5’-tetramethylbenzidine (TMB, Sigma-Aldrich T3405) in 
10mL of 0.05M phosphate-citrate buffer, pH 5.0 (substrate buffer). Add 2µL of fresh 
30%v/v hydrogen peroxide solution per 10mL of substrate buffer solution immediately 
before use. Add 100µL of the resulting solution to each well. Incubate at room 
temperature for 30 minutes. 
11. Add 50µL of 2.5M H2SO4 solution to each well so that the enzymatic reaction is stopped. 
12. Read the plate for absorbance at 450nm on a microplate reader (BioTek Instruments, 
USA ELX808U). 
5.1.5. Cell density and viability 
Viable and dead cell density was measured by performing counts on trypan blue treated cells on 
a Neubauer rulings haemocytometer. The following protocol was followed for this procedure: 
1. The surface of the haemocytometer and the cover slip were cleaned using 70% v/v 
aqueous ethanol. The cover slip was placed on the chamber prior to adding the sample. 
2. 20% v/v trypan blue solution was added to the sample so that the end ratio 
(sample:trypan) was 1:1. Trypan blue is a dye that permeates dead cells while leaving 
the live cells uncoloured. 
3. The trypan blue treated sample was applied to the haemocytometer cell with a pipette. 
4. The haemocytometer was placed on the microscope and read at 10x magnification. 
5. The count was performed on the centre and corner squares of the counting grid. 
6. The total count should lie between 50 and 150 cells. In cases where the count is outside 
this range, the cell sample was diluted with water prior to trypan blue addition. 
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7. Cell density was obtained by dividing the count by total volume considered (each grid 
square has a surface area of 1mm2 and a depth of 0.1mm). The calculation was: 
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5.2. NSD quantification 
5.2.1. HPAEC for NSD quantification 
Due to the relevance of NSDs for protein glycosylation, several analytical methods have been 
developed for quantifying their intracellular pools.263, 288-291 In all methods, two properties of 
nucleotides and nucleotide sugars have been exploited. Firstly, nucleotides and NSDs contain 
conjugated double bonds in their nucleotide component, as can be seen in Figure 8. These 
conjugated double bonds make these molecules optically active, with maximum absorbance 
wavelengths between 257.4nm and 271.6nm. These wavelengths are readily detectable with 
UV-vis detectors commonly available on analytical equipment. Secondly, nucleotides and 
nucleotide sugars are charged molecules at neutral pH because of the phosphate groups they 
contain.  
In all four methods cited, detection of NSDs has been performed by conventional UV-vis 
detectors and the separation of these compounds has been based on their charge. Tomiya et 
al.288 achieved separation and quantification of nine nucleotides and nine nucleotide sugars by 
using high-performance anion exchange chromatography (HPAEC). Both Kochanowski et al.263 
and Nakajima et al.291 developed ion-pairing reverse chromatographic methods. The former 
group was able to resolve eight nucleotides and five NSDs in 47min using a C18 column, 
tetrabutylammonium bisulphate as the ion pairing agent and methanol as the organic modifier. 
The latter group resolved twelve nucleotides and eight NSDs in 30min with an Inertsil C4 
column, the same ion-pairing agent and acetonitrile as the organic modifier. Feng et al.290 
separated and quantified seven nucleotide sugars and thirteen nucleotides in 40min with a 
capillary electrophoresis method. 
Based on resolving power, apparent robustness and the analytical capabilities of our 
laboratory, the method developed by Tomiya et al. was selected as our starting point for NSD 
quantification. Tomiya et al.’s original method was performed on a 10ADvp Shimadzu HPLC 
under the conditions presented in Table 13. 
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Table 13. Tomiya et al.288 HPAEC conditions for NSD quantification 
Conditions Values 
Column CarboPac PA-1 (Dionex, US) 
Guard column PA-1 guard column (Dionex, US) 
Flowrate 1mL/min 
Eluent 1 (E1) 1mM NaOH 
Eluent 2 (E2) 1.0M CH3COONa in 1mM NaOH 
Column Temperature 30°C 
Sample Temperature NA 
Gradient t0min = 20% E2; t10min = 55% E2; t25min = 55% E2; 
t35min = 80% E2; t40min = 100% E2; t50min = 100% E2 
Wavelengths monitored 262.1nm; 271.6nm 
The Tomiya et al. method was implemented in our laboratory on a Waters Alliance HPLC 
(UK) which is composed of a 2695 series separations module coupled to a 2998 model 
photodiode array detector. Preparation of the eluents was as follows: 
E1: 
1. 1L of deionised water (18.2MΩ) was sparged with helium for 5 minutes to displace any 
dissolved CO2. 
2. Once sparged, the appropriate amount of 50% w/v (19.2M) NaOH (Sigma-Aldrich, UK) 
was added and the liquid gauged to 1L. For 1mM NaOH solutions, 52.1µL of 
concentrated NaOH solution were added. For 3mM solutions, 156.3mL were added. 
3. The solution was mixed and filtered through a 0.2µm filter unit (Nalgene, UK) to 
eliminate any particulate matter in the solution. 
E2: 
1. The appropriate amount of >99% sodium acetate (Sigma-Aldrich, UK) was added to 1L 
of E1 eluent. 82.03g were added to E1 to prepare 1M CH3COONa solutions and 123.04g 
were added for 1.5M CH3COONa solutions. 
2. The solution was stirred until the CH3COONa was completely dissolved and then filtered 
through a 0.2µm filter unit (Nalgene, UK). 
Initially, the gradient and eluent composition reported by Tomiya et al. was used, and 
produced the chromatogram presented in Figure 21 for a mixture of eight NSDs and three 
nucleotide standards. In Figure 21, it can be seen that out of eleven standards that were present 
in the injected mixture, only nine were resolved. Each peak was assigned by comparing the 
observed retention times with those obtained from single standard injections. Peak assignment 
was further confirmed by comparing the spectrum of the pure components with those 
measured in the mixture runs. 
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Figure 21. Chromatogram replicating the method by Tomiya et al.288 
Because not all species were resolved, the method was adapted to the conditions in our 
laboratory to obtain improved NSD separation. In order to do so, and based on the method 
development reported by Tomiya and collaborators, the concentration of NaOH in the eluents 
was varied. Conveniently, the allowable range for NaOH concentration was narrow, with Tomiya 
et al. having reported that nucleotides and NSDs degrade at NaOH concentrations above 4mM. 
The NaOH concentration of the eluents was varied between 0.5mM and 3.5mM. With these 
trials, it was found that at a NaOH concentration of 3mM, resolution of all eleven species was 
achieved, as can be seen in Figure 22. 
 
 Figure 22. Chromatogram with 3mM NaOH in E1 and E2 
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As a further effort in optimising the method, we set out to reduce the analysis runtime. As 
discussed in section 2.7.2 of this thesis, in HPAEC, analytes are adsorbed onto the stationary 
phase through coulombic interactions. A second anion (CH3COONa) is then flushed through the 
system, and due to competing interactions, the analytes are eluted differentially from the 
stationary phase. Considering the long E2 gradients defined by Tomiya et al. and the principles 
behind HPAEC, the gradient of E2 was increased in order to reduce analysis time. Having tested 
several gradient profiles, it was found that the chromatogram contracted in time without 
compromising resolution of the eleven standards. However, because the gradients that were 
being tested were exceeding the capabilities of the HPLC, the concentration of CH3COONa in E2 
was increased from 1M to 1.5M. The higher initial concentration of CH3COONa in E2 allowed for 
shallower volumetric gradients of E2 while achieving higher CH3COONa concentrations 
required to elute the NSDs bound to the column. The optimized conditions for the method are 
summarized in Table 14. It is worth noting that maximum concentration of CH3COONa that 
flows through the column is 1M. This value was not exceeded as it is the maximum 
recommended CH3COONa concentration for CarboPac PA1 columns by their manufacturer. A 
chromatogram showing full separation of eleven NSDs and three nucleotides in 20 minutes is 
presented in Figure 23. 
Table 14. Optimised HPAEC conditions for NSD quantification 
Conditions Values 
Column CarboPac PA-1 (Dionex, US) 
Guard column PA-1 guard column (Dionex, US) 
Flowrate 1mL/min 
Eluent 1 (E1) 3mM NaOH 
Eluent 2 (E2) 1.5M CH3COONa in 3mM NaOH 
Column Temperature 30°C 
Sample Temperature 5°C 
Gradient t0min: 20% E2; t6min: 66% E2; t18min: 66% E2; 
t23min: 20% E2; t30min: 20% E2 
Wavelengths monitored 262.1nm; 271.6nm 
 
In Figure 23, it is seen that all injected standards were separated in under 20 minutes after 
injection. It must be mentioned that baseline separation was not achieved for all species, 
especially GDP-Fuc and GDP-Man. However, this did not seem to affect accuracy of 
quantification in these cases and, to our belief, the reduced runtime (<30min) compensates for 
this issue. Additional parameters regarding reproducibility, sensitivity and quantification 
linearity will be detailed in the following section. 
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Figure 23. Representative chromatogram of the optimised method 
Reproducibility, linearity and sensitivity 
The optimised method described in preceding sections was assessed for reproducibility, 
sensitivity, and quantification linearity. As a means to establish reproducibility, the retention 
times for each analyte and its variation over 50 injections is presented in Table 15. From the 
data, we see that retention times vary below 1% of the mean value, except GTP and UDP-GlcA, 
which have variations of 1.27% and 1.13% respectively. Considering the number of species that 
are being resolved in less than 30 minutes, we believe these variations are acceptable and 
confirm the robustness of the separation. 
Table 15. Retention time variation over 50 injections 
Component 
Mean tret 
(min.) 
Std. Dev. 
(min.) 
RSD 
ATP 9.245 0.026 0.28% 
CMP-Neu5Ac 3.794 0.009 0.23% 
CTP 7.049 0.010 0.14% 
GDP-Fuc 12.353 0.072 0.58% 
GDP-Glc 13.332 0.090 0.68% 
GDP-Man 12.743 0.079 0.62% 
GTP 14.697 0.175 1.19% 
UDP-Gal 8.424 0.020 0.24% 
UDP-GalNAc 8.033 0.016 0.20% 
UDP-Glc 8.713 0.024 0.27% 
UDP-GlcA 16.521 0.175 1.06% 
UDP-GlcNAc 8.229 0.017 0.21% 
UTP 9.747 0.044 0.45% 
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It must also be noted that the 50 injections considered for Table 15 were performed over a 
period of three months and were performed with different batches of eluents. The data suggests 
that, with respect to peak identification and separation, the chromatographic method, along 
with preparation of the different eluents, is indeed consistent and reproducible. 
Finally, the range of linear quantification with this HPAEC method was determined by 
generating a series of calibration curves. These, in turn, were subsequently used to quantify the 
pools of nucleotides and NSDs from cellular extracts. To generate the calibration curves, known 
amounts of standards were mixed and serially diluted with deionised water (18.2MΩ). In order 
to populate the calibration curves further, different volumes (30µL, 25µL, 20µL, 15µL and 10µL) 
of each dilution were injected. The amount of each nucleotide and NSD was defined to ensure 
that the measured intracellular pools for each component fell within the range set by the 
calibration curve for each species. Standards for ATP, CMP-Neu5Ac, CTP, GDP-Fuc, GDP-Man, 
GDP-Glc, GTP, UDP-Gal, UDP-GalNAc, UDP-Glc, UDP-GlcA, UDP-GlcNAc and UTP were purchased 
from Sigma-Aldrich (UK). All calibration curves were done in triplicate so that variation in 
measured concentration was assessed. The area of each peak was plotted against the known 
amount of each analyte added to the standard mixtures. These curves were fitted to a linear 
equation with intercept equal to zero: 
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Table 16 presents the obtained values for the slope, m, along with the coefficient of 
determination, R2, which is a measure of how well the data fits the linear equation. 
Table 16. Calibration curve slope and linearity 
Component m R2 
ATP 1.13E-03 0.99967 
CMP-Neu5Ac 5.82E-03 0.99986 
CTP 1.79E-03 0.99968 
GDP-Fuc 1.65E-03 0.99580 
GDP-Glc 1.53E-03 0.99587 
GDP-Man 2.36E-03 0.99977 
GTP 1.33E-03 0.99995 
UDP-Gal 4.94E-03 0.99799 
UDP-Glc 2.91E-03 0.99899 
UDP-GlcA 2.82E-03 0.99477 
UDP-GlcNAc 3.09E-03 0.99117 
UTP 2.87E-03 0.99833 
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The value for the coefficient of determination is above 0.99 for all species. These values 
confirm that, within the range at which intracellular nucleotide and NSD pools are expected, 
quantification with the optimised method is linear and accurate. The calibration curves are 
presented in Appendix V. 
Table 17. Optimised HPAEC sensitivity parameters 
 
52 pmol Injections  78 pmol Injections 
Compound 
Mean Area 
(mV sec) 
Std. Dev. 
(mV sec) 
RSD 
(%) 
 
Mean Area 
(mV sec) 
Std. Dev. 
(mV sec) 
RSD 
(%) 
ATP 47,548 447 0.9%  72,791 626 0.9% 
CMP-Neu5Ac 9,239 104 1.1%  13,994 124 0.9% 
CTP 30,570 159 0.5%  46,577 211 0.5% 
GDP-Fuc 32,938 1,572 4.8%  51,890 496 1.0% 
GDP-Glc 34,349 3,205 9.3%  55,739 312 0.6% 
GDP-Man 20,831 3,430 16.5%  33,768 140 0.4% 
GTP 34,957 315 0.9%  56,388 201 0.4% 
UDP-Gal 10,341 252 2.4%  15,487 93 0.6% 
UDP-GalNAc 17,744 484 2.7%  26,378 140 0.5% 
UDP-Glc 15,794 868 5.5%  22,428 467 2.1% 
UDP-GlcA ND ND ND  20,509 260 1.3% 
UDP-GlcNAc 17,858 344 1.9%  26,404 154 0.6% 
UTP 25,581 187 0.7%  38,892 132 0.3% 
 
Method sensitivity was assessed by finding the minimum amount of sample injected that 
was quantified reliably. The lowest amount of sample injected for all analytes was 52pmol. 
These samples were injected in triplicate, and the standard deviation was calculated for each 
species across these injections. A threshold for relative standard deviation (RSD – i.e. the 
quotient between the mean value and the standard deviation) above 5% was defined as the 
limit for reproducible quantification. When the RSD exceeded 5%, the process was repeated for 
the next lowest injected quantity. With the 52pmol injections, all but three species had RSDs 
below 5%. The ones that exceeded 5% were GDP-Glc, GDP-Man, UDP-GlcA and UDP-Glc. The 
following lowest amount injected for these species was 78pmol. At this level, all species had an 
RSD below 5%. These results are summarised in Table 17. 
From the data presented in Table 17, it can be concluded that the limit for reliable 
quantification with the optimised HPAEC method is 52pmol for all species except GDP-Glc, GDP-
Man, UDP-GlcA and UDP-Glc. For these remaining species, the limit of quantification is 78pmol. 
When this amount is injected, the RSD for measured area in triplicate injections is below 5%, 
with the highest observed value being 2.1% for UDP-Glc. Overall, these results indicate that 
when a sample contains at least 78pmol of a given nucleotide or NSD, quantification is reliable 
and with deviations below 5%. 
5.2. NSD QUANTIFICATION 101 
 
 
Considering that the lowest reported intracellular concentration for NSDs is UDP-Gal with 
9.2µM (seen in Table 10 of this thesis), and that the maximum possible injection volume is 30µL 
on the HPLC, the quantity of injected UDP-Gal would be 276pmol, which is well above the 
78pmol limit of detection of the current method. This suggests that the optimised method 
presented herein is capable of accurately quantifying the intracellular pools of all nucleotides 
and NSDs involved in mAb N-linked glycosylation. 
5.2.2. Extraction of intracellular NSDs 
Recently, several groups have discussed the impact of quenching, washing and extraction 
methods on the quantification of intracellular metabolites.292, 293 The objective of these 
procedures is to ensure that i) the extraction method allows for reproducible retrieval of the 
desired metabolites, ii) that the metabolite pools to be extracted are representative of the 
metabolic state of the cells at the moment of extraction, and iii) that components from the cell 
culture medium do not contaminate the intracellular samples. In order to address these 
concerns, a series of experiments were performed so that a standard methodology for 
nucleotide and NSD extraction could be established. 
Dietmair and collaborators recently published a comparison of 3 quenching methods and 12 
extraction protocols for recovery of intracellular glucose, aminoacids, nucleotides and 
nucleotide sugars.293 Dietmair et al. quenched using 60% aqueous methanol (MeOH) at -40°C, 
60% aqueous MeOH buffered with ammonium bicarbonate (AMBIC) at -40°C and ice-cold 0.9% 
w/v sodium chloride (NaCl) and found that both methanol solutions damaged the cell 
membrane and caused leakage of intracellular metabolites. These findings contrast with those 
reported by Sellick et al., where it was found that AMBIC buffered MeOH yielded the highest 
metabolite recoveries.292 However, the report by Sellick et al. focused on extraction efficiencies 
for metabolomics studies and did not assess extraction of nucleotides and NSDs. Based on the 
publication by Dietmair et al., 0.9% NaCl was selected as the quenching and washing solution in 
the development of this protocol. 
Dietmair et al. also explored different extraction protocols, which included acetonitrile 
(ACN), MeOH freeze, cold 50% MeOH, MeOH/chloroform, hot 80% MeOH, cold 100% MeOH, hot 
EtOH, hot EtOH/HEPES, cold EtOH, hot H2O, potassium hydroxide (KOH) and perchloric acid 
(PCA). From the data reported by this group, seven protocols achieved acceptable extraction of 
nucleotides and NSDs.293 Based on this, two extraction methods (PCA and ACN) were selected 
for comparison. The protocol for PCA extraction was based on Dietmair et al.293 and was the 
following: 
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1. Cell pellets were resuspended in 200µL of 0.5M ice-cold PCA (Sigma-Aldrich). 
2. The above mixture was incubated on ice for 10 minutes. 
3. The incubated mixture was centrifuged for 5min at 18,000g and 1°C in Hermle Z233 
MK-2 centrifuge (Germany). 
4. 200µL of the supernatant were removed and 40µL of 1.1M K2HPO4 (Sigma-Aldrich, UK) 
in 2.5M KOH (Sigma-Aldrich, UK) was added to the mixture so that the PCA was 
neutralized. 
5. The neutralised mixture was centrifuged for 5min at 18,000g and 1°C. 
6. 200µL of the supernatant was taken and stored at -80°C until HPAEC analysis. 
The volume of added PCA was reduced from 1000µL in Dietmair et al. to 200µL and KOH 
from 200µL to 40µL so that the end extract could be injected directly into the HPLC without 
concentrating the sample. 
The protocol for ACN was also based on Dietmair et al.:293 
1. Cell pellets were resuspended in ice cold 50% aqueous acetonitrile (Sigma Aldrich). 1mL 
of 50% ACN was added per 5*106 cells. 
2. The cell suspension was incubated on ice for 15 minutes. 
3. The incubated mixture was centrifuged for 5min at 18,000g and 1°C in a Hermle Z233 
MK-2 centrifuge (Germany). 
4.  Samples were stored at -80°C until HPAEC analysis. 
5. Immediately prior to HPAEC analysis, the samples were thoroughly dried using a 
SpeedVac (Savant SC210A, UK) and then resuspended in 240µL of deionised water. 
For comparing ACN and PCA extractions, samples of protein-secreting cells were taken on 
day six of culture. Six equal volume samples were taken, three to be extracted with PCA and 
three to be extracted with ACN. The samples were then analysed with the HPAEC method 
described in the previous section, and the results are shown in Figure 24. 
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Figure 24. Comparison of PCA and ACN for nucleotide and NSD extraction 
The dark bars show HPAEC results from PCA extraction, while the light bars show ACN extraction. 
Each extraction was performed in triplicate, and a t-test assuming unequal variances was 
performed to assess differences between the two treatments. Three stars represent a significant 
difference with a p<0.001; two stars correspond to p<0.01 and one star is for p<0.05. NSSD means 
there is no statistically significant difference between the two treatments. 
Figure 24 shows that both extraction protocols yield different pools for all nucleotides and 
NSDs with the exception of GTP. In general, the extracted metabolites are lower for the ACN 
extraction than for PCA. However, there are three cases where ACN produces higher extraction, 
which are GDP-Man, UDP-GalNAc and UTP. PCA extracts 43%, 11% and 14% less of these 
metabolites, respectively. In contrast, PCA produces higher pools of ATP (19%), CTP (19%), 
UDP-Gal (14%), UDP-Glc (19%) and UDP-GlcNAc (10%). 
An interesting case is that of ATP, ADP and AMP. Figure 24 shows that PCA produces more 
ATP (20%), while ACN generates 5 times more ADP and 20 times more AMP than PCA. These 
considerable differences may be attributed to degradation of ATP to form ADP and AMP during 
the concentration step using the SpeedVac, given that this process is lengthy (6-10 hours) and 
performed at room temperature. 
Overall, it is possible that ACN has better extraction efficiency of some nucleotides and 
NSDs. However, it has also been shown that the concentrating step required for ACN extraction 
may lead to metabolite degradation. It is worth noting that the time required for concentrating 
the samples for the ACN protocol are not consistent and could lead to undesired sample-to-
sample variation. For these reasons and for the sake of consistency, PCA was selected as the 
most appropriate nucleotide and NSD extraction protocol for the work presented herein. 
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5.2.3. Quenching and washing of cell samples 
The final element to consider was whether quenching and washing with 0.9% NaCl 
influenced the measurement of nucleotide and NSD pools. In order to evaluate the effect of 
quenching and washing with 0.9% w/v NaCl, nine samples of equal volume were taken at day 
six from a culture of protein secreting cells. Three of the samples were left untreated, another 
three were quenched with 4x volumes of ice-cold 0.9% w/v NaCl, and the remaining three were 
quenched and washed with 0.9% NaCl. The overall procedure for quenching and washing was: 
1. A 3mL sample from cell culture is taken and immediately added to 12mL of ice-cold 
0.9% w/v NaCl (Sigma-Aldrich). 
2. The quenched mixture is then centrifuged for 1 minute at 1000g on an IEC CL 30 
centrifuge (Thermo Scientific, UK). 
3. The supernatant is decanted and the pellet is resuspended with another 12mL of ice-
cold 0.9% NaCl. 
4. The washed mixture is centrifuged for 1 minute at 1000g. 
5. The supernatant is decanted and the desired extraction protocol is performed on the cell 
pellet. 
The untreated samples (NQ) were not subjected to any of the steps described above and 
their contents were extracted directly after having been centrifuged. The quenched samples (Q) 
were extracted after step two of the procedure described above. Finally, the quenched and 
washed samples (QW) were treated as described above. After the quenching and washing 
procedure, the pellets were extracted using the PCA method described earlier in this section and 
subsequently injected for the HPAEC analysis which was also developed in this work. The 
results for these experiments are shown in Figure 25. 
In Figure 25, it can be seen that there is no significant difference between samples that were 
not quenched (NQ) and only quenched (Q). It is apparent, though, that there are significant 
differences between NQ and Q with samples that have been quenched and washed. More 
specifically, there is substantially lower recovery for all nucleotides when the samples were 
quenched and washed, when compared to the NQ and Q data (>30% lower recovery in all 
cases). 
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Figure 25. Comparison of quenching and quenching and washing with 0.9% NaCl 
Data for non-treated ( ), only quenched ( ) and quenched and washed  ( ) samples are 
presented. Each treatment was done in triplicate, and an HSD Tukey’s test was performed on the 
data. A significant difference with a p<0.001 is represented by (***), p<0.01 with (**) and p<0.05 
with (*). No stars are presented for data that are not significantly different from each other. 
A similar trend is observed with the NSDs, with the exception of UDP-Gal and UDP-GlcNAc, 
where no significant differences were measured between all three treatments. The reduction in 
recovery of NSDs when the cell pellet was quenched and washed was 7.5% for GDP-Fuc, 20% 
for GDP-Man and 27% for UDP-Glc. Also, and in a similar trend to the one observed for the 
extraction methods, a decrease in ATP recovery of 35% was observed in the QW treatment, 
when compared to the NQ treatment. Again, a corresponding increase in AMP and ADP was seen 
in the QW treatment. It is possible that this effect is due to degradation of ATP during the 
washing and second centrifugation step associated with the QW treatment. From this 
information, it is possible to conclude that washing is detrimental for adequate recovery of 
nucleotides and NSDs. Moreover, because there is no significant effect observed from 
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quenching, this step was also omitted from the overall protocol for extraction and quantification 
of nucleotides and NSDs developed in this work. 
With the findings presented in this section, the final protocol that was defined for extracting 
nucleotides and NSDs from cells was the following: 
1. A sample of 1x106 cells is taken from the cell culture. 
2. The sample is centrifuged at 1000g for 1 minute. 
3. The supernatant is decanted and any excess supernatant is removed with a pipette. 
4.  The cell pellet is then treated with PCA as described in previous sections of this thesis. 
5. The neutralised extract is stored at -80°C until HPAEC analysis. 
6. Immediately prior to HPAEC, the frozen sample is quickly thawed and passed through a 
0.2µm syringe-driven filter unit (Millipore, UK). 
7. The sample is transferred to total recovery vials (Waters, UK) and placed in the 
temperature-controlled autosampler of the HPLC, where it remains at 5°C until it is 
injected for HPAEC analysis. 
A representative chromatogram of intracellular nucleotides and NSDs that were extracted 
following the protocol described above is presented in Figure 26. 
 
Figure 26. Typical HPAEC chromatogram of intracellular nucleotide and NSD pools 
The chromatogram shows adequate separation of four nucleotides and six NSDs that have been 
extracted from cells using the methods described above. The overlay shows reproducibility, both 
of the analytical method, as well as the extraction protocols employed herein. 
The methods described in this and preceding sections culminate with the chromatogram 
presented in Figure 26. In this figure, it can be seen that nucleotides and NSDs have been 
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successfully extracted from cells and have been separated adequately for quantification. 
Confidence in the accuracy of the measured nucleotide and NSD pools stems from the presented 
work regarding the optimised HPAEC technique for nucleotide and NSD quantification, the 
experiments that were performed to select the appropriate intracellular metabolite extraction 
protocol and the work shown on quenching and washing methodologies.  
The work described throughout this chapter has produced an optimised HPAEC-based 
analytical method for accurately quantifying intracellular pools of nucleotides and NSDs in less 
than 30 minutes. In addition, perchloric acid (PCA) extraction of intracellular metabolites was 
selected over acetonitrile (ACN) because the latter methodology was observed to be prone to 
irreproducible degradation of intracellular nucleotides and NSDs. Finally, quenching and 
washing steps prior to metabolite extraction were omitted after it was observed that quenched 
samples yielded statistically indistinguishable nucleotide and NSD pools, and that the addition 
of a washing step had a detrimental effect on the recovery of these metabolites. Results yielded 
from these methods and their use towards the overall goal of this work will be presented in 
subsequent sections of this thesis. 
5.3. Intracellular glucose analysis 
For intracellular glucose analysis, cell samples were taken from culture in parallel to those 
taken for NSD analysis. However, these samples were quenched with four volumes of 0.9%w/v 
NaCl and further washed with four volumes of the same solution, as described in section 5.2.3. 
In contrast with NSDs, the quenching and washing procedure was performed prior to 
intracellular glucose analysis because large quantities of glucose are present in the cell culture 
medium (DMEM; GIBCO, UK). If the cell pellet was not quenched and washed, the observed 
intracellular glucose concentrations would be overestimated and inaccurate due to 
contamination from the medium. Extraction of intracellular glucose was performed using PCA, 
as described in section 5.2.2. 
Once PCA extraction was performed, the intracellular glucose concentration was measured 
by the Amplex Red glucose assay kit from Invitrogen (UK). Amplex Red is an enzymatic assay 
where glucose is reacted with glucose oxidase to produce glucolactone and hydrogen peroxide 
(H2O2). H2O2 is then reacted with the Amplex Red reagent (on a 1:1 ratio) in presence of 
horseradish peroxidise (HRP) to produce resorufin. This is a fluorescent product, with an 
emission and excitation length of 571nm and 585nm, respectively. Because resorufin is reacted 
on a 1:1 ratio with glucose, detected fluorescence of this compound is proportional to the 
concentration of glucose in the sample. 
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The Amplex Red assay was performed according to the manufacturer’s instructions in non-
treated 96-well plates (NUNC, Denmark). Fluorescence of the Amplex treated samples was 
measured on a Tecan Infinite 200Pro fluorescence plate reader (Tecan, UK) with an excitation 
wavelength of 568nm and emission wavelength of 580nm. 
5.4. Mass Spectroscopy for glycan analysis 
The objective of this work is to produce an experimentally-validated mathematical model that 
relates mAb Fc N-glycosylation with nutrient availability during cell culture. Because mAb Fc 
glycosylation lies at the centre of this work, means to determine the glycan distributions of 
mAbs are intrinsically necessary. The following sections will describe the procedures that were 
followed to isolate, purify, derivatize and quantify the glycans bound to mAbs produced through 
cell culture. 
5.4.1. Sample purification 
Prior to mass spectroscopic analysis, mAb-containing samples that were drawn from cell 
culture were purified using the Proteus Protein G antibody purification kit (PROCHEM, USA). 
This purification kit relies on the affinity of Staphylococcal protein G for the Fc of antibodies. 
The Proteus purification kit is small-scale and designed to be used in microcentrifuges, thus 
avoiding use of more sophisticated equipment such as liquid chromatographers. The 
purification was done according to the manufacturer’s instructions. Non-reducing sodium 
dodecyl sulphate polyacrylamide (SDS-PAGE) gels were run after purification to assess removal 
of FBS-associated protein contaminants. 
Figure 27 shows a typical SDS-PAGE gel obtained after protein G purification. In this figure, 
we see that the unpurified supernatant sample (lane 2) shows a large band at approximately 
60kDa, which is believed to be bovine serum albumin (BSA). Standard HFN 7.1 mAb purchased 
from Thermo Scientific (UK) has been added to lane 3, and also shows a band that corresponds 
to the molecular weight of BSA. This is consistent with the specification of the purchased 
antibody standard, given that it is said to contain 0.2% BSA (Thermo Fisher, UK). Protein G 
purified samples were added to lanes 4–7. There we see faint bands at approximately 150kDa 
which correspond to mAb that was not fully reduced. Also in these lanes are bands between 
55kDa-58kDa which correspond to the mAb heavy chain and bands at approximately 28kDa 
which correspond to mAb light chains. Figure 27 also shows that no other visible bands are 
present in the purified samples, leading us to believe that the samples were purified adequately 
with the protein G columns. Sample purity for glycan analysis is of extreme importance, 
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especially for cultures that have been supplemented with BSA. Glycoproteins, such as 
transferrin, may be present in BSA and, if not removed, may skew the glycan profiles measured 
with MS. 
 
Figure 27. Reducing SDS-PAGE gel of purified mAbs 
The lanes in the gel are: 170kDa ladder (1, 8), non-purified cell culture supernatant (2), HFN 7.1 
mAb standard (3) and protein G purified cell culture supernatant (4–7). (A) shows the non-
reduced HFN 7.1 mAb in the standard. (B) shows BSA that is present in both the non-purified 
supernatant and the standard. (C) shows residual intact mAb. (D) are bands corresponding to the 
heavy chain of the mAb. (E) are bands corresponding to the light chain of the mAb. 
The mAb titre after purification was measured by absorbance at 280nm on a Nanodrop 
spectrophotometer (Thermo Scientific, UK), and ranged between 70mg/L and 120mg/L. Finally, 
the purified samples were freeze dried with a Thermo Savant ModulyoD freeze dryer (Thermo 
Scientific, USA). The purified and lyophilised samples were then prepared for MALDI mass 
spectrometry, the procedures for which are described below. 
5.4.2. Buffers 
The following solutions were made or purchased for MS sample preparation: 
1. DTT: 2mg/mL dithioreitol (DTT, Sigma Aldrich) was prepared in 0.6M Tris (Amresco, 
USA), pH 8.5. 
2. IAA: 12mg/mL iodoacetic acid (IAA, Sigma Aldrich) was prepared in 0.6M Tris, pH 8.5. 
3. G-HCl: 8M guanidine HCl (Pierce, USA).  
4. AMBIC: 50mM ammonium bicarbonate – (AMBIC, Fluka), pH 7.7. 
5. AMBIC: 50mM ammonium bicarbonate, pH 8.4. 
5.4. MASS SPECTROSCOPY FOR GLYCAN ANALYSIS 110 
 
 
5.4.3. Reduction and carboxymethylation of mAbs 
The purified and lyophilised sample was reduced and carboxymethylated to break all the 
disulphide bonds present in the mAb. The procedure was as follows: 
 
1. 90µLof DTT and 10µL of G-HCl solution were added to the lyophilised sample. 
2. The mixture was left to incubate for 1hr at 37°C. 
3. 100µL of IAA solution was added 
4. This mixture was incubated for 2hr at room temperature in absence of light. 
5. The product of this reaction was dialysed against the AMBIC buffer for 24hr with regular 
buffer changes. 
6. The samples were then lyophilised and stored. 
5.4.4. Tryptic digestion of mAbs 
In order to improve release of glycans from the reduced and carboxymethylated samples, they 
were treated with porcine sequencing-grade trypsin (Promega, USA). The procedure for tryptic 
digestion was as follows: 
1. The samples from the step above were dissolved in 100µL of AMBIC buffer, pH 8.4. 
2. 50µL of 0.02µg/µL trypsin solution were added. 
3. This mixture was incubated for 14hr at 37°C. 
4. The reaction products purified using Sep-Pak C18 cartridges (360mg 5-105µm) (Waters, 
UK). 
5. The collected fractions from the Sep-Pak purification were concentrated in a Savant 
SPD122P Speed Vac (Thermo Scientific, UK). 
6. All concentrated fractions were then pooled and lyophilised.  
5.4.5. Peptide-N-glycosidase F (PNGase F) digestion 
The purified and lyophilised tryptic digests were then treated with peptide-N-glycosydase F 
(PNGase-F – Roche Applied Science, UK) to release the N-linked glycans bound to them. The 
procedure for this step was the following: 
1. The lyophilised samples from the previous step were resuspended in 200µL of AMBIC 
buffer, pH 8.4. 
2. 5 units of PNGase-F were added to the resuspended tryptic digests. 
3. The reaction mixture was incubated for 24hr at 37°C. 
4. The samples were lyophilised and re-dissolved in 200µL of 5% acetic acid. 
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5. The digests were then purified using Sep-Pak C18 cartridges, using 1-propanol for 
elution. 
6. The 1-propanol fractions were collected and concentrated with the Speed-Vac. 
7. The concentrated samples were pooled and finally lyophilised. 
5.4.6. Permethylation of released glycans 
The released glycans were permethylated in order to ensure adequate ionisation during the 
MALDI analysis. Permethylation of the samples was done with the following protocol: 
1. 5 NaOH pellets were ground with a mortar and pestle to produce a fine powder. 
2. 3mL of anhydrous dimethylsulfoxide (DMSO – Romil, UK) were added to the NaOH 
powder to form a paste. 
3. 1mL of the paste was added to the dry samples immediately before 0.5mL of methyl 
iodide (Alfa Aesar, UK) was added. 
4. The mixture was vortexed  and agitated for 15min at room temperature. 
5. The reaction was quenched by dropwise addition of water. 
6. The permethylated species were extracted using 1mL of chloroform (Romil, UK). 
7. The chloroform was then dried with nitrogen. 
8. The samples were resuspended in 50% aqueous methanol (MeOH – Romil, UK). 
9. The re-dissolved permethylated glycans were purified using Sep-Pak C18 cartridges and 
eluting with aqueous acetonitrile (Romil, UK). 
10. Fractions that eluted with 30% and 50% ACN were collected, concentrated with the 
Speed-Vac and subsequently lyophilised. 
 
Prior to MALDI-MS, the lyophilised permethylated samples were co-crystallised with 2,5-
dihydroxy benzoic acid (DHB, Sigma Aldrich). This was done by dissolving he dry, 
permethylated samples in 10µL of methanol (Romil, UK) and adding 1µL of 20mg/mL DHB in 
70%v/v aqueous methanol. A 1µL sample was taken from the mixture and spotted onto a 100-
well sample plate and dried under vacuum at room temperature. 
5.4.7. MALDI MS data acquisition 
MALDI-MS was performed on a Voyager-DE STR MALDI workstation (Perspective Biosystems, 
UK) equipped with delayed extraction technology. The machine was set in positive reflectron 
mode and data was acquired using the Voyager 5 Instrument Control Software. Data was 
processed using Data Explorer 4.9 software (Applied Biosystems, Germany). Using the software, 
data was baseline corrected and noise filtered (correction factor of 0.7). Obtained mass spectra 
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were then transferred to the GlycoWorkBench software204 for processing. MALDI MS generally 
yields singly charged, sodiated molecular ions, [M+Na]+. Knowing this, peaks on the spectra 
were assigned to glycan structures with the corresponding mass to charge ratio (m/z). 
GlycoWorkBench was also used to calculate the intensity of all assigned peaks and yield relative 
quantification of the observed glycans. 
 
Figure 28. Typical mass spectrum of mAb-bound N-glycans 
Three main peaks can be seen in the spectrum. Each peak corresponds to the glycan structure 
presented beside them. 
Figure 28 shows a typical MALDI mass spectrum of permethylated N-linked glycans that 
have been obtained from mAbs that were produced in cell culture. Peaks have been assigned 
using GlycoWorkBench. The first peak has a m/z ratio of 1,835.77, corresponding to the 
molecular weight of a permethylated G0F structure as shown in the figure. The second peak has 
a m/z ratio of 2,039.80, which corresponds to a permethylated G1F glycan. The third peak has a 
m/z ratio of 2,243.90, which corresponds to a G2F glycan structure. As was reviewed in 
previous chapters of this thesis, these three glycan structures are the most commonly observed 
on the Fc of mAbs. These results, confirm that the methodologies used for MALDI-TOF MS of 
mAb Fc glycans is adequate and yields quantification of the glycan structures that are at the core 
of this thesis. 
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This chapter has described all the experimental methods that were developed and used to 
produce the data that will be presented in the following sections. These include methods that 
were used for mammalian cell culture, the experimental methods for determining the 
intracellular pool of NSDs throughout cell culture, and finally, the methods that were employed 
to determine the glycan profiles of mAbs that are produced from cell culture. 
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Chapter 6  
Results and discussion 
The previous chapters have defined the modelling and experimental framework that was 
developed to achieve our objective of producing a model-based tool that mechanistically 
describes mAb Fc glycosylation as a function of nutrient availability. This chapter will present a 
comparison of the experimental and modelling results and will also describe the different 
optimisation-based strategies that were employed to estimate unknown model parameters and 
discuss the obtained results. 
6.1. Parameter estimation strategies 
Both the glycosylation and cell culture dynamics models were developed independently. 
Because of this, different optimisation strategies have been defined to estimate their unknown 
parameters. The main experimental inputs for the Golgi glycosylation model are the specific 
mAb productivity and the Fc glycan profiles. Specific productivity of the mAb defines the Golgi 
resident protein concentration profiles through the optimisation strategies defined in sections 
3.5.1 and 3.5.2 of this thesis. Once the resident protein concentration profiles are established, 
the glycan profiles are used to estimate the unknown dissociation constants of the glycosylation 
enzymes, as discussed in section 3.6. Similarly, estimation of the unknown parameters of the cell 
culture dynamics model has been split into two problems which must be solved sequentially. 
These two subsets of the cell culture dynamics and NSD model are cell culture dynamics (CCD) 
and intracellular processes (ICP). 
CCD was defined in sections 4.1.1-4.1.3 and is the component that represents how cells grow 
and synthesise mAb as a function of nutrient availability and metabolite accumulation. 
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Estimation of the unknown parameters of the CCD component requires time-course data for Xv, 
Xd, [Glcext], [Glnext], [Lact], [Amm] and [IgG]. 
ICP includes the processes that occur intracellularly. The fundamental input of this 
subsystem is the transport of glucose and glutamine into the cell, as defined by equations 25-28. 
The unknown parameters of ICP are the transport rate coefficients for glucose and glutamine as 
well as the kinetic parameters contained in the reduced model for NSD biosynthesis. Estimation 
of these parameters requires intracellular data for glucose, glutamine and all NSDs. The flux 
leaving this system is consumption of NSDs for glycosylation reactions within the Golgi 
apparatus. Therefore, the flux through ICP is determined by mAb specific productivity as well. 
6.2. Batch culture of HFN 7.1 cells 
The parameter estimation strategies discussed in the previous section also indicate the 
experimental data required. In light of this, a series of batch overgrowth cultures were 
performed using the HFN 7.1 murine hybridoma cell line. Data for Xv, Xd, [Glcext], [Glnext], 
[Lact], [Amm], [IgG], intracellular glucose and NSDs was collected every 10 and 24 hours for the 
duration of the culture. The obtained data was then used to estimate the unknown parameters 
within the CCD, the ICP and the Golgi glycosylation models. In order to minimise error, four 
biological repeats of the batch experiment were done. The experimental data was collected and 
introduced into the parameter estimation function in gPROMS v. 3.4.0. gPROMS estimates 
parameters through the maximum likelihood formulation, which has been described in previous 
chapters of this thesis. 
The estimated parameters for the CCD component of the culture dynamics model are 
presented in Table 18. The profiles calculated with the estimated parameters are shown in 
Figure 29. The experimental data are presented by points and the simulation results are shown 
with solid lines. Figure 29A shows that the simulation reproduces all phases of cell growth 
accurately. Dead cell density, on the other hand, is slightly underestimated towards the end of 
the culture. Considering that equation 13 defines accumulation of dead cells as a function of 
viable ones, it is expected for the decay of Xv to be symmetrical with the accumulation of Xd. 
Symmetry between both profiles is apparent in Figure 29A. The viability (Viab.) and the integral 
viable cell concentration (IVCC) are reported in Figure 29B. These CCD variables were not 
included in the parameter estimation. The figure shows that these variables are reproduced 
accurately by the model. Figure 29C shows mAb titre throughout culture. The model reproduces 
the data relatively well, although it must be mentioned that the standard deviations for this data 
are relatively large. This is likely due to the sensitivity of the ELISA protocol that was followed 
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to monitor mAb titre. However, though, the profile for mAb titre presented in Figure 29C is very 
close to previous reports for the same cell line.294 
 
Figure 29. Xv, Xd, IVCC, viability and [mAb] profiles in batch culture 
The points show the measured data and the lines show simulation results. Standard deviations for 
each point were calculated (n=4) for all data points as well. 
Figure 30 shows the time profiles of nutrients and metabolites produced during the batch 
culture.  The figure shows that the glucose and glutamine profiles are reproduced very well by 
the model. The behaviour of lactate is reproduced relatively well, although its accumulation is 
slightly underestimated during exponential growth. Towards the end of culture, the maximum 
lactate concentration is reproduced well. The behaviour for ammonia is the less well captured 
by the model. Figure 30D shows that the model produced a sigmoidal curve, whereas the 
experimental data shows saturation-type behaviour. This divergence leads to ammonia 
concentration being underestimated at early stages of the batch culture and slightly 
overestimated around 72hr. Glutamine has been reported to degrade to ammonia throughout 
cell culture.295 This degradation would explain the profile of ammonia seen in Figure 30D. 
However, this would also impact the glutamine profile presented in panel C of the same figure. 
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Figure 30. Extracellular glucose, lactate, glutamine and ammonia in batch overgrowth 
Overall, it is possible to conclude that the experimental data has been reproduced accurately 
with the estimated parameters. Furthermore, the estimated parameters which are presented in 
Table 18 fall well within ranges that have been previously reported for murine hybridomas in 
culture.272, 295, 296  
Table 18. Estimated parameters for culture dynamics model 
Parameter Final Value 
µmax 0.0758 
kd,max,glc 0.2341 
kd,max,gln 0.0190 
KM,glc 3.4043 
KM,gln 1.3459 
Kd,glc 0.0615 
Kd,gln 0.0011 
YX/Glc 845.4 
YX/Gln 5573 
YLact/Glc 1.5530 
YAmm/Gln 0.6451 
YmAb/Xv 98.538 
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Given the accurate representation of the dynamics of HFN 7.1 cells in culture, the model and 
its parameters were used to estimate the remaining unknown parameters associated with 
intracellular phenomena – namely, intracellular accumulation of NSDs. 
6.2.1. Intracellular NSDs over batch culture 
As was mentioned previously, samples for intracellular metabolites and were taken every 
10 and 24 hours throughout culture. These samples were treated with the procedures described 
in sections 5.2 and 5.3 of this thesis. The intracellular extracts were then analysed with the 
HPAEC method presented in section 5.2.1 of this thesis. The intracellular NSD profiles that were 
obtained were then used for estimation of the unknown parameters present in equations 34-45. 
Again, parameter estimation was performed with gPROMS v. 3.4.0.  
 
 
Table 19. Estimated parameters for NSD model 
Parameter Final value Parameter Final value  1.585E-06  68.76  2.544E-06  2968 	,  1248.95  991.9 	,  288.2  687.9 ,	  182.7  794.5 ,	  9.485  30.29  22.57  29.43  14.35 , 125.2  26.75 , 3022  227.1 , 1957  59.17 , 90.82  17.65 , 21.13  2.864 , 159.4 , 5.076 , 332.0 , 0.0288 , 39.84  160.0 , 416.9 
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Figure 31. NSD profiles throughout batch culture 
Experimental data is presented with points and model data is shown with solid lines. Again, the 
standard deviation for each point was calculated with n=4. Glucose is presented with red crosses, 
CMP-Neu5Ac is presented in purple, GDP-Fuc is shown in red triangles, GDP-Mannose is shown in 
green, UDP-GalNAc is shown in yellow boxes, UDP-Glc is shown with red circles and UDP-GlcNAc is 
described with blue squares. 
Figure 31 shows all intracellular species involved in the parameter estimation. In this figure, 
we see the measured intracellular pool of glucose as measured with the Amplex Red assay kit. 
Very large measurement errors were observed at 10hr. All remaining time points, except the 
one for 24hrs, were below the limit of detection of the kit. Speculatively, intracellular glucose 
has a relatively high turnover because it is utilized as the main source of energy in mammalian 
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cells. The fact that it accumulates during initial stages of cell culture may be because its 
abundance with respect to number of cells in the culture is high. This could allow the relatively 
low number of cells present during the first 24hrs of culture to internalise it at rates that are 
higher than those at which it is consumed for metabolism. The intracellular glutamine 
concentration profile presented in Figure 31 was produced through simulations using estimated 
parameters. It can be seen that it follows the same trend as glucose. The reasons why this 
metabolite would peak at early stages of culture are similar to those behind initial glucose 
accumulation. 
Figure 31 also shows that the NSDs whose synthesis is more closely related with essential 
nutrients tend to be the most prevalent ones (i.e. UDP-GlcNAc, UDP-Glc, and GDP-Man). Figure 
31 shows that GDP-Mannose seems to spike early during the culture (first 10 hrs) and 
subsequently undergoes a fast decay. Another interesting feature of Figure 31 is that, despite 
the care that was taken with the NSD quantification protocol, GDP-Fuc is not detected at the first 
two time points, and also contains a very high standard deviation at 34hr. This is very likely due 
to two effects: the first is that GDP-Fuc has the lowest availability of all observed NSDs. This 
effect is compounded by the low cell densities observed at the first time points. Quantification of 
CMP-Neu5Ac also seems to yield fairly large variations, particularly between 10 and 48hr of 
culture. Again, this may be due to intrinsic low availability, but also due to the limited amount of 
viable cells in culture at those points.The solid lines in Figure 31 present the intracellular NSD 
concentrations calculated by the model. The estimated NSD parameters that were used for 
simulations are presented in Table 19. 
Observing the modelling results presented in Figure 31, reproduction of the profiles for 
UDP-GlcNAc, UDP-GalNAc, UDP-Glc and GDP-Fuc are adequate. In contrast, the calculated 
profiles for CMP-Neu5Ac and GDP-Fuc show discrepancies.  Instead of peaking at 10hrs, the 
calculated profile for GDP-Man accumulates more gradually during the first 24hrs. GDP-Man is 
also underestimated beyond 72hrs. The overall behaviour of CMP-Neu5Ac, seems to be 
reproduced relatively well. However, the model overestimates concentration of this NSD 
between 72 and 96hrs. 
It is possible that adequate representation of GDP-Man is not achieved given certain 
assumptions underlying the lumped pathways. It is possible that the sharp accumulation of 
GDP-Man during the first 10hr of culture is associated with the mannose salvage pathway. The 
NSD model assumes that this NSD, along with the others are being transferred onto mAbs that 
are being secreted to the culture medium. However, the mannose salvage pathway has been 
reported to reduce net consumption of Mannose and its derivatives. It may be possible that at 
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early stages of culture, mannose is being recycled to form GDP-Man at rates that exceed 
consumption of this NSD in glycosylation reactions. REF:   Direct utilization of mannose for 
mammalian glycoprotein biosynthesis, thus causing the sharp increase observed in the 
experimental data. 
Additional data obtained from intracellular measurements is presented in Figure 32. This 
figure shows the measured intracellular availability of six nucleotides: ATP, ADP, AMP, CTP, GTP 
and UTP. In this figure we see that their profiles are quite consistent throughout cell culture and 
seem to be at concentrations that are comparable to the most abundant NSDs. ATP, however, 
has the highest concentration of all intracellular species quantified by HPAEC with a 
concentration in the range of mM.  
 
Figure 32. Intracellular nucleotide profiles throughout batch culture 
Data for intracellular  ATP, ADP, AMP, CTP, GTP and UTP are presented. The nucleotide data was 
produced with the HPAEC method described in previous chapters of this thesis. 
Overall, and considering the number of simplifying assumptions that were made to describe 
NSD metabolism (e.g. reducing the reactions scheme from36 reactions to only 7), model 
performance is excellent. Apart from GDP-Man, the model has the ability of reproducing the 
experimental data rather well. Another conclusion that can be drawn from these results is that, 
with the exception of GDP-Fuc, the experimental methods to generate intracellular 
concentration profiles of NSDs are adequate. 
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6.2.2. mAb glycosylation profiles in batch culture 
The remaining step to bridge the gap between extracellular nutrient availability is to estimate 
the unknown parameters of the Golgi glycosylation model using the obtained experimental data. 
Previously, it was discussed that the main experimental inputs into the Golgi glycosylation 
model are mAb specific productivity and the observed oligosaccharide profiles bound to the 
mAb. The specific productivity of mAb estimated from the CCD component is required to 
estimate resident protein profiles and the mAb Fc glycan profiles are used to estimate the 
glycosyltransferase dissociation constants so that the profile is matched. 
Following this strategy, the specific mAb productivity estimated from previous steps in this 
procedure was used to calculate the Golgi enzyme profiles presented in Figure 33. As was 
described in chapter 3 of this thesis, the profiles presented in this figure represent the minimum 
amount of total enzyme required to fully process the glycan structures of a protein. In this case, 
these profiles are defined by the time it takes a glycoprotein to traverse the Golgi apparatus. 
This, in turn, is given by the specific mAb productivity. 
 
Figure 33. Estimated Golgi glycosylation enzyme profiles 
The concentration profiles of ManI, GnTI, ManII, GnTII, FucT, GalT and SiaT along the length of te 
Golgi apparatus are presented. The parameters that were estimated and define these 
concentration profiles are presented on the right. 
We must mention that when combining the NSD model and the Golgi glycosylation model, 
the NSD transport proteins are neglected. This assumption is consistent with the optimisation 
strategies discussed in section 3.5.2 of this thesis. The assumption underlying estimation of 
transport protein parameters is to minimise the difference between the rate of transport and 
the rate of consumption of NSDs in the Golgi glycosylation reactions. This may be interpreted as 
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saying that the rate-limiting step of NSD consumption in Golgi is not transport, and is mainly 
controlled by the glycosylation reactions. For this reason, the transport protein profiles were 
not estimated. 
Once the enzyme profiles are defined, the measured glycan profiles are used to estimate the 
unknown dissociation constants of the glycosyltransferases, as discussed in chapter 3 of this 
thesis.  
 
Figure 34. Comparison of measured mAb glycan profiles vs. simulation results 
The dark blue bars represent the mAb glycan profiles that were obtained through MALDI MS. The 
light blue bars show the simulation results for the mAb glycan profile.  
Figure 34. shows that the glycosylation model indeed reproduces the experimentally 
observed glycan profiles for the HFN 7.1 mAb. Table 20 presents the parameters that were 
estimated to produce the results shown in Figure 34. 
Table 20. Estimated dissociation constants 
with measured glycan profiles 
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The bottom row of the table shows percent deviation of the simulation from the 
experimental data. The 7.7% deviation is due to underestimation of the OS34/35 species and 
overestimation of OS19 and OS32. It is likely the model underestimates synthesis of OS34/35 
due to the activity of FucT. It can clearly be seen that the three main glycans present on the mAb 
are core fucosylated. Because these species are in higher abundance, the estimation yields 
parameters that favour their formation. In addition, the two species that are overestimated are 
ones where GlcNAc has not been added to the α-1,6 arm of the biantennary glycan. This is also 
likely related to the estimated FucT activity and to possible differential affinity of GnTII to 
fucosylated and non-fucosylated glycans. With additional experimental data, the cause of these 
divergences could be determined more thoroughly. 
Through these results, it can be seen that all models defined in this work have the ability to 
accurately reproduce experimentally-observed cell culture dynamics, intracellular NSD 
concentration profiles and also the glycan profiles of a mAb. This section has also shown the 
high-quality experimental results that were obtained through the methodologies developed in 
this thesis. 
6.3. Case study: glutamine-limited culture 
Up to this point, the models have been presented as separate entities that have the ability of 
replicating experimental data. However, the overall objective of this project was to generate a 
single mathematical model that mechanistically describes the glycan profiles of mAbs as a 
function of nutrient availability. This section will present simulation results for a case where the 
initial concentration of glutamine is limited. 
Two simulations were run with the coupled model. The parameters used for both 
simulations were the ones estimated in the previous section. The first simulation, which is noted 
as ‘Base Case’ was performed with an initial glutamine concentration of ~3.75mM. The second 
simulation was run with ~1.8mM initial glutamine concentration and is marked as ‘Low Gln’. 
Results for both simulations are compared in Figure 35 through 37. Figure 35 presents 
representative results for the cell culture dynamics element of the coupled model. In this figure, 
we see that viable cell density is clearly affected by the lack of glutamine. In the base case, Xv 
reaches close to 2e6cells/mL. Under glutamine starvation, Xv reaches approximately 1e6 
cells/mL. Interestingly, though, while cells decline quickly after 120hrs in the base case, the 
decline under glutamine starvation is less pronounced. This is possibly due to the additive death 
rate expression that was defined in equation 15. In the base case, both glucose and glutamine 
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are depleted in 96hr yielding a more pronounced death phase. In the glutamine deprivation 
simulation, growth ceases when glutamine is depleted. When this occurs, glucose is no longer 
consumed for growth and remains at a constant concentration after 96hr. Because of this, 
glucose does not contribute to cell death through equation 15, and hence Xv decline is slower in 
the glutamine depletion case.  
 
Figure 35. Cell culture dynamics under glutamine deprivation 
The base case is represented by solid lines whereas the glutamine deficiency simulation is 
presented by broken lines. 
Figure 36 compares the concentration profiles of NSDs under the base case and under 
glutamine deficiency. The effect of glutamine depletion is noticeable in the nitrogen containing 
NSDs. A clear depletion is observed for CMP-Neu5Ac, UDP-GalNAc and UDP-GlcNAc. The inverse 
occurs with the NSDs whose biosynthesis only depends on glucose. Given that glucose is not 
consumed for cell growth after 96 hours, more of it available for transport into cells where it is 
converted to UDP-Glc, GDP-Man and GDP-Fuc. Accordingly, these NSDs reach higher 
concentrations than those observed in the base case. 
The final element to be observed is how glutamine depletion impacts mAb Fc glycosylation. 
Glycan profiles calculated from the base case are compared with those computed under 
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glutamine deprivation in Figure 37. On the left of this figure, we see that there is a clear 
decrease in biantennary oligosaccharide species in under glutamine starvation. 
 
 
Figure 36. NSDs under glutamine deprivation 
NSD concentration profiles simulated under normal conditions are shown with solid lines. 
Simulation results under glutamine depletion are presented with broken lines. 
The right hand side of Figure 37 shows a very interesting result. In the base case, the 
fraction of G1F remains relatively unchanged throughout the cell culture simulation. In contrast, 
under gutamine deprivation, the fraction of this oligosaccharide drops sharply after 120hr, and 
while this occurs, there is a clear increase of Man5 oligosaccharide present on the mAb. 
0.0
5.0
10.0
15.0
20.0
25.0
0 24 48 72 96 120 144 168
C
o
n
c.
 (
µµ µµM
)
Time (hr)
Base Case
Low Gln
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
0 24 48 72 96 120 144 168
C
o
n
c.
 (
µµ µµM
)
Time (hr)
Base Case
Low Gln
0
20
40
60
80
100
120
0 24 48 72 96 120 144 168
C
o
n
c.
 (
µµ µµM
)
Time (hr)
Base Case
Low Gln
0
20
40
60
80
100
0 24 48 72 96 120 144 168
C
o
n
c.
 (
µµ µµM
)
Time (hr)
Base Case
Low Gln
0
50
100
150
200
250
300
350
400
450
0 24 48 72 96 120 144 168
C
o
n
c.
 (
µµ µµM
)
Time (hr)
Base Case
Low Gln
0
50
100
150
200
250
300
0 24 48 72 96 120 144 168
C
o
n
c.
 (
µµ µµM
)
Time (hr)
Base Case
Low Gln
CMP-Neu5Ac GDP_Fuc
GDP-Man UDP-GalNAc
UDP-Glc UDP-GlcNAc
6.3. CASE STUDY: GLUTAMINE-LIMITED CULTURE 127 
 
 
Accumulation of this particular glycan is of significant in the QbD context. mAbs with Man5 
gycans have been reported to be immunogenic and have a decreased serum half-life25, 92 
Observing Figure 36, the reason why Man5 accumulates is straight forward. The moment 
when Man5 begins to accumulate within the system corresponds directly with intracellular 
depletion of UDP-GlcNAc. 
 
Figure 37. mAb glycan profiles under glutamine deprivation 
On the left, the glycan profile calculated for the base case is shown with the dark bars. The light 
bars show the glycans calculated under glutamine depletion. On the right, a graph showing the 
accumulation of G1F throughout culture under the base case is shown in the solid blue line. 
Accumulation of the same glycan is shown with the broken blue line under glutamine deprivation. 
The green broken line shows accumulation of the Man5 glycan under glutamine starvation. 
When no UDP-GlcNAc is available, the N-acetylgucosamine residue cannot be added to 
the α-1,3 arm of the oligosaccharide, and if this step does not occur, ManII cannot trim the 
excess mannose residues form the glycan. 
With this particular example, the impact of nutrient limitation on glycosylation associated 
quality of mAbs is described in a fully mechanistic and quantitative manner. Moreover, this 
case-study highlights the possible applications of quantitative, mechanistic models for further 
bioprocess understanding under the QbD scope. 
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Chapter 7   
Conclusions and future work 
7.1. Summary of results 
This thesis has presented the development of a combined modelling and experimental 
framework that aims to mechanistically and quantitatively describe the relationship between 
nutrient availability during cell culture and the N-linked glycosylation process. 
The thesis first presented the current situation of the pharmaceutical and 
biopharmaceutical industry. It continued by describing the Quality by Design paradigm, along 
with its convenience for development and manufacture of biopharmaceutical products. This 
was followed by a review of the relevant literature concerning N-linked glycosylation, the 
impact bioprocess conditions have on this post translation modification, as well as the impact it 
has on the therapeutic properties of biological drugs. A brief review was also made on the 
analytical techniques that are used to characterise the N-glycan profiles of protein therapeutics. 
Subsequently, the formulation of a dynamic mathematical model that describes the 
intracellular process of N-linked glycosylation was presented. Details surrounding the 
formulation of this model along with additional optimisation-based strategies that were 
developed to estimate its unknown parameters were presented. The validity of the Golgi 
glycosylation model was further demonstrated by comparing its performance with previous 
models of this phenomenon. This Golgi glycosylation model was also shown to adequately 
reproduce the impact a complex perturbation, such as gene silencing, has on N-linked 
glycosylation. 
This was followed by the description of a second mathematical model that was developed to 
represent cell culture dynamics and the biosynthetic pathway of nucleotide sugars. This basis of 
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this model was to capture as many mechanistic features of the NSD pathway as possible, while 
reducing its size and unknown parameters.  
 Subsequent sections detailed the experimental methods that were employed throughout 
this work, including a chromatographic technique that was optimised to separate and quantify 
intracellular nucleotide sugar pools in under 30 minutes. Details regarding the mass 
spectrometric techniques that were employed to analyse the N-glycosylation of a mAb were also 
presented.  
The following sections presented the experimental and modelling results that were obtained 
throughout this work. This section mainly detailed the parameter estimation strategies that 
coupled the modelling work with the experimental results. Finally, a case study describing how 
a combined model which incorporates cell culture dynamics, intracellular NSD metabolism and 
mAb N-linked glycosylation was presented. The results shown by this case study highlight the 
purpose of this work by mechanistically and quantitatively describing how nutrient depletion 
during cell culture impacts the N-glycosylation quality of mAbs. 
7.2. Main conclusions 
The following conclusions can be drawn from this work: 
1. Synergy between pharmaceutical companies and regulatory agencies is essential to 
ensure that the highest quality drugs are produced without additional expense for 
healthcare providers and patients. Quality by Design is a platform that ensures end 
product quality for patients while incentivising large pharmaceutical companies to 
introduce innovation in their products and manufacturing processes. 
2. Under the QbD scope, N-linked glycosylation of therapeutic proteins is key for their 
safety and therapeutic efficacy. Many of the mechanisms by which the N-glycosylation 
process is affected by process inputs are still unknown. Much work has to be done to 
understand the fundamental mechanisms that impact this process. 
3. Quantitative mechanistic models will play a critical role in the implementation of QbD to 
development, manufacture and approval of biopharmaceuticals. 
4. The framework for modelling Golgi N-linked glycosylation that was presented in this 
work is robust and has immediate applicability for guiding genetic engineering 
strategies to knock out or overexpress N-glycosylation genes. This is highlighted by the 
accurate representation of FucT silencing it achieved. 
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5. Strategies for model reduction are critical in the field of systems biology. However, it is 
important to obtain a balanced model that does not compromise mechanistic fidelity for 
simplicity.  Models which are too complex include several unknown mechanisms and 
pathways, which if left disregarded, will negatively impact model accuracy. 
6. Combination of mathematical modelling with experimentation is crucial for accurate 
representation of complex phenomena. This was clear from all the estimation strategies 
that were implemented to extract kinetic parameters from extracellular and 
intracellular data. 
7. The final product of this thesis is a mathematical model that mechanistically links 
nutrient availability during cell culture with N-linked glycosylation. When further 
validated, this model can be used for process development, design and optimisation. 
Because it attempts to capture as many mechanistic features of the underlying physical 
phenomena it describes, it is congruent with QbD principles. Again, with further 
validation, models like this will play a critical role in biopharmaceutical process 
development, control and optimisation. 
7.3. Future work 
Based on the results and conclusions of this thesis, the following are suggestions for future work 
that can be done to as a continuation of this work: 
7.3.1. Golgi glycosylation model improvement 
The model for Golgi glycosylation that was described in this thesis requires experimental 
validation to some of its assumptions. As was discussed previously, the concentration profiles of 
resident proteins within the Golgi are estimates, and would need to be confirmed or 
complemented by experimental work. In addition, these resident protein profiles are fitted to 
three parameter normal functions. Ideally, the mechanisms by which these proteins are 
recycled by COPI coated vesicles would be included in the model. That way, deformation of the 
profiles due to excessive secretory traffic through Golgi would be represented. Mechanistic 
descriptions of this nature would certainly contribute to model fidelity, and allow for an 
improved description of the impact of process conditions on the Golgi glycosylation process. AN 
example of this would be temperature or pH, as was discussed in the body of this thesis. If the 
mechanisms for Golgi enzyme recycling are well established, the impact of temperature on 
glycosylation could be described mechanistically. 
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7.3.2. NSD model improvement 
The model for NSD metabolism that was presented in this thesis is rather simplified. It is 
possible that certain intermediate species along the pathway have heavy regulatory effects. The 
simplest extension to the model would be to consider availability of nucleotides within the 
kinetics. The HPAEC method that was optimised in this work allows for accurate quantification 
of these compounds. Furthermore, their intracellular concentrations seem to be in the same 
order of magnitude as the most prevalent NSDs. It is possible that nucleotide availability indeed 
impacts the biosynthetic pathway. Given that they can be readily monitored through HPAEC, 
including them in the model would be relatively simple. 
7.3.3. NSD quantification 
It is possible that extraction with PCA is not ideal for NSD quantification. However, the caveats 
of ACN extraction were also discussed. Further work on methods for quenching, washing and 
extracting NSDs would lead to improved datasets. This, in turn, would lead to higher confidence 
in estimated parameters within the models. 
7.3.4. Intracellular glucose and glutamine determination 
The methods that were used in this thesis to monitor intracellular glucose and glutamine were 
not adequate. Although the Amplex Red assay kit should be sensitive enough to produce full 
time profiles of intracellular glucose, very few points were measured. The case of glutamine is 
even more interesting. Because glutamine serves as the nitrogen source for the NSD pathway, 
understanding how its intracellular concentration varies with respect to time is desirable. 
Furthermore, analytical methods to measure both of these metabolites are preferable over kits 
because the risk of human error is reduced. Full data sets for intracellular glucose and 
glutamine would contribute to further understanding of the dynamics behind NSD biosynthesis. 
7.3.5. High throughput glycan analysis 
The mathematical models defined in this thesis are dynamic. As such, time courses for glycan 
profiles would contribute to improved model accuracy. An example would be case study. If the 
calculations were to be confirmed experimentally, the time course data for glycan profiles 
would be necessary. 
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7.3.6. Model validation 
Experimental data was used to estimate unknown parameters of the system. These parameters, 
though, have not yet been validated by an independent set of data. Validation experiments 
should lead to improved confidence in the parameter values themselves but would also shed 
light into further mechanistic effects that occur within the system. 
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Appendix I 
Rate expression derivation 
Michaelis-Menten kinetics 
This rate expression derivation applies to the ManI and ManII enzymes.233-235, 251 In a Michaelis-
Menten kinetic mechanism, the substrate binds to the enzyme to form an enzyme-substrate 
complex. Once the complex is formed, the rate-limiting step of the catalytic cycle occurs, thus 
yielding the product. In the case of the general reaction scheme shown in Figure 8, it can be seen 
that ManI and ManII act on different substrates. Because of this, a competitive inhibition term 
will be added to the catalytic cycle. Additional underlying assumptions for this derivation are 
the following: 
a) Equilibrium is reached rapidly for all reactions. 
b) There is competitive inhibition through substrate analogues. 
c) There is product inhibition because the product of these reactions has high binding affinity 
to the enzyme because it is a subsequent reactant itself. 
d) The enzyme needs a water molecule to catalyse the reaction. Since the reaction occurs 
within an aqueous environment (lumen of the Golgi compartments), it is possible to assume 
that the enzymes are saturated with water, and hence, the availability of this component 
does not affect the reaction in any way. 
e) The rate-limiting step is assumed to be the chemical removal of the mannose residue from 
the oligosaccharide chain. 
f) The rate-limiting step is assumed to be irreversible given that the products from the 
reaction will participate in further reactions within the same Golgi compartment. This will 
maintain their concentrations low and greatly reduces the possibility of the reaction 
occurring in the opposite sense. Another factor that facilitates this assumption is that the 
enzymes are saturated with water. This also contributes to reducing the likelihood of a 
reverse reaction. Finally, the co-products of these reactions are mannose residues. These 
mannose molecules have little or no interaction with the enzyme, so it is quite unlikely for 
them to react in the opposite sense. 
These assumptions lead to the following kinetic mechanism: 
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From this kinetic reaction mechanism we can derive the following mathematical expressions: 
Dissociation constants: 
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Total (or initial) enzyme balance: 
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Combining the dissociation constant expressions with the enzyme balance: 
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Solving for the free enzyme term: 
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The reaction rate expression for the rate-limiting reaction is defined as: 
[ ]
,j f j ir k EOS= ⋅       …Eq. 50 
 
Combining Eq. 45 with Eq. 49: 
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[ ]
[ ] [ ] [ ]
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[ ] [ ]
[ ] [ ] [ ]
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Combining Eq. 50 with Eq. 51: 
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
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∑
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i
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z zd
z
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i
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OSr
r , where [ ]0,, Ekr jfjMAX ⋅=  …Eq. 52 
Sequential-order Bi-Bi kinetics 
This rate expression derivation applies to the GnTI, GnTII and GalT enzymes.231, 236, 237 Although 
the underlying concepts of this derivation are similar to Michaelis-Menten, Bi-Bi kinetics 
consider binding of two substrates onto the enzyme for the reaction to occur. In sequential Bi-Bi 
kinetics, the order in which the substrates bind to the enzyme is important. For all three 
enzymes that catalyse reactions with this mechanism, the nucleotide sugar donor first binds to 
the enzyme and triggers a conformational change which creates the binding pocket for the 
oligosaccharide to bind. Thus the NSD binds first, and the oligosaccharide binds second. Because 
the enzyme undergoes a conformational change, the unbinding of the products from the enzyme 
occur in the inverse order: the oligosaccharide product dissociates from the enzyme, inducing 
the enzyme to recover its original configuration from which the by-product of the NSD (which 
for all of these reactions is UDP) can dissociate from the enzyme. Additional assumptions for the 
derivation of these kinetic expressions are the following: 
a) Equilibrium is reached rapidly for all reactions.237 
b) The kinetics of this reaction will be assumed as an ordered, sequential mechanism. In this 
case, the sugar donor must bind to the enzyme, once this occurs, the acceptor binds, and 
through the three species complex reacts to form product and by-product. Since the reaction 
is constrained to this order, the products complex must also dissociate in the corresponding 
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order. The product oligosaccharide unbinds leaving a by-product enzyme complex which 
will dissociate to complete the catalytic cycle.237 
c) These enzymes may act on several different substrates along the N-glycosylation pathway. 
Hence, competitive inhibition from analogue acceptor oligosaccharide (OSz) chains will be 
assumed. 
d) No excess of either of the substrates will be assumed which implies that the reaction rate 
will depend on the concentration of both substrates. (Enzyme is not assumed to be 
saturated with NSD). 
e) Dual product inhibition will be considered for this reaction given that many reports indicate 
that these enzymes have affinity for substrate analogues, which in some cases include 
reaction product analogues.297 
f) The rate-limiting step is assumed to be the transfer of the monosaccharide (GlcNAc or Gal) 
residue to the growing oligosaccharide chain. 
g) The rate-limiting step is assumed to be irreversible due to the consumption of energy during 
this step.64, 65 
These considerations lead to the following reaction mechanism: 
 
From this kinetic reaction mechanism we can derive the following mathematical 
expressions: 
Dissociation constants: 
[ ] [ ]
[ ]k
kf
kd EPc
PcE
K
⋅
=
,
 
→
 
[ ] [ ] [ ]
kd
kf
k K
PcE
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⋅
=
   …Eq. 53 
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[ ]ik
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OSEPc
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→
 [ ] [ ] [ ]
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OSEPcOSEPc
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=   …Eq. 54 
[ ] [ ]
[ ]zk
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zd OSEPc
OSEPcK ⋅=
,
 
→
 [ ] [ ] [ ]
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zk K
OSEPcOSEPc
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⋅
=   …Eq. 55 
[ ] [ ]
[ ]1
1
1,
+
+
+
⋅
=
ik
ik
id OSEPc
OSEPcK → [ ] [ ] [ ]
1,
1
1
+
+
+
⋅
=
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ik
ik K
OSEPcOSEPc   …Eq. 56 
jGnTIIf PcE +, ij OSEPc + ijOSEPc 1+ijOSEB 1++ ij OSEB
jdK , idK , fk 1, +idK
zdK ,
zOS
zjOSEPc
+
jGnTIIf BE +,
BjdK ,
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[ ] [ ]
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=
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Total (or initial) enzyme balance: 
[ ] [ ] [ ] [ ] [ ] [ ] [ ]1
1
0 +
=
+++++= ∑ ikk
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z
zkikkf OSEBEBOSEPcOSEPcEPcEE  …Eq. 61 
Combining the dissociation constant expressions with the enzyme balance: 
[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]
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 …Eq. 62           
Solving for the free enzyme term: 
[ ] [ ][ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]
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The reaction rate expression for the rate-limiting reaction is defined as: 
[ ]ikjfj OSEPckr ⋅= ,       …Eq. 64 
Combining Eq. 63 with Eq. 58: 
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and solving for [ ]ijOSEPc : 
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Substituting Eq. 65 into Eq. 64: 
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Rearranging: 
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,,
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…Eq. 66  
     
Where 
[ ]0,, Ekr jfjMAX ⋅=  
Random-order Bi-Bi kinetics 
This rate equation derivation applies to the GnTIII, FucT and SiaT enzymes.230, 232, 238 In this case, 
there is no conformation change in the enzyme, which means that both substrates can bind 
simultaneously to the enzyme. As with the previous cases, competitive inhibition will also be 
considered in this mechanism due to several substrates competing for the binding sites of the 
enzyme. This entails competitive inhibition, and when considering the random binding order, 
the resulting reaction mechanism is more complex than the previous two. Additional 
assumptions for the derivation of these kinetic expressions are the following: 
a) Equilibrium is reached rapidly for all reactions.232 
b) These enzymes act on several substrates along the N-glycosylation pathway. Therefore, 
competitive inhibition from analogue acceptor oligosaccharide (OSz) chains will be 
assumed. 
c) No disproportionate excess of one substrate with respect to the other is assumed within 
the Golgi compartments; hence, the reaction rate will depend on the concentrations of 
both species. (Enzyme is not assumed to be saturated with NSD). 
d) Dual product inhibition will be considered for this reaction given that both the products 
have affinity for the enzyme.232 
e) The rate-limiting step is assumed to be the transfer of the monosaccharide residue to the 
growing oligosaccharide chain. 
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f) Again, the rate-limiting step is assumed to be irreversible.64, 65 
These assumptions lead to the following kinetic mechanism: 
 
From this kinetic reaction mechanism we can derive the following mathematical 
expressions: 
Dissociation constants: 
[ ] [ ]
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Total (or initial) enzyme balance: 
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Combining the dissociation constant expressions with the enzyme balance: 
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Solving for the free enzyme term: 
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         …Eq. 80 
The reaction rate expression for the rate-limiting reaction is defined as: 
[ ]ikjfj OSEPckr ⋅= ,       …Eq. 81 
Combining Eq. 75 with Eq. 80: 
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and solving for [ ]ijOSEPc : 
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         …Eq. 82 
Substituting Eq. 82 into Eq. 81: 
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         …Eq. 83 
Where [ ]0,, Ekr jfjMAX ⋅=  
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Appendix II 
Transport equations derivation 
In order for transport to occur, the NSD must bind to the transport protein on the cytosolic side 
of the membrane and the dephosphorylated by-product must bind to the transport protein on 
the luminal side of the Golgi membrane. Additionally, it has been reported that the process can 
also occur in the opposite sense.239, 240 In this case, the NSD must bind to the transport protein 
on the luminal side while a dephosphorylated by-product must bind to the cytosolic side of the 
Golgi. Given this information, we have proposed a gradient that determines the transport as: 
[ ] [ ]( )....
,,
____
LG
k
Cyt
k
Cyt
k
LG
kkTkTransp PcBPTPPcBPTPkr −⋅=  …Eq. 84 
If binding of the NSD and the dephosphorylated by-product are considered to be analogous 
to substrate binding in enzymes, we obtain the following kinetic mechanism: 
 
Using procedures analogous to enzyme derivations: 
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K K
TP BP TP Pc BP TP Pc BP
            ⋅ ⋅ ⋅ ⋅            
⋅ = ⋅ =
          
 …Eq. 90 
Total (or initial) transport protein balance: 
[ ] . . . .0 _ _ _ _Cyt G L Cyt G Lf k k k kTP TP TP Pc TP BP TP Pc BP      = + + +          …Eq. 91 
 
Combining the dissociation constant expressions with the transport protein balance: 
[ ]
. . . .
0
. . . .
'
Cyt G L Cyt G L
k k k k
f f f fCyt G L Cyt G L
Pc BP Pc BP
Pc BP Pc BP
TP TP TP TP TP
K K K K
                     = + ⋅ + ⋅ + ⋅ ⋅         …Eq. 92 
Solving for the free transport protein term: 
[ ]0
. . . .
. . . .
1
'
f Cyt G L Cyt G L
k k k k
Cyt G L Cyt G L
Pc BP Pc BP
TP
TP
Pc BP Pc BP
K K K K
  =                  + + + ⋅
 
 
    …Eq. 93 
Combining equations 93 and 90 and solving for [ ]..__ LGjCytj BPPcTP : 
[ ] . .0
. .
. . . .
. .
. . . .
_ _
' 1
'
Cyt G L
k kCyt G L
k k Cyt G L Cyt G L
k k k kCyt G L
Pc BP Cyt G L Cyt G L
Pc BP Pc BP
TP Pc BP
TP Pc BP
Pc BP Pc BP
K K
K K K K
   ⋅ ⋅     =                  ⋅ + + + ⋅
 
 
 
Simplifying: 
[ ]
. .
. .
0
. . . .
_ _
Cyt G L
k kCyt G L
k k Cyt Cyt G L G L
Pc k BP k
Pc BP
TP Pc BP TP
K Pc K BP
              = ⋅ ⋅        + +      
  …Eq. 94 
Considering that the same derivation can be followed for transport in the opposite direction: 
[ ]
. .
. .
0
. . . .
_ _
G L Cyt
k kG L Cyt
k k G L G L Cyt Cyt
Pc k BP k
Pc BP
TP Pc BP TP
K Pc K BP
              = ⋅ ⋅        + +      
 …Eq. 95 
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Substituting equations 94 and 95 into equation 84: 
[ ]
. . . .
, , 0
. . . . . . . .
Cyt G L G L Cyt
k k k k
Transp k T k Cyt Cyt G L G L G L G L Cyt Cyt
Pc k BP k Pc k BP k
Pc BP Pc BP
r k TP
K Pc K BP K Pc K BP
                              = ⋅ ⋅ ⋅ − ⋅
               + + + +               
 
         …Eq. 96 
Finally, if we consider that by-product accumulation in the cytosol is limited given the 
dilution effect of going from a limited volume (Golgi cisternae) to a larger one (cytosol) and that 
the uptake of dephosphorylated nucleotides occurs readily in the cytosol through the nucleotide 
salvage pathways,298 the second term of equation 96 can be neglected so the final expression 
obtained is: 
[ ]
. .
, , 0
. . . .
Cyt G L
k k
Transp k T k Cyt Cyt G L G L
Pc k BP k
Pc BP
r k TP
K Pc K BP
              = ⋅ ⋅ ⋅
       + +       
 …Eq. 97 
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Appendix III 
Glycosylation model parameter derivation 
Enzyme turnover rates 
The turnover rates have been estimated from the literature similarly to previous modelling 
studies. The maximum rate has usually been expressed in units of µmol mgprot-1 min-1. In order 
to obtain the turnover rate in units of µmolprod µmolenz-1 min-1, the reported Vmax has been 
multiplied by the molecular weight of the enzyme. This is valid only if the kinetic analysis has 
been performed with purified enzyme. 
Transport protein turnover rates 
Gilchrist et al.267 performed a quantitative proteomic analysis of the secretory pathway in rat 
hepatocytes. In their study, the only NSD transport protein detected in the Golgi fraction is the 
UDP-GlcNAc transporter and was reported to account for 0.005116 % of all Golgi resident 
proteins. With this value, an average molecular weight of 60,600 g mol-1 (also estimated from 
[267]) and the maximum transport rate for TP1 shown in Table 8Table 9, a maximum turnover 
rate for this transport protein was estimated to be 1,084 min-1. The remaining maximum 
transport turnover rates were derived from this value by assuming that the transport turnover 
rates are proportional to the reaction turnover rates. 
NSD concentration in cytosol and Golgi cisternae 
The concentration of NSDs has been reported for overall cell volume and thus, their distribution 
between the Golgi apparatus and the cytosol is unknown. It has previously been reported that 
TPs have the ability to concentrate them up to 50-fold with respect to extraluminal 
concentrations.239 A 40-fold increase in NSD concentration was assumed (similar to what 
Krambeck and Betenbaugh32 assumed) and a material balance was performed to find the 
distribution of these components on the luminal and cytosolic side of Golgi cisternae. 
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Appendix IV 
Rate of NSD consumption vs. rate of NSD transport into 
Golgi 
The NSD transport parameters were estimated with the methodology presented in the 
parameter estimation section of the main paper. With the estimated parameters, simulations 
were performed in order to assess the performance of the estimated parameters. In the figure 
presented below, the profiles of NSD consumption and transport over the length of Golgi are 
shown. The lines represent the rate of NSD consumption and the symbols represent the rate of 
transport for each NSD into the Golgi along the length of the Golgi apparatus. The vertical dotted 
lines mark the zones where the maturing compartments are defined as either cis, medial, trans 
or trans Golgi network. 
 
In the figure presented above, it is clear that the rate of NSD consumption overlaps with the 
NSD transport rate indicating that the obtained parameters achieve the conditions defined in 
the optimization methodology. The implication behind both sets of data overlapping is that the 
transport of NSDs is not limiting. However, when the concentration of NSDs on the cytosolic side 
of the Golgi membranes is limited due to metabolic effects, transport is hindered (see equation 
97 for NSD transport) and, only then would NSD availability inside Golgi limit the glycosylation 
reactions.
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Appendix V 
HPAEC Supporting information 
 
Calibration curves for 4 nucleotides and 9 NSDs 
These curves were generated by plotting the measured area below the peak vs. the known amount 
of analyte injected. The equation for the linear regression and the corresponding R2 are also 
presented in the figure. 
